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Preface to ”Antioxidants and Second Messengers of
Free Radicals”
For decades, chemical species with unpaired electrons known as free radicals, in particular,
oxygen free radicals, have been considered to act as enemies of living cells, damaging major
bioactive molecules and thus causing degenerative and malignant diseases. Despite this, free radicals
are live for very short periods and are highly reactive molecules that also play and important
roles in the cellular metabolism. This paradox is further stressed by the fact that some products
of the oxidative metabolism of lipids, especially reactive aldehydes, can mimic the bioactivity
of free radicals, while living much longer and even acting on long distance. Therefore, there is
a lack of general understanding of pathophysiological roles played by reactive aldehydes like
malondialdehyde, 4-hydroxynoenal, 4-hydroxyhexenal, acrolein, etc., which are also considered to be
“second messengers of free radicals”. Being generated mostly by non-enzymatic lipid peroxidation,
they often form bioactive adducts with macromolecules important for the pathophysiology of living
cells, even in the absence of severe oxidative stress.
This book is based on the Special Issue of Antioxidants comprising original research papers
and reviews on complex aspects of reactive aldehydes and their macromolecular adducts (especially
with proteins) generated during lipid peroxidation and their interference with natural and synthetic
antioxidants in the physiology of cells and in the pathophysiology of various diseases studied by
modern bioanalytical methods applied in translational and clinical medicine.
Taken together, these scientific papers suggest that understanding the pathophysiology of
reactive aldehydes might indeed be crucial to a better understanding of major human diseases,
while monitoring their production and controlling them by using efficient antioxidants might help
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In the recent years, numerous research on the pathology of oxidative stress has been completed
by intense studies on redox signaling implementing various experimental models and clinical trials.
Nonetheless, there is still a lack of general understanding of pathophysiological roles played by reactive
aldehydes like malondialdehyde, 4-hydroxynonenal, 4-hydroxyhexenal, acrolein, etc., which are
considered as “second messengers of free radicals” [1,2]. Mostly being generated by lipid peroxidation,
reactive aldehydes often form bioactive adducts with macromolecules that are important for the
pathophysiology of living cells, thus, mimicking the effects of reactive oxygen species (ROS) even
in the absence of severe oxidative stress [3–5]. Accordingly, we lack understanding on the complex
effects of antioxidants that might be active in the regulation of toxic and/or hormetic effects of reactive
aldehydes. This knowledge is necessary for better understanding of human physiology from the
earliest days of life as well and for prevention and treatment of various stress- and age-associated
diseases, which require integrative medicine treatment protocols [6,7].
This Special Issue collected original research papers and reviews on complex aspects of reactive
aldehydes and their protein adducts generated during lipid peroxidation and their interference with
natural and synthetic antioxidants in the physiology of cell and in the pathophysiology of various
diseases, studied by modern bioanalytical methods applied in translational and integrative medicine.
Hence, focusing on the damaging effects of 4-hydroxynonenal (HNE) to the earliest events in
our lives, i.e., the process of sperm-egg recognition, the Australian scientists reviewed the negative
effects of HNE affecting the function and the stability of several germline proteins. Additionally,
the authors pointed to the arachidonate 15-lipoxygenase (ALOX15) as a potential therapeutic target
that could be exploited to protect human spermatozoa against oxidative stress [8]. They also prepared
a very informative list of antioxidants tested for the improvement of male fertility summarizing
their efficiencies.
On the other hand, focusing on the other end of the time-scale of human life, the Italian researchers
wrote a very informative review on the relevance of reactive aldehydes in age-related disorders [9].
Reviewing the current knowledge on these complex topics of major relevance for modern biomedicine,
the authors suggest that a major fraction of the toxic effects of oxidative stress observed in age-related
disorders could depend on the formation of aldehyde-protein adducts (in particular, protein adducts
of HNE and malondialdehyde (MDA). They also stressed the relevance of novel redox-proteomic
approaches, which might reveal aldehydic modifications of distinct cellular proteins targeted in and
after the course of oxidative stress, aiming to pave the way to targeted therapeutic strategies for
age-associated disorders.
The importance of novel analytical approaches of redox-proteomics was also shown by researchers
from Austria who described in their original research paper the method for detection of lipid-modified
proteins that does not require an a priori knowledge on the chemical structure of lipid oxidation
products or identification of their target proteins [10]. The method is based on the change of
electrophoretic mobility of lipid-modified proteins, which is induced by conformational changes
and cross-linking with other proteins. The authors have applied this method to successfully study
the effects of oxidized palmitoyl-arachidonoyl-phosphatidylcholine (OxPAPC) on endothelial cells,
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identifying several known but also many new OxPAPC-binding proteins, thus presenting an important
analytical breakthrough. This supports previous research by the Austrian pioneers in the field as
Hermann Esterbauer and collaborators who discovered HNE, thus, constructing the fundaments for
the modern scientific arena of lipid peroxidation [11].
The pathophysiological aspects of lipid peroxidation were further reviewed from two
complementary aspects; by summarizing findings on HNE in redox homeostasis of gastrointestinal
mucosa with possible implications for the stomach in health and in gastrointestinal diseases [12] and
by reviewing options for modulation of oxidative stress and lipid peroxidation by endocannabinoids
and their lipid analogues [13]. In the former article, the authors point to pathophysiological
relevance of the HNE-protein adducts in digestive system of humans, especially stressing increased
accumulation of HNE-modified proteins in gastric mucosa during infection and even after eradication
of H. pillory infection. However, the authors of the later review paper suggest that a link between
the endocannabinoid system (ECS) and redox homeostasis impairment could be crucial for cellular
and tissue damages occurring in redox-dependent processes involving reactive oxygen and nitrogen
species as well as lipid peroxidation-derived reactive aldehydes including acrolein, MDA and HNE.
Consistent with that are the findings on the bioactivities or natural and synthetic antioxidants
targeting reactive aldehydes as second messengers of free radicals in vitro or in vivo presented in the
remaining papers of this Special Issue [14–17]. The authors of one review and two original papers
were studying the structure-activity relations of particular plant extracts on their chemical composition.
This might help us to better understand their activity principles [14–16], while in the last article of this
Special Issue, the authors studied the relationship between antioxidant and growth regulating effects
of synthetic chemical substances, notably of 1,4-dihydropyridine derivatives (DHS) [17]. Namely,
various DHPs are known for their pleiotropic activity, some also act as antioxidants that are already
used for UV-protection or as antihypertensive agents. In their original in vitro study using several
well-known or newly synthesized DHPs to treat human osteoblast-like cells, the authors revealed
some DHPs as possible therapeutic agents for osteoporosis. However, further research is needed to
elucidate their bioactivity mechanisms in respect to signaling pathways involving HNE and related
second messengers of free radicals [17].
Similarly, although working on a very different in vitro model of human skin cells treated with
sea buckthorn seed oil, another group analyzed the effects of the particular oil on the redox balance
and lipid metabolism in UV irradiated skin cells. This research aimed to examine whether the
plant oil can have the UV-protective effect [16]. By doing so, the authors found beneficial effects of
the buckthorn seed oil, which decreased the production of lipid peroxidation products (including
HNE) simultaneously decreasing the cannabinoid receptor expression in UV-irradiated keratinocytes
and fibroblasts.
Another in vitro study used several cell lines to test if HNE might be a relevant factor of beneficial
effects of the widely used Aloe vera extracts (AV) [15]. This study found that the cell-type specific effects
of AV, by itself was not toxic for any type of cells, while it modulated the cellular response to oxidative
stress induced by hydrogen peroxide. Of particular relevance, it was found that high antioxidant
levels of the AV did not interfere with enhanced cellular accumulation of the HNE-protein adducts in
human endothelial cells, as revealed by the genuine cell-based ELISA specific for HNE-His, which was
used for the first time. The authors concluded that these findings might help in understanding the
activity principles of AV, particularly if used for the promotion of wound healing and/or for adjuvant
cancer treatments.
Some options for the modulation of lipid peroxidation pathophysiology by plant extracts reach
in antioxidants were eventually summarized in the review on the relationship between biological
activities of such extracts and their chemical composition in the article focusing on the evening
primrose extracts [14]. The authors of this review point to the biomedical use of the evening
primrose oil (EPO) rich in linoleic acid (70–74%) and linolenic acid (8–10%), which are precursors of
anti-inflammatory eicosanoids. Thus, EPO supplementation may result in an increase in plasma levels
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of linolenic acid and its metabolite dihomo-linolenic acid, which is oxidized by lipoxygenase (15-LOX)
to 15-hydroxyeicosatrienoic acid (15-HETrE) or can be, under the influence of cyclooxygenase (COX),
metabolized to series 1 prostaglandins, which exert anti-inflammatory and anti-proliferative properties.
In addition, linolenic acid itself may suppress the production of inflammatory cytokines. Since linoleic
acid is also a major source of HNE, one may assume that lipid peroxidation generating HNE could be
also important for the multiple biological effects of EPO, as suggested for the Aloe vera extract in the
paper described above [15].
In conclusion, more research is needed to evaluate, using advanced analytical methods and
translation models, how the natural and/or synthetic antioxidants interfere with the pathophysiology
of lipid peroxidation. Yet, by doing so, we could increase not only our understanding of this
important field but also support the development of the modern integrative biomedicine for which both
antioxidants and second messengers of free radicals, represented by HNE, are of highest importance.
Conflicts of Interest: The author declares no conflict of interest.
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Abstract: Germline oxidative stress is intimately linked to several reproductive pathologies including a
failure of sperm-egg recognition. The lipid aldehyde 4-hydroxynonenal (4HNE) is particularly damaging
to the process of sperm-egg recognition as it compromises the function and the stability of several
germline proteins. Considering mature spermatozoa do not have the capacity for de novo protein
translation, 4HNE modification of proteins in the mature gametes has uniquely severe consequences
for protein homeostasis, cell function and cell survival. In somatic cells, 4HNE overproduction has
been attributed to the action of lipoxygenase enzymes that facilitate the oxygenation and degradation
of ω-6 polyunsaturated fatty acids (PUFAs). Accordingly, the arachidonate 15-lipoxygenase (ALOX15)
enzyme has been intrinsically linked with 4HNE production, and resultant pathophysiology in various
complex conditions such as coronary artery disease and multiple sclerosis. While ALOX15 has not
been well characterized in germ cells, we postulate that ALOX15 inhibition may pose a new strategy to
prevent 4HNE-induced protein modifications in the male germline. In this light, this review focuses on
(i) 4HNE-induced protein damage in the male germline and its implications for fertility; and (ii) new
methods for the prevention of lipid peroxidation in germ cells.
Keywords: male fertility; oxidative stress; 4-hydroxynonenal (4HNE); arachidonate 15-lipoxygenase
(ALOX15); lipid peroxidation; reactive oxygen species (ROS)
1. Introduction: Fertility and Oxidative Stress
A decline in fertility rates is becoming an increasingly prevalent issue worldwide, with
current estimates indicating that 1 in every 6 couples experience issues with conception [1].
Furthermore, the contribution of male factor infertility accounts for up to half of these cases [2].
The leading cause of male infertility stems from a loss of sperm function, ultimately resulting in a
loss of fertilization potential [3]. This loss in function is causatively linked to oxidative stress within
the cell [4,5] driven by the presence and/or overproduction of intracellular reactive oxygen species
(ROS). Reactive oxygen species are oxygen-containing molecules that can contain unpaired electrons
(radicals) or be non-radical oxidizing agents [6]. The consequences of ROS are realized through redox
reactions with a great number of biological substrates, producing either further reactive products
or oxidized biomolecules. Within spermatozoa, low levels of ROS are essential for promoting key
stages of development. For instance, ROS actively participate in metabolic pathways during sperm
activation, which leads to cholesterol efflux, cyclic adenosine monophosphate (cAMP) production
and tyrosine phosphorylation, important events that contribute to fertilization competence [5,7–9].
However, if intracellular ROS production escalates beyond the buffering antioxidant capacity of the cell
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in a state of oxidative stress, the redox biochemistry leads to damaging effects such as lipid peroxidation,
organelle degradation, DNA damage and eventually cell death [10,11]. Typically, antioxidants, which
counteract and protect against oxidative stress, are housed within the cytoplasm and mitochondria of
somatic cells [12,13]. However, spermiogenesis, a process that gives rise to the unique architecture
of mature spermatozoa, results in significant cytoplasmic depletion [14,15], thereby diminishing
antioxidant capacity in the spermatozoon [16]. Furthermore, during testicular maturation, there is an
enrichment of long chain poly-unsaturated fatty acids (PUFAs) in the sperm plasma membrane, which
can serve as important substrates for lipid peroxidation [10]. Indeed, PUFAs such as arachidonic acid,
linoleic acid and docosahexaenoic acid are enriched within the sperm plasma membrane [17,18],
and can be broken down into cytotoxic lipid aldehydes that promote cellular damage and the
dysregulation of cell function [19]. Common metabolites of lipid peroxidation within spermatozoa
include reactive aldehyde compounds such as 4-hydroxynonenal (4HNE) and malondialdehyde
(MDA) [19–21]. Herein, we review literature pertaining to the reactivity, production and prevention of
these cytotoxic lipid peroxidation products in the male germline.
2. Aldehydes in the Male Germline
In developing male germ cells and mature spermatozoa, two of the primary aldehyde products
of lipid peroxidation that have been reported to cause cellular damage are MDA and 4HNE [19,22].
Increased levels of MDA are linked to a reduction in sperm concentration, normal morphology and
motility [23,24]. Similarly, MDA is present at higher levels within the sperm of infertile men and is
thought to initiate a loss of motility, reduction in sperm concentration and atypical morphology [24].
The levels of 4HNE within spermatozoa are positively correlated with mitochondrial superoxide
formation [10], suggesting that elevated levels of 4HNE place sperm cells under increased levels of
oxidative stress. Accordingly, the presence of 4HNE has been linked to numerous adverse effects on
sperm function including a decline in motility, morphology, the capacity to acrosome react, and to
engage in interactions with the zona pellucida of oocytes [19,25,26]. Specifically, the exposure of
biomolecules to 4HNE stimulates an upregulation of mitochondrial ROS, generating a cascade of
oxidative stress within human spermatozoa [19], as depicted in Figure 1.
 
Figure 1. The cascade of oxidative stress in human spermatozoa. Mitochondrial reactive oxygen
species (ROS) are produced and initiate the breakdown of the lipid plasma membrane. This promotes
lipid peroxidation and the production of cytotoxic lipid aldehydes such as 4-hydroxynonenal (4HNE).
In turn, 4HNE upregulates ROS production while causing an overall decline in cell function, ultimately
impairing sperm-egg interaction. Figure created with BioRender.
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Overproduction of 4HNE within sperm cells is linked to a reduction in sperm motility [26] and
sperm-zona pellucida (ZP) interaction mediated by the molecular chaperone heat shock protein A2
(HSPA2) [25], and an increase in cell death [19]. There are several non-enzymatic pathways for aldehyde
production, the best characterized being Fenton reactions, whereby ferrous iron (Fe2+) within the cell is
able to interact with lipids (LOOH) allowing the formation of lipid hydroperoxides (LO•) as shown in
Equation (1) [27] and the production of aldehydes (as reviewed by Spiteller and Ayala et al.) [20,27].
LOOH + Fe2+ → LO• + Fe3+ + OH• (1)
Importantly, 4HNE is also produced via enzymatic pathways involving lipoxygenases such
as arachidonate 15-lipoxygenase (ALOX15), with several studies highlighting that key metabolites
such as 13-HpODE lead to the production of 4HNE [20,28], while MDA appears to be synthesized
independent of lipoxygenase activity [29]. 4-hydroxynonenal is considered to be the most toxic lipid
aldehyde produced within the cell [30]. This is due, at least in part, to its reactivity and subsequent
capacity to alkylate proteins, generate DNA damage and ultimately cause cell death [19,25,26,31].
The reactivity of 4HNE lies in its ability to form Schiff bases and/or participate in Michael reactions.
The preferential biological targets for these reactions are proteins, specifically primary amines such
as lysine, but reactions with cysteine and histidine amino acid residues are also common [32,33].
A particular target for 4HNE adduction is succinate dehydrogenase (SDH) [19], a key protein in the
electron transport chain within the mitochondria. Excess 4HNE has been shown to form adducts with
SDH, which result in a loss of function. This ultimately facilitates electron leakage to electron acceptors
in an unregulated fashion, increasing the production of ROS and eventually precipitating a state of
oxidative stress within the cell [19]. Another such example in human spermatozoa is the molecular
chaperone HSPA2 [34], which is also targeted for adduction by 4HNE [25]. Such modifications of
HSPA2 results in a loss of its chaperoning ability and thus significantly attenuates the ability of the
protein to coordinate the expression of receptors on the sperm surface; a maturational event that is
critical for sperm-egg recognition [25]. Ultimately, this sequence of events culminates in a severely
reduced capacity for fertilization [25,26].
Overall, the production of 4HNE has been shown to have a direct effect on the function of
its protein targets, leading to cellular damage in the male germline as well as other cell types.
Therefore, targeting the lipoxygenases responsible for the production of these reactive aldehydes
may be an important strategy to both counter the onset of oxidative stress and reduce the cellular
damage generated by 4HNE. Here, we investigate in more detail the involvement of lipoxygenase
proteins in the enzymatic production of 4HNE.
3. Mechanisms for the Generation of 4HNE: A Focus on Lipoxygenase Proteins
Lipoxygenase proteins are a highly conserved family of enzymes that are ubiquitously found in
plants [35,36], fungi [37] and mammals [38], but are rarely found in lower eukaryotes and prokaryotes
and are absent in archaea and viruses [38–40]. Mammalian lipoxygenases typically consist of singular
polypeptide chains, two functional domains and a molecular mass of ~75–80 kDa [41–43]. The C
terminus contains the catalytic domain, while the N terminus is involved in processes governing
membrane binding and interaction with substrates [42]. The catalytic pocket of the enzyme coordinates
a single, non-heme containing iron atom per molecule [41,44], which is actively involved in the redox
reactions necessary to facilitate the selective peroxidation of PUFAs [41,45]. However, this two domain
structure is not conserved across all prokaryotes [46], and the presence of manganese replaces iron
in the catalytic site of some fungal lipoxygenases [47–49]. The classification system of lipoxygenases
(ALOX-n) defines the carbon position where oxygenation takes place along the PUFA chain. Table 1
indicates the known paralogs of human lipoxygenases, their substrates and metabolic products.
PUFA substrates for ALOX15 include ω-6 fatty acids such as arachidonic and linoleic acid and
the ω-3 fatty acid, docosahexaenoic acid [50]. The mechanisms underpinning lipoxygenase function
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are still not entirely understood. However, it is clear that the iron center can alternate between
ferric (Fe3+/active) and ferrous (Fe2+/inactive) forms [43] and this redox activity assists in hydrogen
abstraction (L-H→L) of PUFAs when the iron atom undergoes a reduction (Fe3+→Fe2+) [41,51].
This reaction mechanism anticipates that the enzyme is converted back to its active form
through oxidation of the iron center (Fe2+→Fe3+) and oxygenation (L→LOO) of the PUFA [41,43].
Importantly, recent studies assessing the enzymatic action of ALOX15 have identified binding sites for
allosteric inhibition, which will allow for further insight into its specific activity [52,53].
Table 1. Paralogs and metabolites of the family of human lipoxygenase enzymes.
Lipoxygenase Enzyme 1 Substrates 2 Metabolic Products References
ALOX5 AA LA EPA 5-HpETE, 5-HETE and DGLA, Leukotrienes [43,54]
ALOX12 AA LA EPA DGLA 12-HpETE, 12-HETE, 12-HPETre, 12-HEPE, 12-HPOTrE [50,54,55]
ALOX15 AA LA DHA 15-HpETE, 15-HETE, 13-HpODE, 13-HODE, 17-HpDHA [50,54,56,57]
ALOX12B AA LA LωHC 12R-HpETE, 12R-HETE, 9R-HpODE, 9HωHC [50,54,58]
ALOX15B AA 15-HpETE, 15-HETE [50,54,59]
ALOXE3 12(R)HpETE 9HωHC Epoxyalchohols (metabolism of 12(R)-HpETE)9TEHωHC [54,60]
3
1,2 Paralogs of the lipoxygenase family are shown along with their corresponding substrates of
arachidonic acid (AA, red), linoleic acid (LA, green), eicosapentanoic acid (EPA) and docosahexaenoic
acid (DHA). Abbreviations: arachidonate lipoxygenase (ALOX), epidermal type lipoxygenase (ALOXE),
hydroperoxyeicosatetraenoic acid (HpETE), hydroxyeicosatetraenoic acid (HETE), 12-hydroxyeicosapentaenoic acid
(HEPE), Hydroperoxyeicosatrienoic acid (HPEtrE) hydroperoxyoctadecadienoic (HpODE), hydroxyoctadecadienoic
(HODE), 12-hydroperoxy-9Z,13E,15-octadecatrienoic acid (12-HPOTrE) hydroperoxydocosahexaenoic acid (HpDHA)
and Dihomo-γ-linoleic acid (DGLA), Linoleyl-ω-hydroxy ceramide (LωHC), 9(R)-hydroperoxyllinoleoyl-ω-hydroxy
ceramide (9HωHC), 9(R)-10(R)-trans-epoxy-11E-13(R)-hydroxylinoleoyl-ω-hydroxy ceramide (9TEHωHC). 3 It is noted
that under normoxic conditions ALOXE3 does not exhibit lipoxygenase activity [60].
Numerous studies have focused on the possible pathogenic implications of the lipoxygenase
family, with a key focus on ALOX5 due to its role in the biosynthesis of leukotrienes, which are
inflammatory mediators [61]. Leukotrienes can cause pathological inflammatory responses in diseases
such as cystic fibrosis [62], inflammatory bowel disease [63] and asthma [64], thereby presenting
a relationship between lipoxygenase activity and immune responses. Chronic inflammation has
the potential to place cells under stress, which in turn can promote cell death or abnormal cell
differentiation [65]; the latter of these, in turn, has the potential to promote tumorigenesis [66]. In the
case of ALOX15, several studies have implicated this protein in the inflammation pathway of diseases
such as colorectal cancer [67], prostate cancer [68] and chronic myeloid leukemia [69]. However, while
the formation of 14,15-leukotrienes from ALOX15 has been proposed [70], the biological relevance of
these specific compounds has not yet been explored.
Interestingly, ALOX15 activity has also been linked to obesity as the enzyme is highly expressed
in omental tissue compared to the subcutaneous fat layer of obese patients [71]. Accordingly, analysis
of ALOX15 transgenic mice supports a link between inflammation, obesity and insulin resistance [72].
Indeed, this study proposes that an overexpression of ALOX15 stimulates the production of
pro-inflammatory mediators, which promote insulin resistance induced through a high fat diet [72].
In turn, insulin resistance results in an overall increased risk in developing type 2 diabetes and
obesity [72]. It is now well established that obesity can have detrimental impacts on both maternal
and paternal fertility, as well as embryo health and development [73,74]. Obesity in males, is linked
with an increased time to conception and a decrease in sperm function [73]. With these lines of
evidence, the activity of ALOX15 may have a systemic and indirect effect on male infertility through
obesity, alongside the direct effects it may have within the male germline through 4HNE production.
The imperative for understanding mechanisms of male infertility is further supported by the growing
evidence that male fertility status may in fact be an effective indicator of general health of the
individual [75–77]. Specifically, studies assessing the fertility of more than 40,000 males have revealed
that important semen parameters such as volume, cell count, and morphology are directly correlated
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with life expectancy [76]. A similar link has also been observed in the context of the prevalence of
infertility in diseased men experiencing inflammatory bowel disease [78], obesity [79–81], diabetes [82],
hypertension and also sexually transmitted diseases such as chlamydia [83], human immunodeficiency
virus (HIV), and hepatitis C [84]. Such data suggest that drivers of poor fertility may originate in
systemic issues rather than being restricted to the male reproductive tract, again emphasizing the
importance of gaining a better understanding of the fundamental aspects of infertility and its origins.
At this time, literature on ALOX15 in the male germline is very scarce. Nevertheless, analysis
of ALOX15 within mature spermatozoa has indicated a putative role for the enzyme within the
cytoplasmic droplet of mammalian species such as boar [85] and mouse [86]. These studies suggest
that ALOX15 works in concert with the ubiquitin pathway to cause organelle degradation, assisting
in the removal of the cytoplasmic droplet [85]. Additionally, the production of an ALOX15 knockout
mouse model has shown that the loss of this enzyme does not compromise sperm production per
se. However, the spermatozoa produced from null males exhibited atypical cytoplasmic droplet
degradation during epididymal transit [85]. Earlier work provided an indication that the bull sperm
acrosome reaction may be suppressed following lipoxygenase inhibition [87]. However, these data
must be interpreted with caution owing to the use of non-specific lipoxygenase inhibitors, and the
absence of substantiating evidence to illuminate the direct role of ALOX15 in the induction of acrosomal
exocytosis. Recent studies have suggested a possible link between this lipoxygenase enzyme and
oxidative stress propagation in human spermatozoa [88] and in mouse germ cells [89,90]. Using an
immortalized spermatocyte cell line [GC-2spd(ts)], we have demonstrated that the treatment of these
cells with an ALOX15 inhibitor resulted in significant reductions in 4HNE protein modifications and
subsequent oxidative stress cascades [89]. However, direct evidence of the ability of PD146176 to
inhibit ALOX15 function is yet to be established and further work is required to verify the function
of ALOX15 in rodent models [91]. Despite these shortcomings, using a double knockout study,
Brütsch and colleagues have established a clear link between ALOX15 activity and a key antioxidant,
glutathione peroxidase 4 (GPX4), in mouse germ cells [90]. In this study, the inactivation of Gpx4
(genotype Gpx4+/−) led to significant sperm defects, including marked reductions in sperm motility
(total, rapid and progressive). These Gpx4+/− mice correspondingly exhibited significantly reduced
litter sizes compared to wild type mice. However, both the motility attributes and the litter sizes of
the animals were significantly improved following a simultaneous knockout of the Alox15 gene (i.e.,
genotype Gpx4+/−/Alox15−/−), thus implicating ALOX15 in the mediation of oxidative damage in the
mouse [90].
In addition to these animal studies, we have recently reported on a possible
role for ALOX15 in human spermatozoa using the selective ALOX15 inhibitor
6,11-dihydro[1]benzothiopyrano[4,3-b]indole (PD146176, Tocris). This (PD146176) inhibits
ALOX15 through non-competitive and non-antioxidant means [92,93] and has previously been shown
to reduce the production of specific ALOX15 metabolites such as 15-HPETE [94] and 13-HODE [95].
Though minimal studies have used PD146176 in spermatozoa, the use of this inhibitor in conjunction
with an oxidative challenge has been documented to give rise to significant ROS reductions in
neuronal cells [96]. This is consistent with our findings in human spermatozoa, that under oxidative
stress conditions ALOX15 inhibition significantly decreased ROS production and lipid peroxidation
levels while also improving the functional competence of sperm populations including their motility,
acrosome reaction rates and ability to undergo sperm-egg interaction processes [88]. Importantly, such
studies are also consistent with those completed in the context of neurological disorders such as
Alzheimer’s disease, where disease progression often relies on oxidative stress and the production of
4HNE. This lipid peroxide end product has been shown to promote the production of amyloid beta
plaques and neuronal death [97–99]. Strikingly, these studies have demonstrated reduced amyloid
plaque production with significant improvements in memory deficits through the inclusion of the
same ALOX15 inhibitor, PD146176 [100,101]. These data provide further evidence for the use of
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PD146176 as a potential therapeutic means to prevent pathologies induced through oxidative stress
and lipid peroxidation.
4. Protecting the Germline from 4HNE-Induced Damage
There are increasing numbers of couples using assisted reproductive technologies (ART) to achieve
conception. This has led to more than 5 million births since the invention of this technology [102].
While ART has undoubtedly changed the lives of many, such technologies are highly expensive and
have a live birth success rate of no more than ~30% [103,104]. There may also be a level of risk
associated with assisted conception where numerous studies have confirmed that higher levels of
DNA damage are present in men with subfertility [105]. This presents the possibility that ARTs could
be inadvertently using damaged sperm cells which may elevate the risk of adverse health outcomes
for the offspring conceived through assisted reproduction [106,107]. Additionally, the lack of selection
pressure on the gametes may eventually propagate further fertility issues for future generations.
A major origin of sperm cell damage arises through the onset of oxidative stress. Congruent with
DNA fragmentation, markers of oxidative stress are also elevated in the infertile population [108]. It is
therefore without surprise that antioxidant supplementation is an extensively studied area for the
mitigation of male infertility. Table 2 summarizes numerous studies that have examined male fertility
following antioxidant supplementation and their corresponding reproductive outcome. This table
was collated through examination of external literature as well as analysis of a variety of detailed
reviews [109–111]. Interestingly, only 5 out of the 28 investigated studies presented improvements to
pregnancy and live birth rates following antioxidant supplementation, with positive effects associated
with astaxanthin [112], L-carnitine + L-acetyl carnitine [113], Menevit® [114], vitamin E [115] and
zinc sulphate [116]. While some studies observed very high levels of variability when measuring
semen parameters, the studies focusing on L-glutathione, lycopene, N-acetylcysteine + selenium,
ubiquinone, selenium and zinc sulphate, consistently presented improvements in at least one or more
semen parameter [116–122]. Other studies using antioxidants such as Co-enzyme Q10, folic acid
+ zinc sulphate, lycopene and L-carnitine + L-acetyl carnitine showed variation in effects between
trials, with some studies reporting improvements to semen parameters [113,118,123–128], while others
showing no positive effects [129–131]. Some of this variation may be attributed to intrinsic variations
within each trial, such as dose regimes, methodology and the duration of treatments. Nonetheless, this
variability, combined with a lack of clinical success in terms of increased pregnancy rates and live birth
rates, highlights a clear need for further investigation into effective alternative strategies to prevent,
or at least limit, ROS production in the male germline to improve a large subset of male fertility issues.
In seeking to account for the lack of consistent clinical success using regimens based on single
antioxidant supplementation as a means for combating male infertility, it is possible that the scavenging
nature of antioxidants [132] fails to provide direct protection against the cascades of lipid peroxidation
and 4HNE production that ensue under conditions of oxidative stress. Interestingly, nucleophiles such
as penicillamine have been shown to successfully reduce cellular ROS in both human spermatozoa
and in oocytes [19,25,133,134]; effects that manifest in the recovery of sperm-oocyte interaction
in vitro [25]. However, this antioxidant has serious off-target toxicity concerns [135], and thus
investigation into the clinical utility of penicillamine is not possible. Another novel antioxidant
formulation therapy in the male germline is Fertilix® (Cell Oxess, Ewing, USA), which has been shown
to protect against DNA damage in antioxidant deficient mice [136]. However, clinical trials have yet to
be performed to establish whether this therapy is an appropriate method for treating infertile men.
Among alternative methods that have shown promise in protecting somatic cells from diseases linked
to lipid peroxidation-dependent mechanisms [137–139], is the stabilization of the lipid membrane
through deuteration [140]. Such success provides an important precedent to investigate the efficacy of
this strategy to protect sperm membranes.
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Table 2. Benefits of antioxidant supplementation for male fertility. A summary of tested antioxidants
and their relative success for the improvement of male fertility as reviewed by Ahmadi et al., Ross et
al., and Majzoub and Agarwal [109–111].
Antioxidant Outcomes References
Astaxanthin
Increased pregnancy rates [112]
Reduced oxidative stress [112]
Co-enzyme Q10
Improved sperm motility [123]
Improved sperm concentration and morphology [124]
Altered antioxidant enzyme activity [124,129]
No improvements to sperm motility, concentration or morphology [129]
Folic Acid + Zinc Sulphate Improved sperm concentration [125,126]
No improvements to sperm motility, concentration or morphology [130]
L-Glutathione Improved motility [117]
L-Carnitine + L-acetyl carnitine
Increased motility (progressive and total) [127,128]
No changes to motility or concentration [131]
Increased pregnancy rates and improved sperm concentration, motility and morphology [113]
Lycopene Improved sperm motility and concentration [118]
Menevit Improved pregnancy rates [114]
N-acetylcysteine
Increased sperm concentration [141]
No significant increase in spontaneous pregnancies [141]
Improved sperm volume, motility and viscosity [142]
Reduced oxidative stress [142]
N-acetylcysteine + Selenium Improved sperm motility, concentration and morphology [119]
Ubiquinone Improved sperm motility, concentration and morphology [143]
Vitamin E
Improved sperm motility [115]
Improved pregnancy rates [115]
Decreased lipid peroxidation products [115]
Vitamin E + Vitamin C
No changes to motility or concentration [144,145]
Reduced DNA damage [144]
Improved ICSI outcomes [146]
Vitamin E + Selenium
Improved morphology [147]
Improved sperm motility [148]
Decreased lipid peroxidation products [148]
Selenium
Improved sperm motility [120]
No changes to sperm concentration [120]
Zinc Sulphate
Improved semen volume, sperm motility and concentration [116,121]
Improved live birth rate [116]
Altered antioxidant enzyme activity [122]
5. Conclusions
In this review we discuss strategies to alleviate oxidative stress in males suffering from fertility
issues (summarized in Figure 2). Here we provide new perspectives on the lipoxygenase–lipid
peroxidation pathway and discuss the merit of ALOX15 as a potential therapeutic target that could be
exploited to protect human spermatozoa against oxidative stress, a key origin of poor cell function.
Overall, this review highlights the importance of correct lipid metabolism in the maintenance of sperm
function and fertility and provides the impetus to explore targeted, lipid-based antioxidant approaches
to prevent lipid-peroxidation induced changes in the male germline.
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Figure 2. Potential strategies to protect human spermatozoa against oxidative stress. This model
explores two strategies to protect against oxidative stress: antioxidant supplementation and
arachidonate 15-lipoxygenase (ALOX15) inhibition. (A) Antioxidant supplementation has been shown
to reduce levels of ROS, hence lipid peroxidation may be prevented, or its products scavenged, allowing
sperm function to be improved. (B) ALOX15 inhibition in human sperm has been demonstrated
to reduce lipid peroxidation and improve sperm function and sperm-oocyte interaction in vitro.
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Abstract: Among the various mechanisms involved in aging, it was proposed long ago that a prominent
role is played by oxidative stress. A major way by which the latter can provoke structural damage
to biological macromolecules, such as DNA, lipids, and proteins, is by fueling the peroxidation of
membrane lipids, leading to the production of several reactive aldehydes. Lipid peroxidation-derived
aldehydes can not only modify biological macromolecules, by forming covalent electrophilic addition
products with them, but also act as second messengers of oxidative stress, having relatively
extended lifespans. Their effects might be further enhanced with aging, as their concentrations
in cells and biological fluids increase with age. Since the involvement and the role of lipid
peroxidation-derived aldehydes, particularly of 4-hydroxynonenal (HNE), in neurodegenerations,
inflammation, and cancer, has been discussed in several excellent recent reviews, in the present
one we focus on the involvement of reactive aldehydes in other age-related disorders: osteopenia,
sarcopenia, immunosenescence and myelodysplastic syndromes. In these aging-related disorders,
characterized by increases of oxidative stress, both HNE and malondialdehyde (MDA) play important
pathogenic roles. These aldehydes, and HNE in particular, can form adducts with circulating or
cellular proteins of critical functional importance, such as the proteins involved in apoptosis in
muscle cells, thus leading to their functional decay and acceleration of their molecular turnover and
functionality. We suggest that a major fraction of the toxic effects observed in age-related disorders
could depend on the formation of aldehyde-protein adducts. New redox proteomic approaches,
pinpointing the modifications of distinct cell proteins by the aldehydes generated in the course of
oxidative stress, should be extended to these age-associated disorders, to pave the way to targeted
therapeutic strategies, aiming to alleviate the burden of morbidity and mortality associated with
these disturbances.
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1. Introduction
In recent years, increased life expectancy due to an improved quality of life and decline in mortality
rates, is leading to a society in which the aging population is growing more rapidly than the entire
population. Life expectancy is projected to increase in industrialized countries. In 2016, 27.3 million
very old adults were living in the European Union, and in the UK, 2.4% of the population (1.6 million)
were aged 85 and over [1]. It has been calculated that there is more than a 50% probability that,
by 2030, female life expectancy will exceed the 90-year barrier, a level that was deemed unattainable
at the turn of the 21st century [2]. The functional disturbances appearing in old age are referred to
as the “aging process”, which entails changes in body composition, imbalances in energy production
and use, homeostatic dysregulation, neurodegeneration and loss of neuroplasticity [3]. The scientific
community has formulated over 300 theories to explain the driving forces behind aging [4], but none
has proven, so far, to be universally applicable. The free radical theory of aging has gained widespread
acceptance, thus becoming one of the leading explanations of the aging process at the molecular level.
It is commonly believed that the aging process is related to an imbalance favoring pro-oxidant over
antioxidant molecules and a consequent increase of oxidative stress [5]. Oxidative stress entails elevated
intracellular levels of reactive oxygen species (ROS), which can cause damage to proteins, lipids,
and DNA. The mitochondria are the primary sources of intracellular ROS (~1–5%), due to the electron
leakage primarily resulting from the electron transport chain [6]. Indeed, mitochondrial dysfunction
has long been considered a major contributor to aging and age-related diseases. In elderly subjects,
mitochondria are characterized by functional impairment, such as lowered oxidative capacity, reduced
oxidative phosphorylation, decreased adenosine triphosphate production, significantly increased ROS
generation, and diminished antioxidant defense [7]. Depending on their concentration in the cells,
ROS are either physiological signals essential for cell life or toxic species which damage cell structure
and functions. In particular, ROS cause the oxidation of polyunsaturated fatty acids in membrane
lipid bilayers, leading eventually to the formation of aldehydes, which have been considered as toxic
messengers of oxidative stress, able to propagate and amplify oxidative injury [8].
Among the aldehydes produced by lipid peroxidation (LPO), malonaldehyde (MDA) and
4-hydroxynonenal (HNE) have gained most attention, since MDA is produced at high levels during
LPO, so that it is commonly used as a measure of oxidative stress, and HNE has been shown to be
endowed with the highest biological activity. The production, metabolism, and signaling mechanisms
of two main omega-6 fatty acids lipid peroxidation products, MDA and HNE, have been extensively
studied and reported in an excellent review [9]. Briefly, MDA and HNE originate from the peroxidation
of polyunsaturated fatty acids. LPO can be described generally as a process under which oxidant,
free radical or non-radical chemical species attack lipids containing carbon–carbon double bond(s).
This process involves hydrogen abstraction from a carbon atom and oxygen insertion, resulting in the
formation of peroxyl radicals and lipid hydroperoxides, as illustrated in Figure 1.
Since aldehydes have high chemical reactivities, mammals have evolved a full set of enzymes
converting them into less reactive chemical species and contributing to the control of their intracellular
concentrations, which reflect the steady-state between the rates of formation by LPO and catabolism
into less reactive compounds. Once formed, MDA and HNE can be reduced to alcohols by aldo-keto
reductases or alcohol dehydrogenases, or can be oxidized to acids by aldehyde dehydrogenases [10].
Moreover, HNE, which is the most reactive among aldehydes, easily reacts with low-molecular-weight
compounds, such as glutathione. This reaction can occur spontaneously or can be catalyzed by
glutathione-S-transferases [10]. HNE and MDA are able to affect several signaling processes. Most of
these effects depend on their ability to bind covalently to proteins and DNA.
21
Antioxidants 2018, 7, 102
Figure 1. Malondialdehyde (MDA) and 4-hydroxynonenal (HNE) formation from polyunsaturated
fatty acids.
Aldehyde–Protein Adduct in Human Disease
LPO-derived aldehydes easily react with proteins, generating a wide variety of intra- and
inter-molecular covalent adducts. Depending on their structural features, they can form Schiff bases
and/or Michael adducts with the free amine group of lysine, the imidazoline group of histidine,
the guanidine group of arginine and the thiol group of cysteine [11]. HNE can affect cell functions,
through its ability to form adducts with proteins involved in signal transduction and gene expression,
including receptors, kinases, phosphatases and transcription factors [11]. MDA can form protein
adducts by specifically modifying the lysyl residues of proteins [12], and modified autologous
biomolecules can generate neoepitopes from self epitopes, capable of inducing undesired innate and
adaptive immune responses, including atherosclerosis [13]. HNE adducts can accumulate progressively
in the vascular system, leading to cellular dysfunctions and tissue damaging effects, which are involved
in the progression of atherosclerosis. Moreover, HNE, by forming HNE-apoB adducts, contributes
to the atherogenicity of oxidized low-density lipoproteins (LDL), leading to the formation of foam
cells [14]. The presence of HNE-protein adducts has been detected in inflammation-related diseases,
such as alcoholic liver disorders and chronic alcoholic pancreatitis, in which the increased formation of
HNE-protein adducts was evidenced in acinar cells adjacent to the interlobular connective tissue [15].
Moreover, HNE-protein adducts have been detected in brain tissues and body fluids in several
neurodegenerative diseases, such as Alzheimer’s disease, Huntington disease, Parkinson’s disease,
amyotrophic lateral sclerosis, and Down syndrome [10].
The involvement of MDA and HNE in age-related diseases has been supported by the observations
that the concentrations of MDA and HNE, in human erythrocytes and blood plasma, increased
during the aging process [16]. The role of reactive aldehydes in age-related pathologies, such as
atherosclerosis [13], neurodegenerations [17], inflammation, and cancer [10] has been discussed by
many excellent reviews. Other age-related disorders, such as osteopenia/osteoporosis, sarcopenia,
immunosenescence and myelodysplastic syndromes have received less attention. In this review,
we focus our attention on to recent advances in the role of LPO-derived aldehydes and aldehyde-protein
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adducts in these age-related disorders, all of which are characterized by increases of oxidative stress
and consequent increases in the generation of LPO-derived aldehydes.
2. Osteopenia/Osteoporosis
Bone remodeling is a highly dynamic physiological process: osteoblasts (bone-forming cells) and
osteoclasts (bone-resorbing cells) work simultaneously to maintain bone density and strength [18].
During aging, bone density decreases and the measure of bone mineral density is commonly employed
to evaluate whether or not a patient is affected by osteopenia or osteoporosis. Osteopenia is the
thinning of bone mass. Such a decrease in bone mass is not usually “severe”, but is considered a very
serious risk factor for the development of osteoporosis. Osteoporosis is characterized by profound
losses of skeletal mass, coupled with architectural deterioration, which increase bone fragility and
susceptibility to fractures. Several recent papers have provided insights into the current prevalence of
osteoporosis in specific older populations. The current National Osteoporosis Foundation guidelines
for the USA, coupled with the most recently available population data from the National Health and
Nutrition Survey, show that the eligibility for osteoporosis treatment increases exponentially with
age; roughly 10% of both men and women meet criteria for treatment at age 50 years, whereas 48%
of men and 79% of women over 80 years meet treatment guidelines [19]. Current treatments for
osteoporosis, which increase bone density and reduce fracture risk, include anti-resorptive medications
(bisphosphonates and denosumab), which primarily increase endocortical bone and cortical thickness,
and anabolic medications (teriparatide and abaloparatide), which increase the periosteal and endosteal
perimeters, without causing large changes in cortical thickness [20].
Increases of ROS levels have been observed consistently in osteopenia and osteoporosis. In aging
people, the number and activity of individual osteoblasts decrease and osteoblast apoptosis increases,
in association with oxidative stress-induced osteoporosis [21]. Some studies explored the relationships
between the use of antioxidants and bone metabolism. Indeed, a marked decrease in plasma
antioxidants was found in aged or osteoporotic rats and in aged or osteoporotic women [22–24].
The loss of antioxidant capacity leads to accelerated bone loss through the activation of a tumor necrosis
factor alpha (TNF-α)-dependent signalling pathway [25]. In turn, the administration of antioxidants
such as vitamin C, E, N-acetyl-cysteine and linoleic acid, had beneficial effects in individuals with
osteoporosis [26].
Osteoblast apoptosis was induced by oxidative stress through the activation of the c-Jun
N-terminal kinase (JNK) pathway [27] and the NF-kB pathway [28]. In unstimulated cells, NF-κB
proteins are sequestered in the cytoplasm because of their association with IκB (inhibitor of κ light gene
enhancer in B cells) proteins. Phosphorylation and degradation of IκB disrupt this association and allow
the translocation of NF-κB proteins into the nucleus. ROS induce the oxidation of critical cysteines
and enhance the activity of several cytoplasmic kinases, which promote IκB phosphorylation and
degradation, including IκB kinase and the PKC family of serine/threonine kinases [29]. Additionally,
ROS-induced modifications control key steps in the nuclear phase of the NF-κB program, including
recruitment of coactivators, chromatin remodeling, and DNA binding. The activation of NF-kB in
osteoblastic cells increased the phosphorylation of p66 (shc) protein, which amplified mitochondrial
ROS generation and stimulated apoptosis [29]. The increase of ROS in osteoblastic MC3T3-E1 cells
induced phosphorylation of MAPKs (mitogen-activated protein kinases), which subsequently triggered
the intrinsic apoptosis pathway. Moreover, the advanced oxidation protein products induced osteoblast
apoptosis in aged Sprague–Dawley rats [30].
The NF-κB pathway is involved in osteoclast activity, as well. Indeed, ROS stimulated osteoclast
differentiation and activity through activation of the NF-κB pathway, and these effects were reversed
upon NF-κB suppression [31].
Other than by the direct actions mentioned above, ROS can affect bone turnover by enhancing the
production of LPO-derived reactive intermediates, thereby causing protein damage and inflammatory
responses [32]. In vitro experiments have proved that HNE, the most biologically active aldehyde
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produced by LPO, can induce intense oxidative stress, inflammatory reactions, and apoptosis in
osteoblasts, via the induction of protein phosphatase 2A activity, which has earned a reputation as a
mediator of oxidative stress-induced apoptosis in these cells [21]. The role of LPO-derived aldehydes
in osteoblast apoptosis is also supported by studies on aldehyde dehydrogenases (ALDH), a family
of enzymes involved in aldehyde degradation [33]. ALDH inhibition by disulfiram resulted in bone
loss in rats [34]. Additional confirmation of the role of ALDH activity in osteoporosis comes from the
results obtained with transgenic mice expressing the Aldh2*2 (Aldh2*2 Tg) dominant-negative form
of ALDH2. These transgenic mice exhibited severe osteoporosis, indicating that ALDH2 regulates
physiological bone homeostasis. Moreover, the Aldh2*2 transgene or treatment with acetaldehyde
induced the accumulation of HNE and the expression of peroxysome proliferator-activated receptor
γ (PPAR-γ) a transcription factor that promotes adipogenesis and inhibits osteoblastogenesis [35].
On the contrary, the activation of ALDH2 by N-(1,3-benzodioxol-5-ylmethyl)-2,6-dichlorobenzamide
(alda-1) had an osteogenic effect, involving increased production of bone morphogenetic protein-2 by
osteoblasts [36]. Taken together, these experimental data seem to delineate a role for the products of
LPO in the induction of osteoporosis. However, the measurements of MDA as an indicator of LPO
in post-menopausal osteoporotic women gave conflicting results. One study disclosed significant
increases in plasma MDA concentrations in post-menopausal osteoporotic women, compared with
control subjects [37], whereas another one failed to detect changes of MDA concentrations between
osteoporotic and non-osteoporotic post-menopausal women [38]. Thus, further studies are needed
to precisely define the role played by LPO-derived aldehydes and to validate the possible inclusion
of targeted therapies aimed to reducing the effects of reactive aldehydes in the development and
progression of age-related osteopenia/osteoporosis.
3. Sarcopenia
Sarcopenia is a geriatric syndrome characterized by a progressive and generalized loss of skeletal
muscle mass, together with low muscle strength and/or poor physical performance in the elderly [39].
A recent study in Brazilians aged 60 years or older demonstrated that the overall prevalence of
sarcopenia in older Brazilians was 17.0%. Sensitivity analysis showed rates of 20.0% in women and
12.0% in men [40]. In order to counteract the age-related muscle decline several interventions have been
explored, including protein supplementation, testosterone replacement in men, estrogen replacement
in women, growth hormone replacement, and treatment with vitamin D. To date, adequate protein
intake and physical exercise are the most promising interventions aiming to prevent and/or delay the
decline of muscle mass [41].
Oxidative stress and inflammation are implicated in the pathogenesis of sarcopenia [42]. It has
been suggested that an increase of oxidative stress might activate apoptosis, leading to the loss of
skeletal muscle fibers, thus contributing to the progression of sarcopenia [43]. Skeletal muscle tissue
is unique, with respect to apoptosis, because muscle cells are one of the three cell types, along with
osteoclasts and cytotrophoblasts, that are multinucleated [44]. The process by which nuclei are
eliminated from multinucleated muscle fibers appears to be similar to apoptosis, since it involves
chromatin condensation and DNA fragmentation. Moreover, it has been suggested that oxidative
stress and the consequent mitochondrial genotoxic damage might play a causal role in the numerical
loss of muscle fibers with aging [45].
Deregulation of redox homeostasis has emerged in recent years as a common pathogenetic
mechanism and potential therapeutic target in collagen VI-related congenital muscular dystrophies,
and in Duchenne muscular dystrophy, as well as in other more prevalent processes, such as age-related
muscle loss [46]. Moreover, sarcopenia can be associated with obesity. This association is defined as
sarcopenic obesity and represents a chronic condition, whose increase in prevalence has been related
to parallel increases in the mean age of the population, the prevalence of obesity, and the changes in
lifestyle during the last several decades [47]. In obese individuals, adipose tissue secretes both bioactive
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molecules, called “adipokines”, and ROS, which might represent the mechanistic link between obesity
and its associated metabolic complications, including sarcopenia [48].
The aging of human skeletal muscle cells is marked by a progressive functional decline of
mitochondria, resulting in the accumulation of ROS [43]. Sod1−/− mice lack the superoxide dismutase
[Cu-Zn] 1 (CuZnSOD1) enzyme and undergo accelerated sarcopenia, i.e., display the characteristics of
aging muscle in an accelerated manner. In Sod1−/− mice, muscle loss was accompanied by a progressive
decline of mitochondrial function, with an increased mitochondrial generation of ROS and faster
induction of mitochondrial-mediated apoptosis and loss of myonuclei. Sod1−/− mice also exhibited
a strikingly increased number of dysfunctional mitochondria near neuromuscular junctions [49].
Increased ROS production is a necessary response to exercise of a sufficient intensity [50]. ROS and RNS
(reactive nitrogen species, such as NO and the peroxynitrite anion) play important roles in the function
of skeletal muscle, as they may mediate muscle adaptive responses, e.g., to physical exercise [51],
by facilitating glucose uptake or inducing mitochondrial biogenesis [52,53]. However, during extended
disuse periods, redox imbalance contributes to deleterious muscle remodeling via myonuclear
apoptosis and atrophy, with the mediation of a redox-sensitive transcriptional regulator, NF-κB [54,55].
ROS can stimulate the production of TNF-α and IL-1β, through the activation of NF-κB-mediated
pathways [56]. Systemic inflammation, impaired responses to stressors, and weakened regenerative
capacity are all associated with sarcopenia. In Wistar rats, aging (40 weeks) was accompanied
by reduced mitochondrial respiratory chain complex activities in saponin-skinned soleus muscle
fibers, increased production of ROS and decreased transcription of the genes encoding mitochondrial
superoxide dismutase 2 (SOD2), PPAR-γ coactivator-1β (PGC-1β) and sirtuin 1, in comparison with
young (16 weeks) rats. Chronic intake of polyphenols normalized Vmax, decreased ROS production
and enhanced SOD2 and PGC-1β expression, in comparison with age-matched untreated rats [57].
Notably, sarcopenia is also accompanied by fat infiltration in the skeletal muscle, which can
not only affect muscle quality and functional performance [58], but might render muscle tissue
prone to oxidative stress-induced LPO. In disease processes marked by increased ROS production,
novel 2,4-dinitrophenylhydrazine (DNPH)-reactive carbonyl groups in proteins, susceptible to
spectrometric or antibody-mediated detection, might be either produced by the direct metal-catalyzed
oxidation of aminoacyl side chains or introduced by stable adduct formation via the reaction of
the latter with reducing sugars or reactive carbonyl species, including MDA and HNE. Age-related
increases in protein carbonyl levels were detected in skeletal muscle by derivatization with DNPH,
followed by fluorescent anti-DNPH antibodies, in descending ranking order, in the extracellular space,
subsarcolemmal mitochondria, intermyofibrillar mitochondria and cytoplasm [59]. By the use of
quantitative proteomics, a number of mitochondrial proteins susceptible to carbonylation in a muscle
type-dependent (slow- vs. fast-twitch) and age-dependent manner were identified in Fischer 344 rat
skeletal muscle. Fast-twitch muscle revealed twice as many carbonylated mitochondrial proteins than
slow-twitch muscle, with 22 proteins showing significant changes (mostly increases) in carbonylation
state with age. Ingenuity pathway analysis revealed that these proteins belonged to functional classes
and pathways known to be impaired in muscle aging, including cellular function and maintenance,
fatty acid metabolism and citric acid cycle. Although proof was not provided that carbonylation was
responsible for any functional changes, these data delineated a catalog of protein targets deserving
investigation, because of their potential implication in muscle aging [60]. In the gastrocnemius muscle
of male C57B1/6 mice, a distinct increase of HNE adducts was noticed, upon the progression of age
from 5 to 25 months. This was accompanied by increased expression of inducible nitric oxide synthase,
decreased expression of G6PDH, activation of JNK, caspase 2, caspase 9, and inactivation of BCL-2,
through phosphorylation at Ser70 [61]. Other observations have been collected in transgenic mice
expressing a dominant-negative form of ALDH2 (ALDH2*2 Tg mice), which indicate a role of HNE as
an inducer of apoptosis. Mice, in whose muscles ALDH activity was selectively attenuated, exhibited
small body size, muscle atrophy, decreased fat content, osteopenia, and kyphosis, accompanied by
increased muscular HNE levels [62].
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Oxidative stress, in sarcopenic patients, can lead to increased LPO production. The mechanistic
importance of apoptosis in the loss of muscle cells in age-related sarcopenia and the involvement of
LPO-derived aldehydes in this process are supported by several studies. The abundance of protein
carbonyl adducts was determined within skeletal muscle sarcoplasmic, myofibrillar, and mitochondrial
protein subfractions from musculus vastus lateralis biopsies, using immunoblotting techniques, in two
groups of 16 old males (“old” and “old sarcopenic”) [63]. Concentrations of cytoprotective proteins
(e.g., heat shock proteins, αβ-crystallin) were also assayed. Aging was associated with increased
mitochondrial (but not myofibrillar or sarcoplasmic) protein carbonyl adducts, independent of (stage-I)
sarcopenia. Mitochondrial protein carbonyl abundance negatively correlated with muscle strength, but
not muscle mass. According to this study, mitochondrial protein carbonylation increased moderately
with age, and this increase might impact upon skeletal muscle function, but was not a hallmark of
sarcopenia, per se. It should be considered, though, that the subjects under study were affected by
low-grade (stage-I) sarcopenia [63].
A recent study, conducted with an urban Spanish cohort of elderly people (≥70 years),
demonstrated a significant increase of MDA and HNE in blood samples of sarcopenic subjects,
with respect to sarcopenia-exempt control subjects [64]. Notably, among several parameters examined in
this study, only MDA and HNE levels were significantly associated with sarcopenia. These observations
have been confirmed by studies demonstrating the presence of plasma MDA/HNE protein adducts
in sarcopenic patients [65]. Interestingly, proteomic analysis of muscle extracts from adult and aged
post-menopausal women demonstrated that ALDH2 and AKR1A1 were up-regulated in aged women,
suggesting that the scavenging of reactive aldehyde products in skeletal muscle cells of the elderly was
enhanced [66]. These results may be interpreted as a demonstration of the existence of a mechanism of
adaptation of muscle cells to increased oxidative stress and to the consequently increased production
of LPO-derived aldehydes.
Taken together, these results support a pathogenic link between oxidative stress, LPO-derived
aldehydes, aldehyde-protein adducts and age-related sarcopenia in humans.
4. Immunosenescence
Immunosenescence takes a relevant part in the aging phenotype, and there is growing
consensus on the idea that it might result from a progressive imbalance, favoring inflammatory
over anti-inflammatory mechanisms, which some authors define as “inflammaging”. According
to this view, continuing antigenic stimulation in the course of life, with accompanying oxidative
stress, steadily leads, as enzymatic and non-enzymatic antioxidant defences fade off with age, to an
up-regulation of inflammatory responses and a remodeling of immune responses, as revealed by the
increased serum levels of pro-inflammatory cytokines, such as IL-6 and TNF-α, and a loss of efficacy of
adaptive responses. Pro-inflammatory cytokines stimulate further the generation of ROS and cytotoxic
LPO products.
As already well documented in other tissues and organ systems, accumulation of ROS and LPO
products might cause significant damage to cell lipids, nucleic acids and crucial cell proteins also in
cells of the immune system. This pro-inflammatory condition negatively affects the overall chances for
good health, self-sufficiency and extended survival of the elderly and is a hallmark of the so-called
“fragility” of the elderly [67,68]. Moreover, the remodeling of immunity strongly contributes to a
number of age-associated diseases (infectious diseases, autoimmunity, cancer, metabolic, vascular and
neurodegenerative diseases). Immunosenescence is best revealed by the changes in the modulation
of survival of T cells, which become more resistant to damage-induced apoptosis. As a consequence,
CD28-senescent T cells increase in number (with effector/memory cells, most of the CD8+ CD45RO+
CD25+ phenotype, prevailing over naïve cells), dysfunctional cells accumulate, and the immunological
space in lymphoid tissues is reduced. Increased activation-induced cell death (AICD), in response to
TNF-α, causes a progressive depletion of lymphoid niches, particularly of the naïve T cell compartment.
At the same time, the generation of immunocompetent T cells in thymus declines with age [68–72].
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The age-dependent shortening of DNA telomeres, which is associated with increased mortality in
individuals over 65 years of age, contributes to the reduction of the potential for clonal expansion and
differentiation of naïve T cells, which is revealed by the dramatic decay of T-cell-receptor excision
circles (TREC). The overall outcome is a reduction in the repertoire of clonal antigenic specificities,
which is reflected in a decreased ability to enact recall immune responses to formerly encountered
antigens (e.g., cytomegalovirus, CMV) and to mount adaptive responses to novel antigenic stimuli,
combined with an increased tendency to autoimmunity [68–72]. The inversion of the CD4+/CD8+ cell
number ratio, the increased fraction of effector-memory cells and the seropositivity for CMV identify
an immune risk phenotype in elderly patients [73]. Reduced B cell function with age reflects the
decreases both of CD19+ cell number and of T helper-mediated cooperation with B cell responses.
Age-associated changes in innate immunity include reductions of antigen uptake by DCs, phagocytosis
and production of lymphocyte-derived chemotactic factor by macrophages, FCγRIII (CD16)-stimulated
production of superoxide anion by neutrophils, and IFN-γ secretion and expression of activating NKp
receptors by NK cells.
Thymus involution is associated with a drastic reduction in organ volume and replacement of
functional cortical and medullary areas with adipose tissue. This process, which starts early in life,
is almost complete by the age of 40–50 years. Increasing formation of lipid-laden cells with aging
has also been observed in lympho-hematopoietic organs, including the thymus [74,75]. Age-related
thymic involution appears to reflect the compound effects of increased rates of thymocyte death in
the thymus and decreased thymic differentiation and output of T cells. The former might result
from intrathymic inflammation and lipotoxicity, the latter from the failure of stromal cell-dependent
thymocyte maturation and survival (Figure 2) [76].
Figure 2. Main aspects of thymic involution. The decrease of hematopoietic cells causes a decrease of
production of T cells from the thymus. HSC: hematopoietic stem cells; LIF: leukemia- inhibitory factor;
OSM: Oncostatin M; SCF: stem cell factor; IL-2: interleukin 2; IL-6 interleukin 6; IL-7: interleukin 7;
IGF-1: insulin-like growth factor 1; TREC: T cell receptor excision circles (modified from [68]).
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The levels of pro-inflammatory chemokines (MIP-1α, MIP-1β, RANTES) secreted by activated
DC, macrophages and endothelial cells and recognized by CCR5 increase in the aging thymus, just
like intrathymic lipid-laden multilocular and adipose cells (LLC), whose number is inversely related
with thymic function [76]. It was suggested that LLC derive from CCR5-expressing, perithymic and
perivascular preadipocytes, migrating into the aging thymus [77]. They produce pro-inflammatory
cytokines (LIF, Oncostatin M, IL-6, TNF-α), thus creating a pro-oxidative, cytotoxic intrathymic milieu,
which might favor thymocyte death [77]. The age-related alterations of lipid metabolism and redox
balance were studied in mouse thymus and isolated thymocytes. An evaluation of the lipidomics
profile of the whole thymus, between the ages of 4 weeks (young age) and 18 months (old age),
revealed increased amounts of triacylglycerides, cholesterol, HNE, sulfatide ceramide and ganglioside
GD1a in the aged thymus. Increased levels of cholesterol esters and HNE adducts were also found in
isolated thymocytes from elder mice, compared with younger individuals. Increased levels of TNF-α
and increased expression of CD204, a scavenger receptor of oxidized LDL, were detected in the thymic
parenchyma of older individuals, as compared to younger ones. GH reduced thymic levels of TNF-α
and HNE and increased the number of thymocytes, in accordance with several observations that
indicated growth hormone as a powerful immunomodulating agent, stimulating thymopoiesis and
limiting the number of adipocytes and fat locules in rodent and human thymus [74]. The levels of MDA
and protein carbonyls (PC), as well as of oxidized and reduced glutathione and the activities of several
antioxidant enzymes were measured in peripheral blood lymphocytes from 100 individuals, equally
subdivided into groups of ages varying from 11–20 to 51–60 years. This study evidenced distinct,
steady increases in MDA and PC levels with age, and decreasing glutathione levels and antioxidant
enzyme activities, documenting a progressive redox imbalance with aging [78]. When rats subjected
to ovariectomy, which undergo premature aging of the immune system, were subjected to dietary
supplementation with polyphenolic antioxidants (soybean and green tea polyphenols), beneficial
effects were observed on several parameters of the immune function (macrophage phagocytosis,
chemotaxis and ROS production; lymphocyte mitogenic responses; NK activity) and redox balance
(catalase and glutathione peroxidase activity, oxidized versus reduced glutathione ratio, MDA levels)
of peritoneal leukocytes [60].
5. Myelodysplastic Syndromes
Myelodysplastic syndromes (MDS) include a heterogeneous range of stem cell disorders
characterized by peripheral cytopenias and increased risk of progression to acute myeloid leukemia.
The incidence of MDS increases markedly with age. It is conservatively estimated that >10,000 new
cases of MDS occur in the United States annually [79]. In MDS, next-generation sequencing allowed the
identification of molecular mutations in nearly 90% of the patients. Consequently, molecular mutation
markers were integrated into current classification systems. The growing insights into molecular
aspects of the pathogenesis of MDS may help to predict the possible evolution towards leukemia [80].
Most MDS patients have anemia and many develop transfusion dependence and iron overload
(IOL). IOL is considered a negative independent prognostic factor, associated with a higher risk of
leukemic transformation and shorter survival [81]. Serologic and molecular markers of oxidative stress
have been evidenced in many patients with MDS [82], with the concentration of the LPO product MDA
being significantly increased in patients with MDS and IOL, compared with IOL-exempt patients and
control subjects. Moreover, both plasma nitrite and MDA concentrations were positively correlated
with the ferritin levels, suggesting a relationship between IOL and the increased production of ROS
in MDS [83]. In regard, it has to be noticed that the impact of iron on the redox balance of cells and
body fluids is strictly dependent on transferrin saturation (TSAT). In the presence of normal TSAT,
the M1 polarization of macrophages is decreased and the production of pro-inflammatory cytokines,
ROS and LPO products are inhibited [84]. Conversely, patients with IOL and high TSAT show higher
O2% saturation levels than patients at the time of diagnosis and normal controls. Antioxidant systems,
with the exception of SOD, exhibit significant activity changes in IOL patients, compared with controls.
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Moreover, iron chelation treatment with deferoxamine has also been shown to reduce cytopenia in
patients with MDS. In a study of 11 patients with MDS who were receiving deferoxamine for up to
60 months, increases in platelet and neutrophil counts were observed in 64% and 78% of patients,
respectively [85]. Furthermore, mitochondrial dysfunction has been detected only in IOL cases, but not
in control subjects [86]. High-level ROS production in MDS can be responsible for genotoxic damage
to nuclear and mitochondrial DNA, resulting in genomic instability, which contributes to disease
progression and leukemia onset [87,88].
Even though the role of ROS in MDS is well established, the role played by LPO products in
the disease and its progression has not been completely assessed. It was suggested that the loss of
ALDHs, which are mainly responsible for the metabolism of reactive aldehydes, might lead to the
alteration of various cell processes, which may foster MDS progression to leukemic transformation [89].
Recent data indicate that ALDH1A1-defective cell lines, as well as primary leukemic cells, are sensitive
to the treatment with drugs that directly or indirectly generate toxic ALDH substrates, including HNE.
On the contrary, normal HSCs are relatively resistant to these compounds, suggesting that LPO-derived
aldehydes could selectively kill ALDH1A1-defective leukemic cells [90]. According to these observations,
in human lymphoid leukemic CDM-NKR cells, high concentrations of HNE caused significant cytotoxic
effects on DNA synthesis and mitochondrial activity, whereas no significant toxicity of HNE was
detected in normal hematopoietic precursor cells [91]. In addition, murine erythroleukemia (MEL)
cells from HNE-treated mice exhibit a higher degree of differentiation, in comparison with dimethyl
sulfoxide-treated MEL cells. These findings indicate that HNE, at concentrations physiologically
detected in many normal tissues and in plasma, induces MEL cell differentiation, by modulating the
expression of specific genes [92].
However, the role of HNE and other reactive aldehydes in the development of leukemia is
controversial. The ALDH1A1 and ALDH3A1 isoforms are important for the metabolism of reactive
aldehydes and ROS, and are expressed at high levels in HSCs. Indeed, the loss of these two isoforms
resulted in a variety of effects on HSC biology, such as increased DNA damage and increased rates
of leukemic transformation [93]. On the other hand, ALDH activity in human leukemic cells also
mediates resistance to a number of drugs [94], and high levels of ALDH activity are predictors of
poor therapeutic outcomes [95]. These conclusions are supported by the identification, by the in silico
screening of the Gene Expression Omnibus database, using the PTL gene signature as a template,
of 2 new agents, celastrol and HNE, which were able to eradicate acute myeloid leukemia (AML) at
the bulk, progenitor, and stem cell level [96].
Serologic and molecular markers of oxidative stress in patients with MDS include increased
concentrations of the LPO product MDA and the presence of oxidized bases in CD34+ cells. Potential
mechanisms of oxidative stress include mitochondrial dysfunction via IOL and mitochondrial DNA
mutation, systemic inflammation, and bone marrow stromal defects [82]. MDA levels in plasma
correlated moderately with serum ferritin and free iron levels and were significantly higher in MDS
patients with iron overload, when compared to healthy blood donors, once more emphasizing the role
of oxidative stress in the development of MDS [97]. Moreover, a cytoprotective effect was reported
of erythropoietin on the plasma membrane of erythroid cells in MDS, which was closely reminiscent
of effects detected in certain conditions of impaired glucose metabolism, which were associated with
increased LPO-dependent cell stress in the elderly [98]. The selective cytotoxic activities exhibited by
LPO products towards transformed hematopoietic cells might be partly responsible for the effectiveness
of hypomethylating drugs, widely employed in the chemotherapy of AML and MDS. In fact, the use
of these chemotherapeutic agents is associated with the generation of enormous amounts of ROS.
Antioxidant supplementation in these patients must be approached with caution, because of the high
probability that it might result in significant reductions of the therapeutic efficacy of hypomethylating
drugs, whose cytotoxic effect is probably mediated by plasma MDA concentrations, which increase
significantly during the 14-day post-chemotherapy period [99].
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In conclusion, it appears that the overall effects of LPO products within the context of MDS
are strictly dependent on their concentrations, the degree of inflammation and the disease phase.
Physiological HNE and MDA concentrations in an early phase of MDS, with low-grade inflammation
and normal iron concentrations, seem to favor blast apoptosis and normal hematopoietic cell
differentiation in bone marrow niches, whereas high HNE and MDA concentrations in later phases
of MDS, with high-grade inflammation and higher than normal iron levels, might favor normal cell
death and awry maturation of bone marrow cells [99].
6. Conclusions
From the overall body of evidence presented, the pathogenic involvement of oxidative
stress and lipid peroxidation appears to be firmly grounded in all of the senile pathological
and dysfunctional conditions examined in this review. In turn, increases in the production of
ROS and reactive aldehydes from lipid peroxidation concur to induce apoptosis, which has been
observed during aging in osteoblasts, muscle cells, thymocytes and hematopoietic cells. The use of
antioxidants as an adjuvant therapy to counteract ROS increases in these disorders gave interesting
results [26,87,100,101]. However, the efficacy of antioxidants in reducing the concentrations of
aldehydes and/or protein-aldehyde adducts in blood or in tissues has not yet been measured. It is
our conception that osteoporosis/osteopenia, sarcopenia, immunosenescence and myelodysplastic
syndromes may all represent concurring expressions of the age-related decay of molecular turnover
and repair capabilities in post-mitotic cells, altogether expressing themselves as the progressive
multiorgan/multisystem failure of senescence. A few systematic redox proteomic approaches,
pinpointing the modifications of distinct cell proteins with LPO products generated in the course of
oxidative stress, have been conducted to date, mostly in the skeletal muscle of rodents. It is warranted
that studies of this kind be extended to the other organ systems undergoing age-associated decay,
and be complemented by functional studies as well. We anticipate that continuing investigation in this
field may pave the way, in the end, to targeted therapeutic strategies aiming to alleviate the burden of
morbidity and mortality associated with these disturbances.
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Abstract: Covalent modification of functionally important cell proteins by lipid oxidation products
(LOPs) is a known mechanism initiating pathological consequences of oxidative stress. Identification
of new proteins covalently modified by electrophilic lipids can be performed by a combination of
chemical, immunological, and mass spectrometry-based methods, but requires prior knowledge
either on the exact molecular structure of LOPs (e.g., 4-hydroxynonenal) or candidate protein
targets. However, under the conditions of oxidative stress in vivo, a complex mixture of proteins
(e.g., cytosolic proteome) reacts with a complex mixture of LOPs. Here we describe a method
for detection of lipid-modified proteins that does not require an a priori knowledge on the
chemical structure of LOPs or identity of target proteins. The method is based on the change
of electrophoretic mobility of lipid-modified proteins, which is induced by conformational changes
and cross-linking with other proteins. Abnormally migrating proteins are detected by mass
spectrometry-based protein peptide sequencing. We applied this method to study effects of oxidized
palmitoyl-arachidonoyl-phosphatidylcholine (OxPAPC) on endothelial cells. Several known, but also
many new, OxPAPC-binding proteins were identified. We expect that this technically relatively
simple method can be widely applied for label-free analysis of lipid-protein interactions in complex
protein samples treated with different LOPs.
Keywords: lipid oxidation; oxidized phospholipids; lipid-protein adducts; electrophoretic mobility
shift assay; gel-shift; proteomics; mass spectrometry
1. Introduction
Lipid oxidation is a characteristic feature of chronic inflammation associated with a variety of
pathologies including, e.g., cardiovascular and neurodegenerative disease [1–5]. Oxidation of free or
esterified polyunsaturated fatty acids (PUFAs) can be induced by reactive oxygen and nitrogen species
or by multiple enzymes, generating a variety of bioactive compounds. In particular, oxidation of sn-2
PUFA residues in phospholipids (PLs) generates a variety of full-length and truncated reactive oxidized
PLs (OxPLs), which are increasingly recognized for their pleiotropic biological action including
proinflammatory and prothrombotic effects, as well as stimulation of angiogenesis and protection
of lung endothelial barrier [6]. OxPLs are known to be present in blood and tissues; their total
concentrations in pathological conditions can reach micromolar range, while in atherosclerotic vessels
total concentrations of several molecular species may be in a high micromolar range [1]. Lipid oxidation
products (LOPs) containing electrophilic terminal aldehyde or α,β-unsaturated carbonyl groups can
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react with nucleophilic groups of biomacromolecules, such as thiol and amino groups of proteins,
forming covalent Michael adducts or Schiff bases. Adduction of LOPs to proteins can alter protein
structure and function, and consequently influence cellular signal transduction pathways [1,7,8].
This covalent modification of proteins may be quite selective, for example, modification of the
β-subunit of IκB kinase prevents IκBα degradation and NF–κB activation [9]. Therefore, the knowledge
of protein targets of LOPs is a prerequisite for better understanding of mechanisms of oxidative stress.
Several approaches to identify protein targets of LOPs that have been developed in the last years can
be divided in two groups. The majority of studies identified proteins in crude preparations, e.g., cytosolic
proteins, that were modified by a specific chemically-pure LOP, e.g., HNE (4-hydroxynonenal). Another
group of publications analysed specific amino acid residues within a defined protein, which may
be modified by one or different reactive LOPs. The most extensively investigated lipid-derived
electrophile is HNE. Identification of HNE-protein adducts has been performed mainly by following
three approaches: (i) tandem mass spectrometry (MS/MS and MS3)-based detection of HNE-modified
peptides [10,11]; (ii) immune detection of HNE-protein adducts by Western blotting followed by liquid
chromatography tandem mass spectrometry (LC-MS/MS)-based identification of immunoreactive
protein bands [12–14]; and (iii) attachment of biotin through click chemistry and enrichment of
modified proteins or peptides using immobilized streptavidin. A variety of carbonyl-reactive probes
have been developed to capture HNE-modified proteins and other carbonyl-containing compounds.
These probes contain typically hydrazide or aminooxy functional groups, which are conjugated with
biotin for streptavidin-based enrichment [15–19]. In addition to these post-labeling strategies, synthetic
alkynyl- and azido-derivatives of HNE have been used to treat cells or isolated proteomes followed
by biotin/streptavidin-based purification of modified proteins [20,21]. Site-specific characterization of
cysteine modifications by different LOPs using thiol-specific probes was reported by Wang et al. [22].
With this chemoproteomic method, which is based on the quantification of unmodified cysteines
(because LOP-modified cysteines are protected from thiol-specific labelling), >1000 reactive cysteines
were quantified in isolated proteomes.
In contrast to the relatively well investigated protein targets of HNE, proteomic approaches to
identify OxPL-protein adducts, are rather limited, because the enrichment methods that are reported
for HNE-protein adducts cannot be directly applied to OxPLs.
Gugiu et al. used biotinylated 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphoethanolamine
(PAPE), which was oxidized on air to generate biotin-labeled OxPAPE (OxPAPE-N-biotin), to identify
OxPAPE protein targets from human aortic endothelial cells [23]. Biological activity of OxPAPE-N-biotin
was proven by upregulation of mRNA of inflammatory genes. Biotinylated OxPAPE-protein
adducts were enriched with avidin beads, separated by sodium dodecyl sulfate polyacrylamide gel
electrophoresis (SDS-PAGE) and detected by Western blotting using HRP-streptavidin (horseradish
peroxidase-streptavidin). Protein bands containing biotinylated adducts detected by Western blot
analysis were cut from an SYPRO Ruby stained gel and subjected to mass spectrometric identification.
Overall, 29 mainly cytosolic and mitochondrial proteins could be identified from positively-stained
protein bands, which were proposed as potential targets of OxPAPE in endothelial cells.
A similar approach was reported by Tallman et al. using a biotin-modified 1-palmitoyl-2-
linoleoyl-sn-glycero-3-phosphatidylcholine (PLPC) probe to identify protein targets of OxPLs in
human plasma [24,25]. In contrast to Gugiu et al., the eluate from streptavidin column was directly
analysed by mass spectrometry (MS) resulting in the identification of 21 plasma proteins representing
potential targets of this synthetic PC.
Fluorescently-labelled OxPL species represent a further method to detect OxPL-protein
adducts. Stemmer et al. used synthetic BODIPY-labeled 1-palmitoyl-2-(5-oxovaleroyl)-sn-glycero-
phosphoethanolamine to identify OxPL target proteins from mouse macrophages [26]. Proteins
were separated by 1D and 2D gel electrophoresis followed by in-gel digestion and MS/MS based
identification of proteins present in fluorescent protein spots/bands.
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Multistep reversed phase C18-solid phase extraction enrichment in combination with aminolysis
was applied by Gao et al. to enrich OxPL-modified peptides from unmodified peptides based on
differences in hydrophobicity [27]. In this study, human platelets were incubated with liposomes
containing 9-keto-12-oxo-10-dodecenoate-PC (KODA-PC) followed by cell lysis and tryptic in-solution
digestion. Resulting peptides were first fractionated by C18-SPE into hydrophobic OxPL-modified
peptides and hydrophilic peptides. Afterwards, hydrophobic OxPL-modified peptides were subjected to
aminolysis, resulting in cleavage of the oxidized fatty acid at sn-2 position from the backbone. The resulting
peptide-lipid electrophile adducts, which are much more hydrophilic than their precursors, were finally
separated by C18-SPE from other hydrophobic compounds. MS/MS-based identification of peptide-lipid
electrophile adducts resulted in the identification of 6 KODA-PC-modified proteins.
The abovementioned methods allowed the identification of a variety of potential targets of OxPLs.
However, all these approaches have some drawbacks because they are either quite biased, since only
a single LOP or a very small set of well-defined LOPs can be used, or require labelling or chemical
modification of LOPs. Label-free identification of LOP-protein/peptide adducts using MS/MS requires
knowledge of the exact structure of the LOP used. Furthermore, protein identification is often based
on only one or two sequenced LOP-modified peptides. Antibody-based detection of unlabelled
LOP-protein complexes from gels may result in false-positive hits, since not all proteins identified from
a single spot/band are modified. Labelling or chemical modification for click chemistry may alter
intrinsic properties of LOPs and, thus, may influence reactivity, selectivity and specificity of binding.
Here we report a novel straightforward approach to identify protein targets of OxPLs without
labelling of the lipids or chemical reactions after the binding has occurred. The method is based
on MS detection of changes in electrophoretic mobility of proteins covalently modified with
electrophilic OxPLs as compared to intact proteins. The method is in principle independent of
the general chemical nature of electrophilic LOPs (e.g., free or esterified), chemistry of covalent
protein modification (e.g., Michael adduction, Schiff base formation), complexity of the LOP-sample
(e.g., individual molecular species or complex mixtures such as OxPAPC, OxPAPE, oxidized
palmitoyl-arachidonoyl-phosphatidylserine, etc.) or proteome (e.g., a pure protein, cell lysate,
membrane-associated proteins, etc.). In other words, this is a technically straightforward, universal and
unbiased method. Here we describe the application of this method for identification of OxPL-binding
proteins in cytosolic and membrane fractions of endothelial cells.
2. Materials and Methods
Unless otherwise specified, all reagents were from Sigma-Aldrich (St. Louis, MO, USA).
2.1. Lipids and Cell Culture
1-Palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine (PAPC) was obtained from Avanti Polar
Lipids (Alabaster, AL, USA) and oxidized by prolonged exposure of pure lipid to air [28]. The extent
of oxidation was monitored by positive ion electrospray MS.
Human umbilical vein endothelial cells (HUVEC) immortalized by telomerase overexpression
were kindly provided by Dr. Hannes Stockinger (Medical University of Vienna, Austria). The cells
were cultured in Nunclon Delta T75 flasks or six-well plates (Thermo Fisher Scientific, Waltham,
MA, USA) in medium 199 (Gibco, Carlsbad, CA, USA) supplemented with 20% foetal calf serum,
penicillin-streptomycin-amphotericin B (Lonza, Basel, Switzerland), and ECGS-heparin (PromoCell,
Heidelberg, Germany) in the 95% humidified atmosphere with 5% CO2 at 37 ◦C. For protein isolation,
90% confluent HUVECs in flasks were washed three times with 10 ml of phosphate buffered saline
(PBS) followed by harvesting in PBS containing cOmplete™ Protease Inhibitor Cocktail (PBS-PI) using
a scraper. Cells were pelleted by centrifugation at 450× g for 10 min.
For Western blotting, HUVECs were cultured until 80% confluence in six-well plates. Prior
to OxPAPC treatment, cells were washed with serum-free medium. OxPAPC in PBS (or the same
volume of PBS without OxPAPC) was added to a final concentration of 80 μmol/L. Cell medium
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was removed immediately or after 6 h followed by cell scraping in PBS-PI. Cells were pelleted
by centrifugation at 450× g for 10 min and resulting cell pellets were resuspended in RIPA buffer
(radioimmunoprecipitation assay buffer) containing protease inhibitors (RIPA-PI). Cell lysis was
performed by sonication on ice.
2.2. Isolation of HUVEC Proteomes
Cells harvested from 10 T75 flasks were pooled, resuspended in 5 mL ice-cold PBS-PI and lysed
by sonication on ice. After incubation of the suspension at 4 ◦C for 30 min with gentle shaking,
PBS-insoluble material was pelleted by centrifugation at 17,000× g for 40 min. The supernatant
containing “PBS-soluble proteins” was transferred to a new vial. The remaining pellet was washed five
times with 5 mL of PBS-PI followed by centrifugation at 17,000× g for 40 min. The supernatant was
discarded, the pellet redissolved in RIPA buffer and incubated at 4 ◦C for 30 min with gentle shaking.
RIPA buffer enables efficient cell lysis and solubilization of membrane proteins while avoiding the loss
of protein immunoreactivity. The final solution is composed of 150 mmol/L NaCl, 1.0% (v/v) IGEPAL®
CA-630, 0.5% (w/v) sodium deoxycholate, and 0.1% (w/v) SDS (sodium dodecyl sulfate), 50 mmol/L Tris,
pH 8.0. After centrifugation at 17,000× g for 40 min, the supernatant (“PBS-insoluble/RIPA-soluble
proteins”) was transferred to a new vial. Protein concentration was determined using the Pierce™
BCA Protein Assay Kit (Thermo Fisher Scientific).
2.3. Electrophoretic Mobility Band Shift Analysis (EMSA)
OxPAPC treatment of isolated proteomes was performed with 12 μg of protein in PBS-PI or
RIPA-PI buffer with varying OxPAPC concentrations ranging from 40–100 μmol/L in a final volume of
30 μL. Samples were incubated at 37 ◦C with gentle shaking. Formation of OxPL-protein adducts was
stopped by addition of 10 μL 4× Laemmli buffer (250 mmol/L Tris-HCl, pH 6.8, 40% (v/v) glycerol,
8% (w/v) SDS, 0.02% (w/v) bromophenol blue, and 10% (v/v) 2-mercaptoethanol) after 0 or 90 min
followed by heating for 5 min at 95 ◦C. Band shift analysis was performed by standard SDS-PAGE using
commercial 4–20% TGX gels (Bio-Rad Laboratories, Hercules, CA, USA) or homemade 10% acrylamide
Tris/glycine gels (composition of the separating gel: 10% (v/v) acrylamide/bis-acrylamide (37.5:1),
375 mmol/L Tris-HCl, pH 8.8, 0.1% (w/v) SDS, 0.033% (w/v) ammonium persulfate, and 0.066% (v/v)
tetramethylethylenediamine; composition of the stacking gel: 3.9% (v/v) acrylamide/bis-acrylamide
(37.5:1), 125 mmol/L Tris-HCl, pH 6.8, 0.1% (w/v) SDS, 0.05% (w/v) ammonium persulfate, and 0.1% (v/v)
tetramethylethylenediamine). Electrophoresis was performed with the Mini-Protean Tetra System
(Bio-Rad) using a Tris/glycine/SDS running buffer (25 mmol/L Tris, 192 mmol/L glycine, 0.1% (w/v)
SDS, pH 8.3) and keeping the current constant at 15 mA per gel. A total amount of 5 μg of protein in
Laemmli buffer was applied to each slot. Visualization of protein bands was done by the EMBL silver
staining protocol [29]. Proteins from samples incubated for 90 min with and without OxPAPC were
selected for proteomics-based identification. To this end, the whole gel (above a molecular weight of
~15 kDa) was cut into multiple pieces with special attention to cut gel pieces of treated and untreated
samples at exactly the same position.
2.4. In-Gel Protein Digestion and Nano-LC-MS/MS Analysis
For in-gel digestion protein bands were excised, washed for 10 min each with 200 μL 50 mmol/L
NH4HCO3 and NH4HCO3: acetonitrile 1:1, followed by dehydration with acetonitrile (HPLC grade,
VWR, Radnor, PA, USA). Each sample was then subjected to reduction with 100 μL of a 50 mmol/L
NH4HCO3 solution, containing 10 mmol/L dithiothreitol at 54 ◦C for 30 min, and to alkylation with
150 μL of a 50 mmol/L NH4HCO3 solution, containing 50 mmol/L iodoacetamide for 20 min at room
temperature in the dark. The gel slices were then washed again with 50 mmol/L NH4HCO3 followed
by washing with acetonitrile and drying in a vacuum centrifuge. For in-gel digestion, the gel slices
were rehydrated in 15 μL of a trypsin solution (5 ng/μL; sequencing grade Trypsin, Roche, Basel,
Switzerland) in 50 mmol/L NH4HCO3 and incubated overnight at 37 ◦C. Peptides were extracted from
40
Antioxidants 2018, 7, 116
the gel matrix with 25 μL 50 mmol/L NH4HCO3 and subsequently two times with 25 μL of 5% (v/v)
formic acid in an ultrasonic bath. All supernatants were combined and analysed by nano-LC-MS/MS.
Nano-LC separations were performed on an UltiMate 3000 RSLCnano system (Thermo Fisher
Scientific, Waltham, MA, USA). The flow rate of the nano-HPLC system was set at 250 nL/min and the
UV absorbance was detected at λ = 214 nm. The flow rate of the loading pump was set at 20 μL/min.
The trap column dimensions were 300 μm id × 5 mm length, packed with PepMap C18 (Thermo Fisher
Scientific, Waltham, MA, USA). After a sample loading time of 10 min, the trap column was switched
in line with the nanocolumn. The sample was eluted in back flush mode. The mobile phases were:
(A) 99.9% (v/v) water (HPLC grade, VWR) and 0.1% (v/v) formic acid; and (B) 80% (v/v) acetonitrile
(HPLC grade, VWR) and 0.08% (v/v) formic acid. The mobile phase for the loading pump was water with
0.05% (v/v) trifluoroacetic acid. The HPLC gradient for separation was 4% B for 10 min, 4–40% B in 90 min,
and 40–90% B in 5 min, 90% B for 5 min, 4% B for 20 min. For separation an Acclaim PepMap RSLC
column (C18, 75 μm × 150 mm, 2 μm, 100 Å; Thermo Fisher Scientific, Waltham, MA, USA) was used.
Eluted peptides were ionized via stainless steel emitters using a Nanospray Flex™ ion source (Thermo
Fisher Scientific) and directly introduced into a LTQ XL mass spectrometer (Thermo Fisher Scientific).
The following electrospray ionization parameters were used: spray voltage, 1.7 kV; capillary
temperature, 200 ◦C; capillary voltage, 30 V. The collision energy was set automatically depending on the
mass of the parent ion. The data were collected in the centroid mode using one MS experiment followed
by five MS/MS experiments of the most intensive ions (intensity at least 5 × 103). Dynamic exclusion was
used for data acquisition with exclusion duration of 2 min and an exclusion mass width of ±1.5 Da.
For peptide identification, RAW-files were converted into MGF-files using ProteoWizard [30]
and analysed with the MASCOT search engine (Matrix Science, London, UK). All MS/MS spectra
were searched against the SwissProt protein sequence database. Following search parameters were
used: carbamidomethylation on cysteine was set as a fixed modification; oxidation on methionine
was set as a variable modification; trypsin was set as enzyme; the precursor mass tolerance was set to
3 Da; the fragment mass tolerance was set to 0.8 Da; the maximal number of missed cleavages was
set to 2. The results were filtered to peptide scores ≥30 and to a 1% false discovery rate using Mascot.
Representative MS/MS spectra of certain OxPAPC modified proteins can be found in Supplementary
Material (Figures S2–S6). To calculate protein abundance of all proteins in a particular proteome
fraction based on Exponentially Modified Protein Abundance Index (emPAI) score [31], MGF-files of
all samples of a particular fraction were merged and analysed with the MASCOT search engine.
2.5. Data Analysis
Mascot search results from all single bands from treated and untreated samples were compared.
A protein was regarded as modified by OxPAPC, if the corresponding protein was found in the primary
band of both, OxPAPC treated and untreated samples, as well as in higher molecular weight regions of
OxPAPC-treated samples compared to control samples. At least five unique peptides of each modified
protein had to be identified in higher molecular weight regions.
2.6. Protein-Protein Interaction Network Construction and Functional Annotation
To analyse protein-protein interaction networks and to perform functional annotation of identified
proteins, the Search Tool for the Retrieval of Interacting Genes (STRING) database was used.
2.7. Western Blotting
For Western blotting, samples from OxPAPC-treated live cells (see Section 2.1) and samples
from gel band shift analysis (see Section 2.3) were used. SDS-PAGE was performed as described in
Section 2.3. Proteins were transferred by semi-dry blotting to a BioTrace NT nitrocellulose membrane
(Pall Corporation, Port Washington, NY, USA) using the Trans-Blot Turbo System (Bio-Rad) for 30 min
keeping the voltage constant at 25 V. Afterwards the membrane was incubated in Tris-buffered
saline, 0.05 % (v/v) Tween 20 (TBST) containing 3% (w/v) BSA for 60 min. Primary antibodies
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diluted in TBST containing 1% (w/v) BSA, were added to the membrane and incubated over night
at 4 ◦C with gentle shaking. After three washing steps for 5 min with TBST, the membrane was
incubated with horse radish peroxidase (HRP)-linked secondary antibodies for 60 min. After five
washing steps for 5 min, the membrane was incubated with the Clarity ECL substrate (Bio-Rad) for
4 min. Chemiluminescence imaging was performed using the G:BOX Chemi XX6 (Syngene, Frederick,
MD, USA). The following primary antibodies and corresponding dilutions were used: anti-HSP90β
(anti-heat shock protein HSP 90-beta) (ADI-SPA-844-050; Enzo Life Sciences, Farmingdale, NY, USA),
1:1000 dilution; anti-β-Actin (A2103; Sigma-Aldrich, St. Louis, MO, USA) 1:1000 dilution; anti-BAP31
(B-cell receptor-associated protein 31), anti-Integrin α2, anti-CD13, anti-VDAC1 (sc-393810, sc-74466,
sc-166105, sc-390996; Santa Cruz Biotechnology, Dallas, TX, USA) all diluted 1:500. The following
secondary antibodies and corresponding dilutions were used: HRP-linked Anti-rabbit IgG (7074;
Cell Signalling Technology, Danvers, MA, USA), 1:3000 dilution; or HRP-linked mouse-IgGκ binding
protein (sc-390996; Santa Cruz Biotechnology, Dallas, TX, USA), 1:8000 dilution.
3. Results
3.1. Incubation with OxPLs Changes the Electrophoretic Mobility of Certain Proteins
In order to reduce the complexity of the proteome and to separate water-soluble, mainly cytosolic
proteins, from membrane-associated proteins, we split the HUVEC proteome into a PBS-soluble part
and a PBS-insoluble/RIPA-soluble part. Both samples were subjected to EMSA after treatment with
varying concentrations of OxPAPC. If OxPAPC was not covalently bound to proteins (i.e., at time 0),
the electrophoretic mobility of PBS-soluble proteins was not influenced (Figure 1, lane 2 compared
with control lane 1). Incubation of the proteome at 37 ◦C for 90 min without OxPAPC, likewise did
not influence the electrophoretic mobility of proteins (Figure 1, lane 4). However, if the sample was
incubated with OxPAPC for 90 min, clear changes, including band shifts, band-smearing, and intensity
changes can be observed (Figure 1, lane 3).
Figure 1. Gel band shift analysis of PBS-soluble human umbilical vein endothelial cell (HUVEC)
proteins. Oxidized palmitoyl-arachidonoyl-phosphatidylcholine (OxPAPC) incubated with proteins
for 90 min significantly changed the electrophoretic protein profile (lane 3). OxPAPC which is not
covalently bound to proteins does not influence the electrophoretic mobility of proteins (lane 2). Lane 1:
control sample time point 0; lane 4: control sample time point 90. The final OxPAPC concentration in
treated samples was 100 μmol/L. Main visible changes are marked with asterisks.
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These OxPAPC-induced changes of the electrophoretic protein profile were also observed within
the PBS-insoluble/RIPA-soluble proteome (Figure 2). Similarly to the experiment with hydrophilic
proteins, unbound OxPAPC did not influence the electrophoretic mobility of hydrophobic proteins
(Figure 2, lane 2 compared with control lane 1). Treatment of proteins with two different concentrations
of OxPAPC for 90 min induced significant changes such as band shifts, band smearing, and intensity
changes (Figure 2, lanes 4 and 5).
Figure 2. Gel band shift analysis of PBS-insoluble/RIPA-soluble HUVEC proteins. OxPAPC incubated
with proteins for 90 min significantly changed the electrophoretic protein profile (lanes 4 and 5).
OxPAPC which is not covalently bound to proteins does not influence the electrophoretic mobility of
proteins (lane 2). Lane 1: control sample time point 0; lane 3: control sample time point 90. The final
OxPAPC concentration in treated samples was 40 and 80 μmol/L. Main visible changes are marked
with asterisks.
The band shift assay was performed using several independent protein preparations from
HUVECs at different passages. In all cases we observed clearly visible and reproducible changes of
the electrophoretic protein profile in silver-stained gels (data not shown). Since each visible band
contained multiple proteins, it was impossible to reliably identify OxPAPC-modified proteins by
targeted excision and sequencing of bands that became weaker or stronger upon OxPAPC treatment.
Therefore, we applied an alternative approach, namely cut the whole gel into pieces and identified
position of each protein in the gel as described in the next paragraph. The method successfully
identified OxPAPC-modified proteins due to their abnormal migration in the gel.
3.2. Protein Targets of OxPAPC Identified by LC-MS/MS
In order to identify proteins that changed their electrophoretic mobility and thus represent targets
of OxPAPC, protein bands from samples incubated with and without OxPAPC were analyzed by
nano-LC-MS/MS. The whole gel (above a molecular weight of ~15 kDa) was cut into multiple pieces
with special attention to cut gel pieces of treated and untreated samples at exactly the same position
(Figure 3).
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Figure 3. Representative region of a gel showing changes in pattern of protein silver staining. The grid
shows how the bands were excised for in-gel trypsinisation and LC-MS/MS (liquid chromatography
tandem mass spectrometry) analysis.
The bands were subjected to in-gel digestion and resulting peptides were identified by LC-MS/MS.
Comparison of proteins identified from individual bands from treated and untreated samples clearly
showed that in OxPAPC-treated samples several proteins shifted from their major band location to
positions in higher molecular weight regions. A protein was regarded as modified by OxPAPC, if the
corresponding protein was found in (i) the primary band of both samples and (ii) in higher molecular
weight regions of OxPAPC-treated samples compared to control samples.
From the PBS-soluble fraction, 21 proteins were shifted to higher molecular weight regions
in OxPAPC treated samples and thus regarded as modified by OxPAPC (Table 1). Since in total
over 500 proteins were identified in both control and OxPAPC-treated samples, ~4% of the detected
proteome was identified as modified.
Table 1. Potential OxPAPC target proteins identified from the PBS-soluble fraction.
Protein Accession Reported OxPL Target *
14-3-3 protein theta 1433T_HUMAN
40S ribosomal protein SA RSSA_HUMAN
60 kDa heat shock protein, mitochondrial CH60_HUMAN
78 kDa glucose-regulated protein GRP78_HUMAN [23,26]
Actin, cytoplasmic 1 ACTB_HUMAN [23]
Chloride intracellular channel protein 1 CLIC1_HUMAN
Elongation factor 1-gamma EF1G_HUMAN
Elongation factor 2 EF2_HUMAN
Endoplasmin ENPL_HUMAN [26]
Glyceraldehyde-3-phosphate dehydrogenase G3P_HUMAN
Heat shock protein HSP 90-beta HS90B_HUMAN
L-lactate dehydrogenase A chain LDHA_HUMAN
L-lactate dehydrogenase B chain LDHB_HUMAN
Myosin-9 MYH9_HUMAN [23]
Protein-glutamine gamma-glutamyltransferase 2 TGM2_HUMAN
Puromycin-sensitive aminopeptidase PSA_HUMAN
Pyruvate kinase PKM KPYM_HUMAN [26]
Spectrin alpha chain, non-erythrocytic 1 SPTN1_HUMAN
Tubulin alpha-1A chain TBA1A_HUMAN
Tubulin beta chain TBB5_HUMAN [23]
Vimentin VIME_HUMAN [23,26]
* These proteins were identified to by targets of oxidized phospholipids (OxPLs) by proteomic based studies using
comparable OxPLs and endothelial cells [23] or macrophages [26]. OxPAPC, oxidized palmitoyl-arachidonoyl-
phosphatidylcholine; PBS, phosphate buffered saline.
In the PBS-insoluble/RIPA-soluble fraction 37 proteins were identified as potential targets
of OxPAPC (Table 2). In this proteome, over 700 proteins could be detected both in control and
OxPAPC-treated samples, thus ~5% were detected as modified.
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Table 2. Potential OxPAPC target proteins identified from the PBS-insoluble/RIPA-soluble fraction.
Protein Accession Reported OxPL Target *
ADP/ATP Translocase 2 ADT2_HUMAN
Aminopeptidase N AMPN_HUMAN
ATP synthase F(0) complex subunit B1 AT5F1_HUMAN
ATP synthase subunit alpha, mitochondrial ATPA_HUMAN [23]
Brain acid soluble protein 1 BASP1_HUMAN
Coiled-coil domain-containing protein 47 CCD47_HUMAN
Cytoskeleton-associated protein 4 CKAP4_HUMAN [23]
Endoplasmin ENPL_HUMAN [26]
Erlin 1 ERLN1_HUMAN
Fatty aldehyde dehydrogenase AL3A2_HUMAN
Flotillin 1 FLOT1_HUMAN
GTPase IMAP family member 1 GIMA1_HUMAN
Guanine nucleotide-binding protein G (i) subunit alpha-2 GNAI2_HUMAN [23]
Guanine nucleotide-binding protein G(I)/G(S)/G(T) subunit beta-1 GBB1_HUMAN [26]
Guanine nucleotide-binding protein G(I)/G(S)/G(T) subunit beta-2 GBB2_HUMAN
Inhibitor of nuclear factor kappa-B kinase-interacting protein IKIP_HUMAN
Integrin alpha-2 ITA2_HUMAN
Leucine-rich repeat-containing protein 59 LRC59_HUMAN
Myoferlin MYOF_HUMAN
NADH-cytochrome b5 reductase 3 NB5R3_HUMAN
NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 9 NDUA9_HUMAN
Perilipin 3 PLIN3_HUMAN
Polypeptide N-acetylgalactosaminyltransferase 1 GALT1_HUMAN
Polypyrimidine tract-binding protein 1 PTBP1_HUMAN
Prohibitin PHB_HUMAN
Prohibitin 2 PHB2_HUMAN [26]
RNA-binding protein Raly RALY_HUMAN
Serine/arginine-rich splicing factor 1 SRSF1_HUMAN
Serine/arginine-rich splicing factor 9 SRSF9_HUMAN
Sideroflexin-3 SFXN3_HUMAN
Trifunctional enzyme subunit alpha, mitochondrial ECHA_HUMAN
Trifunctional enzyme subunit beta, mitochondria ECHB_HUMAN [23]
Vesicle-trafficking protein SEC22b SC22B_HUMAN
Voltage-dependent anion-selective channel protein 1 VDAC1_HUMAN [26]
Voltage-dependent anion-selective channel protein 2 VDAC2_HUMAN [26]
X-ray repair cross-complementing protein 6 XRCC6_HUMAN
60S ribosomal protein L19 RL19_HUMAN
* These proteins were identified to by targets of OxPLs by proteomic based studies using comparable OxPLs and
endothelial cells [23] or macrophages [26].
The number of identified peptides of a modified protein was plotted against the estimated
molecular weight region on the gel, where the protein was detected. The distribution of peptides
corresponding to individual proteins in gel bands cut out in different gel regions is shown in Figure 4.
The examples include voltage-dependent anion-selective channel protein 1 (VDAC-1), heat shock
protein HSP 90-beta (HSP90β), and actin cytoplasmic 1 (β-actin). A clear increase of the number of
peptides identified in higher molecular weight regions was observed in OxPAPC-treated samples.
To investigate if proteins modified by OxPAPC represent only highly abundant proteins in
the particular proteome, the Exponentially Modified Protein Abundance Index (emPAI), which is
automatically calculated by Mascot, was used. The MS/MS RAW-data of all protein bands of a particular
proteome fraction were merged and searched against the SwissProt protein sequence database using
Mascot. emPAI scores of the most abundant proteins, representing together ~85% of total proteins, are
shown in Figure 5. The analysis was performed separately for soluble and membrane RIPA-soluble
proteins. In the PBS-soluble fraction, several highly abundant proteins were found to be modified by
OxPAPC (Figure 5A), while the most highly abundant proteins from the RIPA-soluble fraction formed
no adducts with OxPAPC (Figure 5B). Nevertheless, the majority of highly abundant proteins was not
modified in both fractions and vice versa. Additionally, low abundance proteins were modified in both
proteomes. The data suggest that the property of proteins to be modified by OxPAPC is not a simple
function of its abundance.
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Figure 4. Peptide distribution of selected representative OxPAPC-modified proteins. A clear increase of
peptides identified in higher molecular weight regions is observed after OxPAPC treatment. (A) Peptide






























Most abundant proteins                                      360  
unmodifiied proteins
OxPAPC-modified proteins
Figure 5. Protein abundance, based on exponentially modified protein abundance index (emPAI) score.
Most abundant proteins, representing ~85% of total proteins, were plotted. The property of proteins
to be modified by OxPAPC is not a simple function of their abundance. (A) PBS-soluble proteins;
and (B) PBS-insoluble/RIPA-soluble proteins.
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STRING analysis of OxPAPC-modified proteins from the RIPA-soluble fraction showed a clear
enrichment of proteins located at membrane organelles in general (Figure 6A; green nodes) and
proteins located at the mitochondrial membrane (Figure 6A; blue nodes) in particular. Furthermore,
these mitochondrial proteins form a tight protein-protein interaction network. STRING analysis of
the PBS-soluble fraction showed an enrichment of proteins related to protein folding (Figure 6B;
red nodes) and proteins representing structural constituents of the cytoskeleton. Based on these results,
mitochondrial (membrane-) proteins, proteins involved in protein folding and cytoskeletal proteins,





Figure 6. STRING analysis of proteins identified as targets of OxPAPC from the PBS-insoluble/RIPA-
soluble fraction (A) and from the PBS-soluble fraction (B). The RIPA-soluble fraction of modified
proteins contains mainly proteins located at membrane organelles (green nodes: membrane-bounded
organelle; GO: 0043227). Furthermore, several modified proteins are located at the mitochondrial
membrane (blue nodes: mitochondrial part; GO: 0044429). In the PBS-soluble fraction, proteins related
to protein folding (red nodes: protein folding; GO: 0006457) and proteins related to the cytoskeleton
(blue nodes: structural constituent of cytoskeleton; GO: 0005200) are enriched.
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3.3. Confirmation of OxPAPC-Induced Protein Modifications by Western Blotting
To confirm that the apparent abnormal migration of OxPAPC-treated proteins in the gel was not
an artifact of MS detection, we performed western blot analysis of selected proteins to detect these
proteins by antibodies. Since β-actin is a rather highly abundant protein, which was identified to
be modified by OxPAPC in the PBS-soluble fraction, we used a polyclonal anti-β-Actin antibody to
analyse OxPAPC-actin adducts. We could observe a significant decrease of the amount of β-actin at its
major band, as well as a slight band shift of actin in OxPAPC treated samples (Figure 7). Results from
MS however, indicated that β-actin was also present in higher molecular weight regions (Figure 4).
However, no β-actin was detected in higher molecular weight areas by this antibody.
Figure 7. Western blot analysis of β-Actin from the OxPAPC-treated PBS-soluble fraction.
The OxPAPC-treated sample incubated for 90 min, shows a decrease of actin immunostaining and a
slightly slower band migration. The final OxPAPC concentration was 100 μmol/L.
Since two other polyclonal and monoclonal anti-β-actin antibodies were also not able to detect
OxPAPC-actin adducts (data not shown), we concluded, that OxPAPC-induced modifications and
cross-links of β-actin hampered its recognition by antibodies. Another possible explanation is that the
amount of OxPAPC-modified β-actin in high molecular weight regions of gel/blot may be too low
for antibody-based detection. To test this possibility, we cross-linked proteins using formaldehyde.
Similarly to OxPAPC-treated samples, the antibody could not detect formaldehyde-modified β-actin
(Figure 8). After 10 min incubation time the protein amount was decreased, after 30 min the signal
was completely lost, but still no β-actin could be detected in higher molecular weight regions
(Figure 8). Application of other anti-β-actin antibodies showed the same result (data not shown).
We hypothesize that electrophilic molecules either induce irreversible denaturation of protein or modify
immunodominant domains of β-actin and, thus, prevent its recognition by antibodies. Thus, although
Western blotting cannot detect high molecular weight adducts of actin, the loss of the intact protein
upon OxPAPC treatment clearly shows that the protein is modified by OxPAPC thus confirming the
findings of MS analysis.
Figure 8. Western blot analysis of β-Actin from the formaldehyde-treated samples. After formaldehyde-
induced artificial cross-linking of proteins, actin could not be detected by antibodies any more.
Another protein identified to be modified by OxPAPC using the band shift assay was HSP90β.
Using anti-HSP90β antibody we could detect a slight shift of the major band, as well as protein adducts
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in the higher molecular weight region upon treatment with OxPAPC (Figure 9). These findings are in
agreement with the peptide distribution detected by LC-MS/MS.
 
(A) (B) 
Figure 9. Western blot analysis of HSP90β from the OxPAPC-treated PBS-soluble fractions from two
different preparations (A,B). OxPAPC induces a slight band shift of HSP90β and the generation of
high molecular weight protein-OxPAPC complexes. Samples were treated for 0 or 90 min with a final
OxPAPC concentration of 0 or 100 μmol/L.
3.4. OxPAPC Modifies Proteins in Live HUVECs
To investigate if identified protein targets of OxPAPC from isolated proteomes are also modified
in cell culture, HUVECs were treated with OxPAPC in cell culture medium and subjected to Western
blotting analysis. OxPAPC-protein adduct formation was analysed with three different proteins from
the RIPA-soluble fraction (Figure 10). Proteins located in the plasma membrane and/or mitochondrial
outer membrane, were selected for detection. Similarly to experiments with β-actin, antibodies were
not able to detect band shifts in the higher molecular weight region, apparently due to a loss of protein
immunoreactivity. However, similarly to β-actin, a decrease of signal intensity was observed for all
three proteins after treatment with OxPAPC. These data confirm modification of proteins by OxPAPC





Figure 10. Western blot analysis of (A) Aminopeptidase N (CD13), (B) Integrin α-2 (CD49b)
and (C) VDAC-1 after treatment of HUVECs with OxPAPC. Samples were treated for 0 or 90 min with
a final OxPAPC concentration of 0 or 80 μmol/L. BAP31: B-cell receptor-associated protein 31 which
was identified to not be modified by OxPAPC.
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4. Discussion
OxPLs are increasingly recognized as signalling molecules inducing pleiotropic effects in different
cell types [6]. Some of the effects (e.g., angiogenesis) depend on electrophilic properties of OxPLs [32]
but cannot be explained by simple toxicity of electrophiles. Rather, sub-toxic concentrations of OxPLs
seem to regulate specific signal transduction pathways, thus inducing important cellular reactions.
OxPL-induced angiogenesis is just one example justifying the need for analysis of proteins that are
covalently modified by OxPLs and may be involved in development of (patho-) physiological reactions
to these lipids. Such an analysis is not a simple task because (i) oxidation of PUFA-PLs generates a
complex mixture of molecular species containing electrophiles with different size, lipophilicity and
reactivity; and (ii) cells contain thousands of proteins, some of which may be more prone to oxidation
than other. Several methods for identification of OxPL-protein adducts have been published (see
Introduction); all of them are based on identification of proteins by mass spectrometry. Although
these methods produced important results on cellular targets of electrophilic OxPLs, each procedure
has certain limitations. Three of these methods used OxPCs or OxPEs labelled at the head groups
with biotin or fluorescent dye [23–26]. It is apparent that such chemical modification (i) may be more
difficult to introduce into other classes of OxPLs and (ii) addition of a bulky group can change the
binding characteristics of OxPLs. The method published by Gao et al. [27] is based on chromatographic
separation of peptide adducts of OxPLs according to their hydrophobicity before and after cleavage of
the fatty acid, which is a highly demanding technique that may be difficult to establish for other types
of LOP.
Here we describe a simple method for identification of proteins covalently modified by OxPLs.
The method is based on a combination of EMSA with LC-MS/MS (EMSA-MS). The procedure may be
characterized as “double-unbiased” because no preliminary information on either oxidized lipids or
proteins that are treated with these lipids is needed for the identification of the most reactive protein
targets. In other words, this method is independent of the complexity of both the proteome and the
LOPs, or from the type of covalent adducts. Furthermore, this approach does not require any kind
of chemical tag- or antibody-assisted protein extraction or detection. We demonstrate application of
this method for extracts from endothelial cells treated with OxPAPC, but it is to be expected that other
types of LOPs and protein mixtures can be analysed using this universal procedure as well. In support
of this possibility, we observed band shifts of HUVEC proteins treated with a chemically different LOP,
2-chlorohexadec-15-yn-1-al (Figure S1).
By applying the EMSA-MS to HUVEC lysates, we were able to identify several protein targets
of OxPAPC both in soluble and membrane cell fractions (Tables 1 and 2). It was found that OxPAPC
induced not only small shifts in protein band migration, but also the formation of SDS-resistant
(supposedly covalent) complexes migrating in high molecular weight regions of the gel (Figure 4).
Intermolecular cross-linking is the most probable mechanism generating significantly shifted bands.
Since our EMSA analysis used isolated proteomes, any kind of OxPAPC-mediated biological protein
modification or changes in protein expression levels as the cause of observed band shifts can be
excluded. Comparison of semi-quantitative abundance (emPAI) scores of modified and unmodified
proteins showed that the property of proteins to be modified by OxPAPC is not a simple function of
their abundance (Figure 5). These results imply that OxPL-protein adducts are not randomly formed
and that a certain selectivity of binding is existing. Using Western blot analysis we could prove that
selected OxPAPC protein targets identified from isolated proteomes were also modified in live cells
treated with OxPAPC (Figure 10).
We found that <5% of detectable proteins from HUVECs demonstrated a band shift after treatment
with OxPAPC. In absolute numbers, we found 21 OxPL-modified proteins in the soluble fraction of
HUVECs and 37 proteins in RIPA-solubilized membrane fraction. Gugiu et al. have analysed binding
of OxPLs to proteins in human aortic endothelial cells using a different detection principle, namely
biotin-labelled OxPAPE [23]. Twenty-eight modified proteins were identified, which is close to the
number found in our work. Interestingly, nine proteins were also found in our samples (Tables 1
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and 2). Stemmer et al. used fluorescently labelled OxPAPC components POVPC and PGPG and found
>50 modified proteins in mouse macrophage cell line [26]. From these, nine proteins were also identified
in our study (Tables 1 and 2). In summary, comparison of our results with two published studies on
cells treated with OxPLs points to a similar sensitivity of the methods (dozens of modified proteins
were identified in each cell type). Partial, but significant, overlap of our hits with those obtained using
independent methods supports the reliability of results generated by EMSA-MS. Furthermore, using
STRING analysis, we observed enrichment of proteins related to (i) cytoskeleton; (ii) protein folding;
and (iii) mitochondria (Figure 6). All these are known as common themes in electrophile-modified
proteome, thus further supporting the validity of the EMSA-MS method [11,15,20,33–40].
Similarly to other methods described above, our technique has limitations. Since the method
does not identify exact structures of lipids modifying amino acids, false positive hits (i.e., proteins
modified by chemically different LOPs) may arise due to transformation of added LOPs to their
reactive derivatives, or due to generation of reactive oxygen species in the course of incubation.
However, because the ‘target’ LOP is present in large molar excess as compared to its secondary
products generated in the course of incubation, the secondary products can only have a limited impact
on the whole electrophile-modified proteome and false positive results are unlikely to significantly
bias the results. On the other hand, false negative results are also possible. Certain modifications by
LOPs can have no effect on protein electrophoretic mobility and, therefore, some modified proteins can
be falsely characterized as non-modified. Further studies are needed in order to understand how lipid
adduction changes protein mobility. It seems likely that the method predominantly identifies multiply
modified protein. This has certain advantages, because such proteins may be especially sensitive to
LOPs and, as a consequence, play a mechanistic role in oxidative stress-induced damage. In other
words, although the lipid specificity of EMSA-MS is not investigated, the method may be especially
helpful for identification of proteins that are most sensitive to LOPs. Thus, the major application of the
EMSA-MS technique is a search for protein targets of LOPs with the following mechanistic analysis of
their role in oxidation-induced pathology.
An unexpected finding done in this work is that modification with OxPLs strongly inhibited
recognition of proteins by standard commercial antibodies. OxPAPC-induced cross-linked high
molecular weight complexes detected by MS could only be immunostained in case of HSP90β (Figure 9).
Slight band shifts were observed on Western blots of modified β-actin and HSP90β (Figures 7 and 9).
For all other analysed proteins, only a distinct decrease of signal intensity was observed by Western
blotting after treatment with OxPAPC (Figure 10). Since artificial cross-linking using formaldehyde
did not improve detection of high molecular weight adducts of actin, insufficient actin amount in
shifted bands as the cause of the lack of signal in high molecular weight areas of gel can be excluded.
We hypothesize that electrophilic molecules may induce irreversible denaturation of proteins that
prevents partial refolding of SDS-treated proteins on blotting membranes and, thus, prevent binding
of antibodies that recognize 3-D epitopes. Alternatively, for antibodies recognizing linear epitopes,
immunodominant domains of proteins may be covalently modified by LOPs thus preventing their
recognition by antibodies. Independently of the mechanism(s) of immunoreactivity loss, our data
suggest that (i) Western blotting cannot be recommended for detection of band shifts induced by
lipid adduction to proteins and (ii) β-actin should be used with caution as a housekeeping gene in
experiments where the cells are exposed to oxidative stress.
In summary, here we describe a novel combination of electrophoretic mobility shift assay with
MS-based protein sequencing, which allows identification of proteins modified by LOPs without an a
priori knowledge of reactive lipid species or target proteins. We applied this method to endothelial
cells and identified several known, but also many new, OxPAPC-binding proteins. We expect that
this technically relatively simple method can be widely applied for label-free analysis of lipid-protein
interaction in variable protein samples treated with different LOPs.
Supplementary Materials: The following are available online at http://www.mdpi.com/2076-3921/7/9/116/s1,
Figure S1 Gel band shift analysis of PBS-soluble HUVEC proteins. Figure S2 Selected MS/MS spectra of VDAC-1.
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Figure S3 Selected MS/MS spectra of Aminopeptidase N. Figure S4 Selected MS/MS spectra of HSP90β. Figure S5
Selected MS/MS spectra of Integrin alpha-2. Figure S6 Selected MS/MS spectra of ADP/ATP translocase 2.
Author Contributions: Conceptualization: B.G. and V.N.B.; investigation: B.G., D.K. and N.V.; supervision: B.G.
and V.N.B.; writing—original draft: B.G.; writing—review and editing: V.N.B.
Funding: This work was supported by the Austrian Science Fund (grant No. P27682-B30).
Acknowledgments: The authors thank Wolfgang Sattler (Medical University of Graz, Austria) for providing
2-chlorohexadec-15-yn-1-al and Olga Oskolkova (University of Graz, Ausria) for providing OxPAPC.
Conflicts of Interest: The authors declare no conflict of interest.
Abbreviations
BAP31 B-cell receptor-associated protein 31
emPAI Exponentially Modified Protein Abundance Index
EMSA Electrophoretic mobility band shift analysis
HNE 4-hydroxynonenal
HRP horseradish peroxidase
HSP90β heat shock protein HSP 90-beta
HUVEC human umbilical vein endothelial cell
KODA-PC 9-keto-12-oxo-10-dodecenoate-phosphatidylcholine










PBS-PI phosphate buffered containing protease inhibitor cocktail
RIPA buffer, Radioimmunoprecipitation assay buffer
PL phospholipid
PLPC 1-palmitoyl-2-linoleoyl-sn-glycero-3-phosphatidylcholine
PUFA polyunsaturated fatty acid
SDS sodium dodecyl sulfate
VDAC-1 voltage-dependent anion-selective channel protein 1
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Abstract: Maintenance of integrity and function of the gastric mucosa (GM) requires a high
regeneration rate of epithelial cells during the whole life span. The health of the gastric epithelium
highly depends on redox homeostasis, antioxidant defense, and activity of detoxifying systems
within the cells, as well as robustness of blood supply. Bioactive products of lipid peroxidation, in
particular, second messengers of free radicals, the bellwether of which is 4-hydroxynonenal (HNE),
are important mediators in physiological adaptive reactions and signaling, but they are also thought
to be implicated in the pathogenesis of numerous gastric diseases. Molecular mechanisms and
consequences of increased production of HNE, and its protein adducts, in response to stressors
during acute and chronic gastric injury, are well studied. However, several important issues related
to the role of HNE in gastric carcinogenesis, tumor growth and progression, the condition of GM after
eradication of Helicobacter pylori, or the relevance of antioxidants for HNE-related redox homeostasis
in GM, still need more studies and new comprehensive approaches. In this regard, preclinical studies
and clinical intervention trials are required, which should also include the use of state-of-the-art
analytical techniques, such as HNE determination by immunohistochemistry and enzyme-linked
immunosorbent assay (ELISA), as well as modern mass-spectroscopy methods.
Keywords: 4-hydroxynonenal; lipid peroxidation; redox balance; oxidative stress; stomach;
peptic ulcer; gastritis; Helicobacter pylori; gastric cancer; non-steroid anti-inflammatory
drugs-induced gastropathy
1. Introduction
The gastrointestinal tract (GIT) represents a highly specialized interface between the environment
and an organism’s internal medium, aimed primarily to digest food, and absorb nutrients and water.
In addition, it fulfils a wide variety of other functions, including, but not limited to, immune defense,
excretion of metabolic waste/detoxification, secretory and regulatory functions, and as a physical
barrier. Last but not least, it is a vital niche for gut bacteria [1]. The GIT has to withstand harsh
conditions, due to exposure to food/chyme, digestive enzymes, different, often very aggressive
pH conditions, and numerous bacteria; therefore, high efficiency of protection and regeneration is
required for its maintenance and function. This is particularly important in the case of the stomach,
whose lumen contains aggressive hydrochloric acid, often reaching pH values of 1–2, and proteolytic
enzymes, such as pepsin [2]. Toxins, which may be ingested together with food, as well as some
drugs, may contribute to damaging the gastric mucosa (GM). Furthermore, in more than half of the
human population worldwide, Helicobacter pylori (H. pylori) bacteria [3] persist in the GM, and may
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cause chronic gastritis and peptic ulcer, thus being a major contributor to the pathogenesis of gastric
adenocarcinoma and mucosa-associated lymphoid tissue (MALT)-lymphoma [4].
The redox balance is a major homeostatic parameter and a regulatory factor for the metabolic
functions of the whole organism and also the GIT [5]. Redox imbalance, often referred to as
“oxidative stress”, may be caused either by excessive exposure to oxidants, or by decreased activity
of counter-regulatory enzymatic systems and a lack of antioxidants [6]. A certain degree of
lipid peroxidation may take place in many cellular processes under physiological conditions, but
redox imbalance that is observed in many diseases very often leads to excessive accumulation
of oxidized lipids and their degradation products. Among such products of lipid peroxidation,
4-hydroxy-2-nonenal (HNE) is ubiquitous, and one of the most studied compounds, also considered
as a “second messenger of free radicals” [7]. HNE is generated from omega-6 fatty acids. Along
with its role in the pathogenesis of multiple diseases, it has been shown to be involved in various
signaling pathways. It contributes to the regulation of energy metabolism, detoxification, cell
proliferation and differentiation, maintenance of the cytoskeleton, and metabolic adaptations to
redox derangements [8–10].
Considering the sophisticated functions of the mucous membrane and the wide variety of
damaging exposures, the maintenance of the redox balance in GM is particularly challenging [5].
In order to sustain the lifelong function of the GIT, the cells of the mucosal epithelium have a high
rate of proliferation, and an exceptional regenerative potential. However, this system is prone to
derangements, which can result in gastritis, peptic ulcer, and gastric cancer. Gastrointestinal diseases
cause severe health problems and overall socioeconomic damage [3]. Progress in understanding the
roles of lipid peroxidation and its reaction product, HNE, in health and disease, stimulated studies
focused on specific diseases of the GIT. This review is aimed at addressing important issues related to
the role of HNE in normal functioning and in the development of diseases of the stomach.
2. Approaches to Determine HNE in Samples of Patients Suffering from Stomach Diseases
Along with conventional approaches to measure the concentrations of substances of interest
in biological liquids like blood (serum, plasma, and whole blood), urine, cerebrospinal fluid, etc.,
with several other options available in the case of stomach diseases. First, the stomach is accessible to
endoscopy, which is a routine clinical intervention. During endoscopy, it is possible to obtain biopsies
of the mucous membrane from different parts of stomach for further morphological studies. Second,
gastric juice can be obtained for chemical analysis. Third, a number of “breath-tests” (determination of
metabolites of ingested reagents in exhaled air) are available for gastroenterological diagnostics. Finally,
feces samples can be taken, for example, to test H. pylori bacterial contamination [3]. The researchers
have to keep in mind that blood flows from stomach through the portal vein to the liver; many
substances, such as xenobiotics, lipid peroxidation products, some hormones, and cytokines, may
be degraded there and, thus, may be measured in the peripheral blood within normal concentration
ranges, despite evidence of toxicity/inflammation [11].
HNE and other lipid peroxidation products, including acrolein, malonic dialdehyde, and many
others, can be measured as biomarkers of redox imbalance [7]. However, their high reactivity
and capacity for interactions with multiple functional groups of macromolecules, as well as their
transfer to blood and/or urine from other compartments of the organism, may significantly lower
steady-state concentrations of free lipid peroxidation products. Most of the detectable HNE are found
to be conjugated to proteins or glutathione (GSH). Through a Michael-type reaction of nucleophilic
addition, HNE binds covalently to cysteine, lysine, and histidine residues within proteins [12].
Development of specific antibodies against HNE–histidine adducts facilitated further research and
enabled implementation of respective analytical methods [13,14].
In this regard, HNE-immunohistochemistry (qualitative/semiquantitative evaluation) is a widely
used method of HNE determination, in order to map tissue or intracellular distribution of respective
HNE-conjugates in human samples obtained by gastric biopsy [12]. A variety of HNE-ELISAs have
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been introduced that are applicable for quantitative evaluation of the levels of HNE-adducts in
biological fluids, like blood serum, urine, or gastric juice [15]. Other antibody-based methods, which
are often applied successfully, include immunofluorescence, immunogold electron microscopy, and
immunoblotting [16]. However, since the use of antibodies for analytical purposes is often associated
with technical problems, such as inaccessibility of some epitopes and/or their alterations, this may
result in incomplete quantification [15]. Furthermore, higher degrees of protein modification can
decrease the epitope recognition (non-linear dependence); therefore, the results of analyses based
on antibody-dependent techniques should be interpreted very carefully. For clinical purposes,
in particular, when histological samples are evaluated, the use of semiquantitative methods for
HNE detection may be particularly reasonable [17–20]. Free HNE can be accurately determined by
high performance liquid chromatography, and a number of modifications of mass spectroscopy-based
methods [21]. However, due to the high reactivity of free HNE and its low steady-state levels,
the determination of HNE conjugates reveals more biologically/clinically relevant information,
and may have substantial advantages [12]. The formation of protein conjugates is proportional
to the mean levels of free HNE; therefore, antibody-based methods of staining and quantitative
determination of HNE are considered to be quite accurate and reliable, especially if HNE–histidine
adducts are monitored [12]. The last generation mass spectrometric techniques and instrumentations,
in combination with enrichment and separation techniques, have been successfully applied to the
determination not only of HNE, but also of its adducts with amino acids in proteins [22–24].
3. HNE in the Stomach under Physiological Conditions
In the lumen of the stomach, ingested food is exposed to low pH (hydrochloric acid) and
proteolytic enzymes, such as pepsin, contributing to denaturation and degradation of proteins.
However, a highly acidic medium facilitates, also, a variety of chemical reactions between different food
components [1,2]. Modeling of chemical processes taking place during gastric digestion reveals the
possibility of iron- or metmyoglobin-catalyzed generation of substantial amounts of hydroperoxides
and other lipid peroxidation products from components of common diets containing meat and
unsaturated fats at low pH in the presence of water-dissolved oxygen. Notably, the ingestion of
food rich in polyphenols dramatically lowers the generation of hydroperoxides, which may be,
at least in part, responsible for the preventive effects of fruits and vegetables [2]. On the other
hand, accumulation of lipid peroxidation products in the GM may be enhanced by consumption of
large amounts of unsaturated fats that may be a part of many “healthy” diets or popular supplements
containing polyunsaturated fatty acids (PUFAs) [25]. Therefore, food products containing significant
quantities of PUFAs should be carefully processed and properly stored, in order to prevent their
oxidation. Steady-state levels of HNE in the GM result from the rates of their generation/absorption
and utilization [26]. The acidity of the chyme may also influence the stability of hydroperoxides
and the likelihood of Michael addition within the gastric lumen, whereas the cells of the gastric
epithelium are well protected from the acidic content by mucus. Noteworthy, H. pylori bacteria produce
ammonia to provide protection from hydrochloric acid [27,28] and, therefore, create an alkaline local
microenvironment at infection sites, that is more favorable for Michael reactions (Figure 1).
Formation of HNE conjugates with glutathione and adducts with proteins may have
heterogeneous consequences for the cells, depending on the role of respective residues. Depletion of
reduced glutathione may increase vulnerability of the cells to oxidants and shift the redox balance
to the pro-oxidant side. Addition of HNE to cysteine residues may alter function of proteins, and
may have significant regulatory consequences, whereas binding to other sites (for example, histidine
or lysine residues) may have not much effect on function, and can rather reflect the degree of HNE
accumulation and possible oxidative damage [12,29,30] (Figure 2).
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Figure 1. Schematic presentation of major sources of 4-hydroxynonenal (HNE) in gastric mucosa and
the ways of its further transformations. Free HNE is a highly reactive molecule, capable of reacting
with numerous targets within cells. HNE interfering with redox-sensitive pathways (for example,
by binding to cysteine residues) may affect the function of redox-sensitive proteins. Conjugation of
HNE with histidine or lysine residues of peptides and proteins are thought to be less important for
signaling. However, even in these cases, HNE may bind enzymes, cytokines, and receptors, so they may
have important regulatory roles. Hence, such aldehyde-protein adducts can represent a source of HNE
and cause secondary oxidative stress, while they can also be used as biomarkers for immunochemical
detection of HNE, denoted as advanced lipoxidation end products (ALEs).
The epithelium of the GIT is highly proliferating and, depending on the location, it is completely
renewed every 3–10 days. Therefore, the immunohistochemical pattern of HNE adducts mainly reflects
the metabolic conditions within the mucosa (e.g., oxidative stress, exposure to xenobiotics) during the
last few days before taking the sample. Different HNE levels may occur rather as a result of recent
alterations, than due to accumulation (for example with age), and are likely to depend on both the
renewal rate of epithelial cells and the rate of lipid peroxidation.
A certain degree of accumulation of HNE–histidine adducts in the mucosa of gastric corpus
and antrum was demonstrated for the majority of healthy volunteers [19]. Notably, almost all the
samples, obtained from asymptomatic apparently healthy subjects, regardless of whether the patients
have been H. pylori-positive or not, have shown mild to moderate HNE-immunopositivity in the
cytoplasm of the gastric glandular epithelium, with only a few HNE-negative samples [19]. A likely
explanation of these findings suggests that HNE may play a role in normal signaling and regulation
of cellular functions in the GM under physiological conditions. HNE levels appear to be strictly
maintained within a homeostatic range, providing adaptations to adverse factors, like metabolic
or emotional stress, exogenous toxins that are occasionally ingested with food, or latent H. pylori
infection. Only excessive and/or prolonged oxidative stress may cause GM injury and inflammation,
as discussed below (Figure 2).
Interestingly, most of the H. pylori-positive subjects never experience clinically overt forms of
gastritis, peptic ulcer, or gastric cancer [31]. This observation is in line with observations that apparently
healthy H. pylori-positive subjects show no difference in HNE–histidine conjugates in GM compared
to controls, despite occasional presence of inflammatory cells in the samples [19]. It is likely that
asymptomatic subjects have sufficient compensatory power to cope with the negative influence of the
pathogen. Only excessive virulence of certain H. pylori strains or lowered resistance of the host may
result in clinically significant manifestations. In this regard, it is known that sedentary lifestyle may
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cause deleterious metabolic changes associated with activation of sympathetic tone (with subsequent
parasympathetic impairment) [32]. Genetic defects, psychoemotional stress, and a number of other
factors, may also contribute to autonomic imbalance that may lead to increased vulnerability of
the GM [33–35]. It has been reported that patients with chronic peptic ulcer disease show altered
autonomic function, as measured by Holter electrocardiogram monitoring [36]. The relationships of
heart rate variability alterations with endothelial dysfunction [37], as well as oxidative stress [38], were
earlier noticed. Hence, not clearly intuitive, the relationships of autonomic function and redox balance
attract growing attention. For example, an anti-inflammatory action of cholinergic (parasympathetic)
signaling [39,40], adrenergic pathways’ interference with H2O2-mediated insulin signaling [41] and
thermogenesis in adipose tissue [42], were demonstrated. Moreover, the link between redox balance
and autonomic function was hypothesized [43], and is further confirmed by a recent observation
that selective Nrf2 deletion in the rostral ventrolateral medulla in mice evokes hypertension and
“sympatho-excitation” [44].
Numerous epidemiological observations associate H. pylori-positivity with so called extra-gastric
manifestations that include, but are not limited to, atherosclerosis, insulin resistance/diabetes type 2,
diseases of liver and pancreas, and others [45–49]. Proposed pathogenesis mechanisms include initial
damage of GM caused by H. pylori and its virulence factors, oxidative stress and lipid peroxidation,
local inflammation, release of pro-inflammatory cytokines and other bioactive mediators to the blood
circulation, causing systemic effects and metabolic derangements [4,50–52]. Indeed, in H. pylori-positive
healthy male subjects with a sedentary lifestyle, higher levels of fasting insulin and elevated
homeostatic model assessment index (HOMA-index) were observed, compared to H. pylori-negative
matches [47]. Another study showed significantly increased heart rate and sympathetic tone in
H. pylori-positive asymptomatic volunteers. However, levels of the water-soluble HNE derivative
1,4-dihydroxynonane mercapturic acid (DHN-MA), iso-PGF2, pro- and anti-inflammatory cytokines,
C-reactive protein, and a number of selected hormones, were not different between the groups,
indicating that either the degree of local mucosal damage was not strong enough to cause marked
elevation of studied parameters, or their mild/moderate elevation is obscured by the passage of blood
through the liver [52].
4. HNE in Patients with H. pylori-Associated Gastritis and Peptic Ulcer
Despite its recent decline, the prevalence of H. pylori infection is still very high worldwide,
ranging from rates between 20% and 40% in Western countries, to over 90% in many developing
countries [3]. There is clear evidence that this microorganism is a causative factor for chronic gastritis
type B and peptic ulcer. However, as mentioned above, most H. pylori-positive subjects are clinically
healthy, and never develop gastritis or ulcer, suggesting that besides H. pylori and its virulence factors,
conditions of the host organism play a crucial role in the outcome of this complex host–microbe
interaction [4,53]. This idea fits well into the framework of the classical concept of balance of factors
of “aggression” and “cytoprotection” in GM. On the cellular level, this paradigm is consistent with
our current understanding of the principles of redox balance maintenance under stress conditions [6].
GM injury and subsequent inflammation may take place when the capacity of antioxidant mechanisms
is not sufficient to protect the cells from the damaging factors and related oxidative stress [5].
Peptic ulcer and gastritis are, for a long time, known to be associated with redox imbalance
and excessive lipid peroxidation [54], as confirmed in numerous studies and with different study
models [55]. Clinical studies are less abundant, and only a few of them address the issue of oxidative
stress and lipid peroxidation in GM. The use of gastric endoscopy enables obtaining of mucosal tissue
samples for further histological examination. In the group of H. pylori-positive peptic ulcer patients,
significantly higher accumulation of HNE–histidine adducts in GM compared to control group was
clearly demonstrated [19]. In some cases, severe immunopositivity of nuclei and perinuclear spaces,
along with diffuse accumulation of HNE–histidine conjugates in cytoplasm of the cells was observed,
pointing to an impaired redox balance in the GM of these patients [18,19].
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Figure 2. Physiological and pathophysiological effects of HNE on the gastric mucosa depend on the
HNE concentration. Steady-state HNE levels inversely correlate with the cellular redox status, and are
a function of the rate of its generation and metabolization. HNE content is regulated by the activities
of alcohol and aldehyde dehydrogenases, and of glutathione S-transferases, depending mostly on
the level of reduced glutathione and affinity to cellular proteins [56]. The overall pathophysiological
consequences of HNE generation reflect the tissue/cellular redox (im)balance, and depend on the type
of cells and the reaction of neighboring cells to the onset of lipid peroxidation. The cells often behave
as individuals, not as a homogenous population, which is relevant for carcinogenic effects of HNE and
for its involvement in (regulation of) host defense against cancer [57–60].
The pharmacological approach to treat chronic gastritis and peptic ulcer via eradication of H. pylori
proved to be very successful from the clinical point of view, as it allows most of the patients to be cured
of these diseases [61]. In addition, there are reasons to expect that eradication of this microorganism
may be useful for prevention and/or treatment of other diseases associated with H. pylori, including
metabolic syndrome, type 2 diabetes, non-alcoholic fatty liver disease, or atherosclerosis [62–64]. How
an infection with H. pylori may result in systemic pathological effects, as well as the biochemical
mechanisms that may contribute to metabolic deteriorations in H. pylori-positive patients, needs to be
further elucidated.
Despite obvious clinical efficiency, there are reports indicating persistence of HNE–histidine
adducts, hyperaccumulation in peptic ulcer patients, even after successful eradication of H. pylori, at
least in the period of 4 weeks after completing antimicrobial treatment [18]. This is consistent with
clinical observations that some patients still have symptoms (epigastric pain, nausea, reduced appetite,
etc.) for several months after treatment [65]. It might be possible that metabolic dysfunction in these
patients, as an integral part of ulcer disease, contributes to pathogenesis of gastric injury independent
of persisting H. pylori occurrence. The combination of these two as well as any additional factors is
known to increase the risk of ulcerations. In this regard, smoking, psychoemotional stress, unhealthy
lifestyle, and suboptimal nutrition may be crucial for the outcome of host–microbial interaction [34,66].
Thus, it depends on the power of intrinsic cytoprotective mechanisms (genetics, sufficient blood
microcirculation in stomach, effective autonomic regulation) and exogenous factors (H. pylori, ingestion
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of toxins, and products of PUFA peroxidation), and may vary from long-term asymptomatic carrying
to chronic gastritis type B, with the periods of exacerbation and remission, peptic stomach ulcers,
and/or duodenum or transformations in the form of MALT-lymphoma or gastric adenocarcinoma.
5. HNE in Gastric Carcinogenesis
The GM is exposed to different types of exogenous chemical agents, and reactive species are
generated in the stomach during digestion. Some of them may be toxic and cause damage to the gastric
epithelium, and some may also be carcinogenic [2]. Chronic inflammation and oxidative stress caused
by H. pylori infection are also major contributors to malignant transformation of the cells of GM [50,67].
The idea to eradicate H. pylori in all carriers, even in asymptomatic ones, is gaining popularity, as
some recently published trials showed positive results [68]. Moreover, eradication of H. pylori seems
to be reasonable also in patients with early stages of gastric cancer undergoing endoscopic resection,
since it decreases the rates of metachronous cancers compared to control group [69]. In this context,
genotoxicity of supraphysiological levels of HNE and other lipid peroxidation products may be
important for carcinogenesis, as well [70,71].
The role of HNE in malignant transformation and growth is ambiguous. On the one hand, HNE
can diffuse from the site of generation into the nucleus and bind, covalently, to DNA molecules, causing
mutations and supporting carcinogenesis [71], while, on the other hand, it is influencing pathways
regulating proliferation, differentiation, and apoptosis of transformed cells. Depending on the activity
of detoxifying systems in cancer cells, HNE may be toxic to them or can stimulate their growth and
enforce resistance to cytostatic drugs [72].
While, in the case of acute and chronic GM injury caused by H. pylori and gastrotoxic agents,
oxidative stress and increased lipid peroxidation is well documented, in case of gastric cancer, it is not.
As it was shown by Ma et al. (2013), serum levels of major lipid peroxidation products, such as HNE,
malonic dialdehyde, conjugated dienes, and 8-iso-prostaglandin F2α, were all decreased in cancer
patients compared to control group [73]. Hence, though not statistically significant, lower levels of
HNE were also observed in H. pylori-positive vs. H. pylori-negative patients, that may support the
idea that moderate (or local) activation of lipid peroxidation may stimulate systemic activation of
detoxification mechanisms through, for example, Nrf2-dependent mechanisms [72].
6. HNE in Alcohol- and Non-Steroid Anti-Inflammatory Drug (NSAID)-Induced Gastropathy
Alcohol and a rapidly growing use of NSAIDs are, jointly, the second most important cause
of gastric injury after H. pylori [66]. Evidence from well-established animal models of GM injury
suggests two principal mechanisms responsible for tissue damage. The first, a direct toxic effect on
GM, and the second, limitation of gastric microcirculatory blood flow that is essential for a proper
rate of proliferation, mucus secretion, etc., through decreased levels of gastroprotective prostaglandin
E2 with subsequent endothelial dysfunction and autonomic dysregulation, that may cause oxidative
stress [74,75]. Both mechanisms contribute to the development of severe local oxidative stress, excessive
lipid peroxidation, and accumulation of its products, including HNE, mostly covalently bound to
proteins [54].
The important role of autonomic dysregulation is often ignored in case of diseases of stomach. It is
known that an elevated sympathetic tone limits blood flow in the organs of gastrointestinal tract, and
caused endothelial dysfunction, which is crucial for gastroprotection; therefore, autonomic imbalance
may significantly potentiate the damaging effects of alcohol and NSAIDs [76,77].
7. Pharmacological and Non-Pharmacological Approaches to Reduce Redox Imbalance in GM
Considering multiple etiologic and pathogenic factors that may interact with each other and
contribute to GM damage, there are a number of different approaches in order to prevent or treat
gastric injuries (Table 1).
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Eradication of H. pylori with a combination of two antibiotics and proton pump inhibitors has
been proven to be effective in most of the H. pylori-positive patients suffering from gastritis and peptic
ulcer [61]. However, in some of these patients, elimination of the microbial factor is not sufficient,
and symptoms, as well as redox imbalance, may persist long after completion of the treatment [18,65].
Moreover, eradication of H. pylori does not significantly lower the risk of gastric cancer, at least within a
few years after eradication, and the statistical difference becomes significant only after 8–10 years [78].
Therefore, other approaches are also needed in order to overcome these limitations and to address
other aspects of GM injury pathogenesis.
Table 1. Selected pharmacological and non-pharmacological interventions and their effects on HNE
production/utilization in gastric mucosa.
Intervention Target Process/Pharmacological Effect References
Proton pump inhibitors, H2
histamine receptor inhibitors
Reduction of acidity, decreased proteolytic activity of gastric
juice/decreased gastric injury (production of HNE) [61,66]
Antibiotics H. pylori eradication/decreased gastric injury (productionof HNE) [61,66]
NO, CO, H2S-releasing
NSAIDs
Release of CO, NO, and/or H2S modulates redox signaling,
improves endothelial function, and improves





Reduced lipid peroxidation of PUFAs in stomach/reduced




Nrf-2 activators induce expression of antioxidant genes and
increase detoxification of HNE [20,80]
Interval hypoxic training Improvement of autonomic control of microcirculation andfunction of internal organs [81,82]
Exercise, intermittent fasting,
caloric restriction
Activation of autophagy, reduction of systemic
inflammatory response, improvement of protein quality




Mechanism unknown, suggested influence on
microcirculation and/or endothelial function [84,85]
Since substantial amounts of gastrotoxic substances may be ingested with food or generated
during digestion, the idea to use drugs, supplements, or certain types of food able to neutralize toxins
or reduce the rate of lipid peroxidation was actively explored. Indeed, subjects consuming more fruits
and vegetables show lower incidence of gastric diseases, especially gastric cancer [86]. Studies also
show that polyphenols reduce the formation of hydroperoxides in stomach and in in vitro models
of gastric digestion [2,79]. Pre- and probiotics [87], as well as a number of plant-derived traditional,
medicines or extracts, were also shown to be protective against gastric and intestinal mucosal damage
and may improve redox balance in mucous membranes in different parts of the GIT [20]. Thus, a
number of natural compounds present in fruit and vegetables (e.g., phenolic flavonoids, lycopenes,
carotenoids, glucosinolates) act as radical-trapping antioxidants, and they represent not a only useful
and convenient beneficial health-promoting approach, due to their natural occurrence and abundance,
but also a model for the development of novel drugs aimed to modulate redox balance [88].
The molecular mechanisms underlying protective effects of beneficial compounds are often
not yet elucidated, but at least some of them may act via a hormetic response, when moderate
prooxidant action causes the activation of defense mechanisms (for example, by induction of target
genes of the Nrf-2 transcription factor) [72]. Alternatively, they may contribute to increased mucosal
microcirculation through improvement of endothelial function or parasympathetic tone, as it has been
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shown for Actovegin, which has been used as an anti-ulcer drug for several decades [85]. Among
non-pharmacological interventions that showed some efficiency in the case of peptic ulcer disease
is also interval hypoxic training [81]. Exact gastroprotective mechanisms in this case are not clear as
well, but it is likely that the mechanism includes improvements of autonomic balance and enhanced
microcirculation [82].
Therapeutic use of NSAIDs is overwhelming, and in order to reduce their gastrotoxicity, a wide
range of new formulations are introduced or are under development [89]. For example, a number
of nitric oxide (NO)-, carbon monoxide (CO)-, or hydrogen sulfide (H2S)-releasing derivatives of
acetylsalicylic acid and other NSAIDs were shown to be as pharmacologically effective as traditional
drugs, but have preventive effects against NSAID-induced gastrotoxicity via improvement of
endothelial function, and anti-inflammatory and cytoprotective effects [75,76]. Protective actions
of these drugs may be also closely related to HNE signaling pathways and maintenance of redox
balance in GM.
8. Conclusions
The integrity, high functional activity, and sufficient regeneration rate of GM in harsh conditions
is very challenging. The health of gastric epithelium highly depends on the efficiency of redox
balance maintenance, antioxidant defense, and activity of detoxifying systems within the cells, as well
as robustness of blood supply. The products of lipid peroxidation, in particular, of HNE and its
protein/histidine adducts, are important mediators in physiological adaptive reactions, cell signaling,
and are also implicated in pathogenesis of numerous gastric diseases. Hence, while the mechanisms
and consequences of HNE generation in response to strong stressors during acute and chronic gastric
injury are well studied, many other important issues related to gastric carcinogenesis, tumor growth
and progression, the condition of GM after eradication of H. pylori, and many others, still need
extensive studies and new comprehensive approaches.
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Abstract: Growing evidence supports the pivotal role played by oxidative stress in tissue injury
development, thus resulting in several pathologies including cardiovascular, renal, neuropsychiatric,
and neurodegenerative disorders, all characterized by an altered oxidative status. Reactive oxygen
and nitrogen species and lipid peroxidation-derived reactive aldehydes including acrolein,
malondialdehyde, and 4-hydroxy-2-nonenal, among others, are the main responsible for cellular
and tissue damages occurring in redox-dependent processes. In this scenario, a link between
the endocannabinoid system (ECS) and redox homeostasis impairment appears to be crucial.
Anandamide and 2-arachidonoylglycerol, the best characterized endocannabinoids, are able to
modulate the activity of several antioxidant enzymes through targeting the cannabinoid receptors
type 1 and 2 as well as additional receptors such as the transient receptor potential vanilloid 1,
the peroxisome proliferator-activated receptor alpha, and the orphan G protein-coupled receptors 18
and 55. Moreover, the endocannabinoids lipid analogues N-acylethanolamines showed to protect cell
damage and death from reactive aldehydes-induced oxidative stress by restoring the intracellular
oxidants-antioxidants balance. In this review, we will provide a better understanding of the main
mechanisms triggered by the cross-talk between the oxidative stress and the ECS, focusing also on
the enzymatic and non-enzymatic antioxidants as scavengers of reactive aldehydes and their toxic
bioactive adducts.
Keywords: oxidative stress; lipid peroxidation; reactive aldehydes; reactive oxygen and nitrogen
species; free radicals; endocannabinoids; cannabinoid receptors; peroxisome proliferator-activated
receptors; transient receptor potential vanilloid; G protein-coupled receptors
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1. Introduction
Oxidative stress and lipid peroxidation are the consequences of a deregulated redox homeostasis
that results in the accumulation of highly reactive molecules and cellular injury, especially in
those tissues with a high oxygen consumption, such as heart, kidney, and brain, thus leading to
cardiovascular [1,2], renal [3], and neurodegenerative diseases [4–6], just to mention a few. Examples of
the possible repercussions of free radical damage are provided in this review with special emphasis on
lipid peroxidation-derived reactive aldehydes including acrolein (ACR), malondialdehyde (MDA),
and 4-hydroxy-2-nonenal (4-HNE), among others [7].
To get a deeper insight into the cellular pathways that regulate reactive oxygen and nitrogen
species (ROS/RNS) as well as reactive aldehydes formation, there is a growing interest in identifying
free radical scavenging molecules that can prevent cell death following oxidative stress-induced
damage of cellular membranes. In this perspective, over the last few years, the endocannabinoid system
(ECS) has attracted significant attention because of the existing cross-talk between endocannabinoids
(ECs) as well as their lipid analogues and various redox-dependent processes. Therefore, the pathways
by which the ECs and their lipid-related mediators contribute to the modulation of oxidative stress and
lipid peroxidation represent a significant research area that will yield novel pharmaceutical strategies
for the treatment of diseases characterized by a redox imbalance.
The cannabinoid receptors type 1 (CB1) and 2 (CB2), together with additional ECs receptor targets,
take part in the complex ECS and, because of their wide distribution, they may play a role in mediating
the antioxidant properties of ECs [8–10]. However, the great diversity of results in this field discloses
the requirement of a better understanding on the pathways by which these receptors are involved in
regulating oxidative stress and lipid peroxidation processes.
In this review, we will provide an overview of the role of the ECS in pathological conditions
related to a redox status imbalance, leading to a better comprehension of the intricate routes that are
associated to the antioxidant properties exerted by the ECs, thus enhancing the research in finding a
therapeutic benefit for cannabinoid-based drugs in various redox-dependent disorders.
2. Oxidative Stress and Lipid Peroxidation
Oxidative stress can be described as an imbalance between the production of oxidant species and
the antioxidant defenses, which may affect cellular redox homeostasis leading to molecular alterations
and thus resulting in cell and tissue damage [11]. The term “oxidants” is a general term used to identify
several groups of reactive molecules among which ROS and RNS are considered the most interesting
from a biological point of view. ROS/RNS are natural byproducts of aerobic metabolism and are
produced by all living multicellular organisms. ROS include free oxygen radicals and non-radical
molecules, such as superoxide anion (O2•−), hydroxyl (•OH), peroxyl, alkyl, and alkoxyl radicals,
as well as singlet oxygen (1O2), hydrogen peroxide (H2O2), ozone (O3), and hypochlorous acid
(HClO), while RNS include nitrogen compounds such as nitric oxide (•NO), nitrogen dioxide (NO2•),
nitrate (NO3−), nitrite (NO2−), and peroxynitrite (ONOO−) [12,13].
In mammals, the main cellular sources of ROS/RNS are the mitochondrial and microsomal
electron transport chains [14], the NADPH oxidase enzymes (NOXs), which consist of seven isoforms
with various tissue distributions and mechanisms of activation [15,16], the flavoenzyme endoplasmic
reticulum oxireductin 1 [17], nitric oxide synthase (NOS) [18], cytochrome P450 enzymes [19],
cyclooxygenases (COXs), lipoxygenases (LOXs) [20], xanthine oxidase [21], diamine oxidase [22],
and prostaglandin synthase [23]. In addition to these endogenous sources, the ionizing radiation,
ultraviolet rays, pathogens, xenobiotics (e.g., drugs, herbicides, fungicides, trace metals, etc.),
and environmental pollutants (e.g., smog, cigarette smoke, smoke from wood combustion, etc.)
are identified as exogenous sources of ROS/RNS [24], which may seriously alter the fundamental
oxidants-antioxidants balance.
To date, growing evidence confirms that ROS/RNS are produced by healthy cells in a highly
regulated fashion in order to maintain the intracellular redox homeostasis. Moreover, ROS/RNS
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regulate several cellular functions ranging from immune defense to gene expression regulation,
thus acting as reactive molecules secreted against circulating pathogens [25] or as second messengers
of specific signaling pathways [26]. The crucial role played by ROS/RNS in immune defense was
demonstrated by the discovery of the chronic granulomatous disorder (CGD), a hereditary disease
characterized by NOX type 2 (NOX2)-defective phagocytes [27] which are unable to produce ROS/RNS.
This genetic defect leads CGD patients in developing a primary immunodeficiency due to the inability
of host innate defense to kill and digest ingested pathogens such as bacterial and fungal cells [28–31].
Moreover, ROS/RNS play also an important role in the cardiovascular system because of their
ability to regulate blood pressure. In particular, the endothelial NOX2 isoform regulates the release
of •NO, the endothelium-derived relaxing factor, which modulates the caliber of blood vessels,
through the production of O2•−. In hypertension and other vascular pathologies, NOX2 seems to be
up-regulated leading to a reduced •NO bioavailability and to the consequent oxidants-antioxidants
imbalance in the endothelium, further worsening the oxidative state [32–34]. Moreover, in vivo
studies of single nephron function and in vitro studies performed on perfused juxtaglomerular
apparatus preparation demonstrated that also the normal renal functions are modulated by ROS/RNS.
In particular, O2•− and •NO, which are generated by NOX type 3 (NOX3) and NOS type 1 (NOS1)
enzymes, respectively, modulate afferent arteriolar tone and control Na+ reabsorption and renal
oxygenation by regulating the tubuloglomerular feedback response [35–37]. Furthermore, in the loop
of Henle, ROS/RNS increase the absorption of NaCl by modulating the activity of the Na+/H+
exchanger [38,39]. In airway and pulmonary artery smooth muscle cells of the lung, NOX2-generated
ROS/RNS act as signaling intermediates, which regulate the proliferation and differentiation by
the activation of the nuclear factor-κB (NF-κB) and NOS2, and they further show an important role in
O2 sensing [39–41].
Moreover, ROS/RNS formation by mucosal cells of the colon seems to modulate the serotonin
production by enterochromaffin cells through a NOXs-dependent system, thus contributing to
the regulation of serotonin secretion as well as intestinal motility [42]. ROS/RNS have also
a fundamental role in the central nervous system (CNS), in particular in central autonomic
neurons. To this regard, ROS/RNS produced by NOX2 in the nucleus of the solitary tract,
in the hypothalamic paraventricular nucleus, and in the subfornical organ modulate angiotensin
II signaling, thus contributing to the regulation of cardiovascular homeostasis [43,44]. Moreover,
in microglia but not in astrocytes, H2O2 formation by NOX2 enzyme is involved in the regulation of
cell proliferation [45].
Beyond the role as signaling molecules, it has been shown that the aberrant ROS/RNS formation
is the leading cause of cell and tissue oxidative stress-induced damage. Indeed, it is well known that
excessive levels of ROS/RNS may directly damage lipids containing carbon-carbon double bounds
such as cholesterol, glycolipids, phospholipids, and polyunsatured fatty acids (PUFAs), which are
abundant within cellular membranes. To this regard, free radical–mediated lipid peroxidation of PUFAs
is one of the main mechanisms by which ROS/RNS induce the generation of reactive aldehydes [46].
Due to their abundance of reactive hydrogens, PUFAs are more oxidation-prone lipids compared to
monounsatured fatty acids. PUFAs include the ω-3 (e.g., linolenic acid, eicosapentaenoic acid and
docosahexaenoic acid) and ω-6 (e.g., linoleic acid and arachidonic acids) fatty acids.
Lipid peroxidation is a chain reaction, which, once started, proceeds through three main
steps referred to initiation, propagation and termination [47]. Moreover, lipid peroxidation may
occur by several mechanisms: (1) free radical-mediated oxidation [47], (2) enzymatic oxidation,
and (3) spontaneous oxidation [48]. In this review, we will focus mainly on the free radical–mediated
mechanisms that lead to the formation of reactive aldehydes from PUFAs. In particular, the free
radical-mediated oxidation of PUFAs occurs through the following reactions: (1) During the initiation
phase, ROS/RNS free radicals attack PUFAs ripping off one hydrogen atom, leading to lipid
radicals formation. (2) During the propagation phase, lipid radicals react with oxygen molecules,
thus producing peroxyl radicals, which, in turn, react with nearby lipids resulting in the formation of
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new lipid radicals and lipid hydroperoxides. Due to their high instability, lipid hydroperoxides are
further degraded into reactive secondary products, such as ACR, MDA, 4-HNE and other reactive
aldehydes [7]. (3) During the termination phase, peroxyl radicals may react with other radicals thus
generating less reactive compounds, which block the propagation phase (Figure 1) [49].
Figure 1. Schematic diagram of the free radicals-mediated peroxidation of polyunsatured fatty acids
(PUFAs). ROS/RNS: reactive oxygen and nitrogen species; ACR: acrolein; MDA: malondialdehyde;
CTA: crotonaldehyde; 4-HNE: 4-hydroxy-2-nonenal; 4-HHE: 4-hydroxy-hexanal; 4-ONE: 4-oxo-nonenal.
During the initiation phase (1), ROS/RNS free radicals react with PUFAs and rip off an allylic hydrogen
thus forming lipid radicals. Generally, lipid radicals tend to be stabilized by a molecular rearrangement.
(2) In the propagation phase, lipid radicals react with oxygen to form lipid peroxyl radicals, which in
turn react with PUFAs or other nearby lipids resulting in the formation of new lipid radicals and
lipid hydroperoxides (3). During the termination phase (4), antioxidants or lipid radicals block
the propagation phase by donating a hydrogen atom to lipid peroxyl radicals resulting in the formation
of non-radical products. Nevertheless, lipid hydroperoxides are highly unstable therefore they are
further degraded into reactive secondary products such as ACR, MDA, 4-HNE, and other reactive
aldehydes (5).
Today, it is well accepted that oxidative stress and lipid peroxidation are key features in
the pathogenesis of several disorders. Indeed, it has been reported that lipid peroxidation products
may interfere in vivo with several biological processes, such as substrate-receptor interaction,
signal transduction, gene expression, and homeostatic responses to intracellular and environmental
stimuli [50–53]. Currently, the main objective of research focused on oxidative stress, lipid peroxidation,
and reactive aldehydes is the characterization of the pathogenic mechanisms in several disorders as
well as the identification of specific biomarkers for diseases.
Among the reactive aldehydes, the most frequently studied are ACR, MDA, 4-HNE, 4-hydroxy-
hexanal (4-HHE), 4-oxo-nonenal (4-ONE), and crotonaldehyde (CTA) (Figure 2).
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Figure 2. Chemical structures of the main reactive aldehydes produced by lipid peroxidation.
ACR: acrolein; MDA: malondialdehyde; CTA: crotonaldehyde; 4-HNE: 4-hydroxy-2-nonenal; 4-HHE:
4-hydroxy-hexanal; 4-ONE: 4-oxo-nonenal.
Some of these compounds are known to contribute to the pathogenesis of several diseases,
such as atherosclerosis, rheumatoid arthritis, neuropsychiatric disorders, heart disease, cellular
reperfusion injury, cancer, and metabolic disorders such as diabetes and hepatic diseases [4,5,7,12,54].
Reactive aldehydes are a group of electrophilic molecules with different features: some of them
are very unstable, characterized by a short half-life, while others are long-lived and highly reactive.
In the past years, the endogenous formation of reactive aldehydes has drawn great interest. The
ability of aldehydes to easily diffuse across biological membranes [55], and to form adducts with
macromolecules such as phospholipids, nucleic acids and proteins [7,46,56–58], is of particular concern.
Adducts consist of covalent modifications, which involve the formation of Schiff bases or Michael
addition reactions. To this regard, the reactive aldehydes toxicity against peptides and proteins is due
to their ability to alter their structure and/or function through the formation of cross-links between
different amino acid chains, thus potentially leading to the production of aberrant protein aggregates
(Figure 3) [59]. Concerning the toxicity of reactive aldehydes against DNA, it has been shown that
these compounds may react against nucleobases, among which the most affected is guanine, due to its
chemical structure prone to oxidative modifications. The most studied DNA modifications caused by
reactive aldehydes are the exocyclic adducts (Figure 4) [57,58,60].
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Figure 3. Schematic representation of protein adducts formation and protein-protein cross-linking by
4-HNE. Reactive aldehydes are able to modify peptides/proteins by the formation of toxic adducts
which may alter the structure and/or the function of targeted peptides/proteins. These adducts consist
of covalent modifications which occur through the formation of Schiff bases or through Michael addition
reactions: (1) Schiff base formation on primary amine (lysine residue) through the reaction between
peptides/proteins and 4-HNE, (2) Michael addition of 4-HNE on amino groups (lysine/histidine
residues) or thiols (cysteine residue) through the reaction between peptides/proteins and 4-HNE,
and (3) Protein-protein cross-linking through the reaction between 4-HNE with histidine and lysine
residues from different peptides/proteins.
 
Figure 4. Hypothetical DNA adducts produced by reactive aldehydes.By reacting with DNA,
in particular with the deoxyguanosine nucleobases, several reactive aldehydes such as ACR, MDA,
4-HNE, 4-ONE and CTA produce DNA modifications named exocyclic adducts that alter the DNA
structure and, if not correctly repaired, may produce carcinogenic effects.
4-HNE and 4-ONE are generated from lipid peroxidation of ω-6 PUFAs (e.g., arachidonic acid
and linoleic acid) [61]. Among reactive aldehydes, 4-HNE is the most studied, and its toxic effects
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can be explained by its ability to form protein adducts by reacting with thiols and amino groups
of cysteine, histidine, and lysine amino acid residues [62]. For a detailed explanation of the main
4-HNE-modified proteins, see the following publication [63]. 4-ONE is an electrophilic compound
that reacts both in vitro and in vivo with nucleobases, in particular with 2′-deoxyadenosine and
2′-deoxycytidine [64–67].
Unlike 4-HNE and 4-ONE, 4-HHE is generated from ω-3 PUFAs (e.g., docoshexaenoic acid,
eicosapentaenoic acid and linolenic acid) and, because of its chemical structure, it is considered a soft
electrophil with a lower reactivity compared to 4-HNE [7].
MDA, which is widely used as a marker of lipid peroxidation [68], contains at least two
unsaturations [7] and is generally produced by PUFAs. Regarding its toxicity, MDA modifies target
proteins through the formation of Schiff base complexes, which occur on the amino groups of lysine,
histidine, arginine, glutamine, and asparagine amino acid residues as well as on the N-terminal of
peptide chains [69]. For a detailed explanation of the main MDA-modified proteins, see the following
publication [63]. Moreover, in vitro mutagenicity of MDA has been observed by several authors using
the Salmonella tiphimurium assay [70–72]. Several studies showed the presence of both MDA and
MDA-protein adducts in rheumatoid arthritis patients compared to healthy controls [73–76]. Moreover,
high levels of circulating autoantibodies against MDA-modified epitopes have been detected in serum
or plasma of patients affected by rheumatoid arthritis [77–79]. CTA or 2-butenal is a carcinogenic
aldehyde formed by lipid peroxidation, which is also commonly found in air pollution, in cigarette
smoke and in other combustion processes. CTA is able to form adducts with DNA [80–83] and proteins.
In accordance with in vitro mutagenesis assay with Salmonella typhimorium, CTA is a mutagenic
compound [84] able to induce hepatocellular carcinoma in rats [85]. About protein modifications,
CTA reacts preferentially with lysine and histidine amino acid residues, thus forming β-substituted
butanal adducts [86].
ACR or propenal is a metabolite of PUFAs lipid peroxidation, but it is also a ubiquitous environmental
pollutant by-product derived by incomplete combustion of organic matter and plastic, cigarette smoke,
overheated cooking oils, as well as by anticancer treatment with cyclophosphamide [87,88]. Among
reactive aldehydes, ACR is the strongest electrophile, which shows a high reactivity with cysteine,
histidine, and lysine amino acid residues. Moreover, ACR forms cyclic adducts with nucleosides
in vitro, and is recognized as a potent mutagen [89].
Despite their harmful properties, growing evidence has also demonstrated the hormetic
effects of reactive aldehydes [51,63,90–93]. The term “hormesis” refers to a highly conserved and
dose-dependent response of biological systems in which low doses of noxious stimuli activate an
adaptive response that increases the functionality and/or resistance of the systems to more severe
stress. Conversely, high doses of noxious stimuli cause inhibition or detrimental effects [94]. To this
regard, low levels of reactive aldehydes may modulate cell signaling, cellular proliferation and
many other processes [7,61,89,95]. A typical example is represented by 4-HNE, which may also act
as a signaling molecule by modulating the activity of different stress-related transcription factors,
such as nuclear factor-erythroid 2-related factor 2 (Nrf2), activating protein-1, NF-κB, and peroxisome
proliferator-activated receptors (PPARs) [96–100]. Moreover, low levels of 4-HNE may stimulate
the activity of protein kinase C (PKC), may increase cell proliferation, and the expression of
cyclooxygenase type 2 (COX-2) and prostaglandin E2 (PGE2) [51].
3. The Endocannabinoid System: Endocannabinoids, Their Lipid Analogues, and the Receptors
Over the last years, the ECS has attracted considerable attention as a signaling system because of
its emerging regulatory functions in health and disease.
Several components jointly make up the ECS, and they specifically consist of (1) the ECs,
endogenous bioactive lipid mediators generated in the brain and in several peripheral tissues;
(2) two membrane G-protein-coupled receptors (GPCRs) referred to as CB1 and CB2, and others,
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not yet identified, receptors; and (3) several proteins implicated in the biosynthesis, release, transport,
and degradation of these lipid mediators [101].
N-arachidonoyl-ethanolamine or anandamide (AEA) and 2-arachidonoyl-glycerol (2-AG),
both derived from the arachidonic acid, are the best characterized members of the main families
of ECs (N-acylethanolamines (NAEs) and monoacylglycerols (MAG), respectively) and exert their
biological effects by interacting with CB1 and/or CB2 receptors [102]. AEA, an endogenous eicosanoid
derivative isolated from pig brain in 1992, was the first EC to be identified [103], and it is well known
to modulate several physiological functions being present in the autonomic and in the CNS as well as
in the gastrointestinal tract and in the cardiovascular, immune and reproductive systems [104,105].
The second EC ligand to be discovered was 2-AG [106], which has been identified in brain and
reproductive tissues in higher concentrations compared to AEA [107–109]. Moreover, 2-AG has also
been found in the heart, endothelial cells and circulating cells such as macrophages and platelets [104].
Even though AEA and 2-AG interact with both CB1 and CB2 [110], they show different affinity
and efficacy. In particular, depending of on the specific tissue, AEA can be either a partial or a full
agonist of CB1, whereas it shows a low overall efficacy for CB2, for which it is a relatively weak
ligand [111]. On the contrary, 2-AG appears to be a full agonist of both receptors [112] showing higher
CB1 and CB2 efficacy than AEA.
Unlike what has been thought for many years, CB1 expression is not restricted to the brain,
where it represents the most abundant of all GPCRs [113,114], but it has been also identified, albeit at
much lower concentrations, in various peripheral tissues and cell types including adipose tissue, liver,
skeletal muscle, kidney, bone, pancreas, myocardium, human coronary artery endothelial and smooth
muscle cells and inflammatory cells (macrophages, lymphocytes) [104,115,116].
In the brain, CB1 is widely present in cerebral cortex, hippocampus, caudate-putamen,
substantia nigra pars reticulata, globus pallidus, entopeduncular nucleus, and cerebellum [117].
Interestingly, accumulating evidence supports a new mechanism of action of CB1 signalling in
the brain, since it has been found in mitochondria, where it probably modulates neuronal energy
homeostasis [118]. On the other hand, the CB2, also known as the “immune cannabinoid receptor”,
is primarily expressed in immune and hematopoietic cells. However, its presence has also been
established at lower, although functionally relevant, levels in the brain, liver, gut, exocrine and
endocrine pancreas, reproductive cells, bone, myocardium, human coronary endothelial and smooth
muscle cells, and inflammatory cells (e.g., lymphocytes, macrophages, neutrophils) [104,115,119].
CB1 and CB2 are seven-transmembrane-domain proteins both coupled with Gαi/o proteins,
which inhibit adenylyl cyclase (AC) leading to a reduced protein kinase A (PKA) and PKC activity
and to the consequent inhibition of voltage-gated Ca2+ channels and activation of inwardly rectifying
K+ currents [120]. Furthermore, through a common pathway mediated by Gαo proteins, CB1 and
CB2 are also able to modulate Ras-related protein (Rap) (a member of the Ras small G protein family)
and, in particular, it has been postulated that the activation of Gαo would release Rap1 guanosine
triphosphatase (GTPase) activating protein (Rap1 GAP), which then would be free to inhibit the activity
of Rap [121]. Moreover, several observations demonstrated that, depending on the CB1 agonist,
this receptor could also interact with Gαs proteins [122,123].
On the basis of the cell type, the signaling of CB1 and CB2 may also involve G protein independent
mechanisms, leading to the activation of mitogen-activated protein kinases (MAPKs) including
p38- and p44/42-MAPKs, c-Jun N-terminal kinase (JNK), PKA and PKC, COX-2, and ceramide
signaling [124–126].
However, beyond binding the CB1 and CB2 there is increasing pharmacological evidence
for additional receptor targets for ECs [127], such as the transient receptor potential vanilloid 1
(TRPV1) [127–129], the PPARs family [130,131] and the orphan G protein-coupled receptors 119
(GPR119), 55 (GPR55) and 18 (GPR18) [132]. TRPV1 is a member of the vanilloid transient receptor
potential cation channel subfamily, abundantly expressed in the cardiovascular system, peripheral
nervous system, CNS and in epithelial cells of the bladder and the gastrointestinal tract. It is known to
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act by activating PKA and the endothelial nitric oxide synthase (eNOS), thus stimulating the production
of •NO and the release of calcitonin gene-related peptide and substance P [133,134], which, in turn,
lead to the altered ion permeability [135].
The finding that some pharmacological actions of AEA can be mediated by the activation of TRPV1
suggests the capability of this endogenous lipid compound to act as an “endovanilloid” [136,137],
although AEA induces typical TRPV1-mediated effects with a lower affinity compared to CB1 [127].
PPARs are a family of transcription factors constituted by three different isoforms (α, β/δ, and γ),
widely expressed in tissues with a higher oxidative capacity such as the cardiovascular system and,
in particular, cardiomyocytes, endothelial cells, and vascular smooth muscle cells [104], but also in
several brain areas and in peripheral tissues such as kidney and liver [138].
After being activated by a ligand, PPARs stimulate gene expression by creating heterodimers
with the retinoid X receptor (RXR), thereby binding to specific peroxisome proliferator response
elements (PPREs) in the promotor region of target genes [139]. They are involved in different
biological processes, such as energy homeostasis, lipid and lipoprotein metabolism, cell proliferation
and inflammation, blood pressure control and hypertensive-related complications, such as stroke and
renal damage [140,141]. Furthermore, among the different members of the PPARs family, PPAR-α is
recently attracting great attention for its anti-oxidative properties [142].
Moreover, AEA has been shown to exert anti-inflammatory and analgesic actions, and to control
feeding behavior by activating the isoform α and γ of PPARs receptors [130,143,144]. Unlike AEA,
2-AG has no affinity for TRPV1 and is only able to activate PPARs [144,145].
As above mentioned, additional GPCRs were suggested to participate in non-CB1/CB2-mediated
actions of ECs including the GPR18, GPR119 and GPR55 [146].
The GPR18, widely expressed in the cardiovascular system, CNS, spleen, and testis, is coupled
with Gαi/o proteins whose activation results in the AC inhibition and in the modulation
of the PI3K/Akt and extracellular signal-related kinases (ERK 1/2) pathways [104]. The Gαs
coupled-GPR119, primarily expressed in human and rodent pancreas, foetal liver, gastrointestinal
tract and in rodent brain, stimulates AC leading to increased intracellular adenosine 3′,5′-cyclic
monophosphate (cAMP) levels, thus regulating incretin and insulin hormone secretion [147].
Finally, the GPR55, which is expressed in human brain and liver, but also in rat spleen, vasculature,
intestine, foetal tissues, decidua, and placenta, is coupled with Gα12/13 proteins and increases
intracellular Ca2+ via the activation of RhoGTPase nucleotide exchange factors (RhoGEFs) [148].
Different from the classical neurotransmitters, the ECs are not stored in intracellular vesicles but
are synthesized “on demand” from membrane phospholipid precursors in response to stimuli that
trigger an increase in intracellular Ca2+ levels [131], and then released from postsynaptic neurons to
act on presynaptic CB1/CB2 through a retrograde mechanism [149,150]. However, recent findings
suggested that AEA could be stored inside the cell into adiposomes, which are thought to connect
plasma membrane to internal organelles along the metabolic route of this EC [151].
Although 2-AG and AEA are both derived from arachidonic acid, they do not share the same anabolic
and catabolic enzymes [126]. Depending on the available precursors and the distinct physiological or
pathological conditions [131], AEA can be synthesized by multiple routes. The main pathway for AEA
biosynthesis consists of the enzymatic cleavage of the precursor N-acyl-phosphatidylethanolamine
(NAPE), which is mediated by the NAPE-phospholipase D (NAPE-PLD) [152], whereas the
biosynthesis of 2-AG begins with the hydrolysis of 2-arachidonoyl-phosphatidylinositol that occurs
through the activity of diacylglycerol lipase (DAGL) and phospholipase Cβ [153].
ECs have a short duration of action, being rapidly metabolized by intracellular enzymes such
as fatty acid amide hydrolase (FAAH), the main enzyme responsible for AEA degradation [154–156],
and monoacylglycerol lipase (MAGL), which favors 2-AG catabolism [157].
Additional oxidative enzymes, including COX-2, LOXs and cytochrome P450 may also play a role
in the metabolism of both AEA and 2-AG by transforming them in bioactive eicosanoids [158,159],
which may activate cannabinoid receptor-independent mechanisms [160].
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Beyond the ECs, several other endogenous mediators have attracted considerable attention, despite
some of them showed poor affinity for CB1 and CB2 [126]. Among them, palmitoylethanolamide
(PEA), stearoylethanolamide (SEA), and oleoylethanolamide (OEA), belonging to the family of
NAEs, are the best characterized. However, other lipid analogues have recently been discovered
and include N-arachidonoyldopamine (NADA), Cis-9,10-octadecanoamide (oleamide or ODA),
and N-arachidonoylglycine (NAGly) [161], commonly referred to as endovanilloids because of
their ability to activate TRPV1. Additionally, 2-arachidonoylglyceryl ether (noladin ether, 2-AGE),
O-rachidonoylethanolamine (virodhamine), and arachidonoyl-L-serine (ARA-S) have also been
identified [105].
Although still debated, NAEs are generally thought to be cannabinoid-receptor inactive, and they
appeared to be responsible for enhancing AEA activity through the so-called “entourage effect”,
which consists in the inhibition of FAAH leading to an increase of AEA tissue levels [162].
PEA and OEA, shorter and fully saturated analogues of AEA, are well-documented high affinity
PPAR-α and TRPV1 endogenous ligands and have been shown to exert roles in many physiological
and pathological conditions such as satiety, inflammation, pain and memory consolidation [163–168].
Furthermore, due to their high expression in the CNS, growing evidence established their protective
effects in neurodegenerative and neuropsychiatric disorders [169–172]. Moreover, PEA is also an
endogenous agonist of GPR55, while OEA can bind GPR119.
As already mentioned, NADA belongs to the endovanilloid class of ECs and is an endogenous
ligand of CB1, TRPV1 and PPAR-γ [105]. Since this compound is widely distributed in the brain,
particularly in the striatum, hippocampus, cerebellum, and dorsal root ganglia, it has been shown to
exert a role in neuronal pain and inflammation [105]. Interestingly, NADA also showed antioxidative
and anti-inflammatory effects on glial cells [105].
2-AGE is an endogenous analogue of 2-AG, able to bind to CB1, PPAR-α and very weakly to
CB2 [143,173]. Moreover, thanks to its chemical structure, 2-AGE is more stable compared to AEA and
2-AG, which are rapidly hydrolysed in vivo [102].
Virodhamine is the ester of arachidonic acid and ethanolamine and is more expressed in
the periphery compared to the brain, where it is rapidly converted to AEA, due to its chemical
instability. Virodhamine has been shown to act as a full agonist of CB2 and a partial agonist of CB1,
whereas at higher concentrations it can be also a CB1 antagonist [174]. Furthermore, it appeared to
activate also PPAR-α [143] and GPR55 [175].
NAGly is an efficacious ligand of the orphan GPR18, with no CB1, CB2, or TRPV1 activity,
and shows analgesic, anti-inflammatory, and vasorelaxant properties [176].
AraS is another ECs-like compound structurally similar to AEA, which was demonstrated to
produce endothelium-dependent arterial vasodilatation and to activate p44/42 MAPKs in cultured
endothelial cells, effects also observed after ECs treatment [105]. To date, AraS has been shown to be a
low efficacy agonist to GPR18 without binding CB1/CB2 or additional ECs receptors [105].
Lastly, ODA is a full agonist of cannabinoid receptors with selectivity for the CB1, whose activation
is the primary responsible for ODA effects [105].
As suggested by the wide range and distribution of the cannabinoid receptors and by the several
compounds that take part in the ECS, the latter is now considered as a complex signaling system
that may play a key role in physiological and pathological conditions. Thus, targeting these intricate
pathways can represent a challenge in finding a therapeutic benefit for cannabinoid-based drugs in
various disorders.
4. Modulation of Oxidative Stress and Lipid Peroxidation through Cannabinoid Receptors by
Endocannabinoids and Their Lipid Analogues
It is well documented that there is an important cross-talk between the ECS and various
redox-dependent processes. Indeed, the ECS has been reported as a novel therapeutic target against free
radical-induced lipid peroxidation. In fact, it has been shown that ECS is implicated in the development
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of a growing number of diseases linked with redox homeostasis deregulation, including those
associated with metabolic disorders, such as type 2 diabetes and obesity, cardiovascular diseases,
as well as various neuropsychiatric and neurodegenerative disorders, ischemia/reperfusion (I/R)
injury, and renal diseases [2,4,5,54,177].
In the past decade, various and complex pathways have been studied to clarify the role of ECs in
the modulation of redox imbalance, whose knowledge is the specific aim of this review.
There is accumulating evidence that shows the ability of ECs to alter the expression and/or
the activity of enzymes implicated in the generation of these reactive small molecules (such as NOX2
and NOX4), and to modulate the production of cellular ROS/RNS by controlling mitochondrial-derived
ROS/RNS generation [177].
Alternatively, ECs and their lipid analogues may modulate oxidative stress and lipid peroxidation
either by conveying beneficial free radical scavenging effects or through targeting CB1 and CB2 [8–10].
Furthermore, CB1 and CB2 are differentially involved in oxidative stress modulation. In fact,
several studies highlight that the activation of CB1 results in a redox imbalance enhancement,
whereas CB2 stimulation is responsible for lowering ROS/RNS formation [9]. The beneficial or
detrimental effects of ECs may be cell- and injury-type-specific and may depend on the stage of
the disease progression as well [8].
This aspect was further investigated by Han and colleagues, who demonstrated a different role of
CB1 and CB2 in regulating macrophage activity, and, in particular, the former appeared to be directly
involved in the induction of intracellular ROS/RNS formation with consequent pro-inflammatory
macrophage response, while the latter, after being activated by AEA, was able to negatively regulate
CB1-stimulated ROS/RNS generation, through a pathway involving the small G protein, Rap1 [9].
The authors further showed that blocking CB1 while selectively activating CB2 might suppress
pro-inflammatory responses of macrophages.
These data are consistent with other studies using cisplatin-induced renal dysfunction [178–181],
in which it was observed that blocking the CB1 [179], or activating the CB2 [180,181], led to
the attenuation of the cisplatin-induced increase of renal 4-HNE and ROS/RNS-generating enzymes
(NOX2 and NOX4) expression, thus protecting against tubular damage.
Other examples of the opposite effects of CB1 and CB2 come from studies conducted in animal
models of obesity and type 1 and 2 diabetes mellitus, where an increase of oxidative stress is
observed [182–184]. In fact, in these models, increased levels of ECs in various renal cells contribute to
the development of oxidative stress, as a result of renal CB1 activation, whereas inhibition of CB1 or
activation of CB2 are able to ameliorate such effects (Figure 5) [185].
Overall, the over activation of the ECS that occurs in many type of tissue injury may
induce oxidative stress, inflammatory cell infiltration, and the consequent cell death through CB1
activation [8,179], while it may also serve as an endogenous compensatory mechanism to limit early
inflammatory response and interrelated oxidative stress-cell death through the activation of CB2 [186].
Interestingly, a cross-talk between redox homeostasis and ECS is particularly involved in
the regulation of the cardiovascular system and metabolic tissues (i.e., liver, skeletal muscle and
adipose tissue) [187,188], where CB1 and CB2 are widely distributed. Furthermore, previous studies
have suggested increased ECs levels in many cardiovascular disorders, such as cardiomyopathies,
atherosclerosis, and hypertension [189].
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Figure 5. Role of endocannabinoids (ECs) and their lipid analogues in modulating reactive oxygen and
nitrogen species (ROS/RNS) and reactive aldehydes formation. AM281: 1-(2,4-dichlorophenyl)-5-(4-
iodophenyl)-4-methyl-N-4-morpholinyl-1H-pyrazole-3-carboxamide; SR141716: rimonabant; CB: can
nabinoid receptors; AEA: anandamide; 2-AG: 2-arachidonoyl-glycerol; TRPV: transient receptor
potential vanilloid; CTA: crotonaldehyde; NAGly: N-arachidonoylglycine; GPR18: G protein-
coupled receptor 18; GPR55: G protein-coupled receptor 55; LPI: L-α-lysophosphatidylinositol; ECs:
endocannabinoids; PEA: palmitoylethanolamide; PPARs: peroxisome proliferator-activated receptors;
SOD: Cu2+/Zn2+-superoxide dismutase; MDA: malondialdehyde; PPRE: peroxisome proliferator
response element; RXR: retinoid X receptor; NOX: NADPH oxidase enzyme; GSH: glutathione; GSSG:
oxidized glutathione; ACR: acrolein; MAPK/ERK1/2: mitogen-activated protein kinases/extracellular
signal-regulated kinases; PKA: protein kinase A; cAMP: adenosine 3′,5′-cyclic monophosphate;
CAMKII: Ca2+/calmodulin-dependent protein kinase; AC: adenylyl cyclase.
It is well known that cardiovascular diseases are associated with oxidative stress, which leads to
the accumulation of lipid peroxidation-derived reactive aldehydes and may consequently cause an
increase in the formation of ROS/RNS and/or a decrease in the antioxidant defense [2].
In this regard, it has been demonstrated that, after being activated by AEA, CB1 expressed
in endothelial cells [190] and in cardiomyocytes in a murine model of doxorubicin-induced
cardiomyopathy [8], induce the activation of the p38-JNK-MAPK pathway and increase the generation
of ROS/RNS. These effects lead to cell death and resulted to be partially attenuated by
the pharmacological inhibition of CB1 [9].
In contrast to CB1, the activation of CB2 appeared to exert cardioprotective effects by reducing
O2•− production and decreasing endothelial cell activation. These findings are in agreement with
recent studies showing that CB2 activation, by ECs and their analogue lipid mediators, protects against
oxidative stress-induced tissue damage in experimental models of I/R injury [191–195], cardiovascular
inflammation, and/or atherosclerosis [191,196,197].
Among the cardiovascular diseases, atherosclerosis is due to altered homeostatic redox processes
with progressive ROS/RNS over production, which leads to the generation and deposition of toxic
oxidized low-density lipoproteins (oxLDL) in the vessel wall. It has been clearly demonstrated that
OxLDL promote the activation of NOXs and the synthesis of O2•− by a cluster of differentiation 36
(CD36) scavenger receptor-mediated method, effects that can be counteracted by several compensatory
mechanisms including the involvement of the ECS [198].
Support for this comes from the observation that increased production of O2•− and enhanced
NOXs activation in atherosclerosis correlated with increased rates of 2-AG biosynthesis in the vessel
wall, which may be a compensatory response to oxidative stress via CB2 signaling [199].
In agreement with these results, it has been observed that the genetic disruption of CB2 in
Apolipoprotein E-deficient mice (ApoE−/−), a murine model of atherosclerosis, is the cause of
80
Antioxidants 2018, 7, 93
boosted O2•− generation, whereas its stimulation reduced vascular O2•− release, resulting in
the suppression of ROS/RNS generation and a subsequent reduction in the size of atherosclerotic
lesions (Figure 5) [200].
Further evidence of the protective effects of ECs in atherosclerosis comes from the demonstration
that CB1 inhibition in ApoE−/− mice is able to promote the down-regulation of vascular angiotensin II
type 1 receptor (AT1), which is responsible for NOXs activation when stimulated by angiotensin II [201].
Consequently, the decreased expression of AT1, mediated by CB1 inhibition, leads to the reduction of
NOXs activity and oxidative stress, thereby improving endothelial function and exerting beneficial
direct vascular effects [201].
Since the discovery that the levels of NAEs are higher in several pathological conditions linked
with redox homeostasis impairment, these compounds are attracting great attention as a survival
response toward oxidative damage [202].
Indeed, it has been clearly shown that NAEs, particularly 16:0 and 18:0, exert protective effects in
many diseases by the inhibition of free radical-induced lipid peroxidation [203], which is considered
one of the main causes of cell damage and death [204].
In particular, previous findings discovered an involvement of two long-chain NAEs, PEA and
SEA, in the inhibition of lipid peroxidation in liver mitochondria membranes of acute hypoxic
hypoxia animal model [203], a pathological condition associated with an increase in partially reduced
oxygen products, which represent the main cause of lipid oxidation-induced formation of reactive
aldehydes [205]. The authors suggested that the inhibitory effect of NAEs on lipid peroxidation
depends on the length of acyl chain and is related to their ability to protect membranes [206].
These results are in good agreement with other data showing that OEA treatment of rat heart
mitochondria is able to reduce the production of MDA, which is one of the end products of lipid
peroxidation in cell membrane [203].
Among NAEs, OEA, PEA, and AEA appeared to inhibit Cu2+-induced in vitro lipid peroxidation
in plasma lipoproteins [202] and cardiac mitochondria [207], consequently showing antioxidant
properties in the pathogenesis of atherosclerosis. Moreover, Zolese and collaborators demonstrated
that, depending on its concentration of incubation, PEA exerts both anti-oxidative and pro-oxidative
effects on radical-induced oxidation of plasma LDL [208]. The authors showed that higher PEA
concentrations could be responsible for its pro-oxidant effect, whereas PEA at lower levels is able to
suppress reactive aldehydes, generated by lipid peroxidation, and to decrease the consumption rate of
LDL endogenous anti-oxidants, thereby showing anti-oxidant properties [208].
In the context of cardiovascular diseases is also interesting to mention hypertension, which is
characterized by (1) deregulation of ECS with increased activity of FAAH and MAGL, (2) increased
levels of AEA, 2-AG, and NADA, and (3) increased expression of CB1 [209], effects that are
accompanied by an imbalance of redox homeostasis (decreased activities of glutathione peroxidase
(GPx), glutathione reductase (GR) and the antioxidant enzymes Cu2+/Zn2+-superoxide dismutase
(SOD) and catalase (CAT)).
It has been demonstrated that increased levels of AEA, following chronic administration of
the FAAH inhibitor URB597 in a rat model of hypertension [210], significantly enhanced the expression
of the CB1, thus preventing the hypertension-induced decrease of SOD, glutathione (GSH) and
glutathione transferase (GT) activities and consequently lowering ROS generation and inducing
hypotension. However, it has been postulated that the enhanced AEA levels are responsible for
the perturbation of membrane phospholipid metabolism resulting in PUFAs chain cyclization or
fragmentation. This causes an increase in the formation of α,β-unsaturated reactive aldehydes such as
4-HNE, MDA, and 4-ONE in the liver of hypertensive rats [209].
It is well documented that ECS and oxidative stress may also play a role in the pathophysiology
of liver diseases [188,211]. For instance, DeLeve and collaborators [212] reported that CB1
activation is responsible for liver inflammation and, therefore, induces non-alcoholic liver disease,
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whereas the CB2 stimulation appeared to have protective effects in liver damage through reducing
liver oxidative stress [213].
Accumulating evidence supports the involvement of ECS as a therapeutic potential in many
neurodegenerative pathologies such as Alzheimer’s and Parkinson’s diseases, in which oxidative
stress has been recognized as one of the hallmarks of the pathology [4,171,172,214–217].
Indeed, the brain is a tissue with a high oxygen consumption whose cell membranes are
particularly rich in PUFA side-chains and, therefore, highly sensitive to lipid peroxidation and oxidative
damage [54,183,218].
NOXs enzymes have been shown to be significant sources of ROS/RNS during tissue injury
and, in particular, it has been observed that the activation of NOX2 contributes to oxidative
imbalance–induced CNS damage [219], while its inhibition is able to ameliorate cerebral oxidative
stress injury [220].
A recent study conducted by Jia and collaborators defined AEA as a promising candidate
for the treatment of oxidative stress–related neurological disorders [221]. In particular, AEA has
been found to protect a mouse hippocampal neuron cell line from H2O2-induced redox
imbalance by increasing SOD and GSH intracellular levels, reducing oxidized glutathione (GSSG),
increasing the GSH/GSSG ratio, and lowering NOX2 expression. All of these effects were completely
abolished by both CB1 antagonist administration and CB1-siRNA, suggesting that the ability of
AEA to ameliorate oxidative stress in hippocampal neurons may be mediated by CB1 activation
(Figure 5) [221].
Similarly, it has been also reported that the stimulation of CB1 is able to reduce intracellular
ROS/RNS generation and NOX2 expression thus enhancing nigrostriatal dopaminergic neurons
survival in a mouse model of Parkinson’s disease [222].
These findings supporting the beneficial effects of CB1 activation against ROS/RNS formation
in the brain seem to be controversial in comparison to what above mentioned for the cardiovascular
and renal tissues. An explanation for this argument comes from growing evidence suggesting that
the pathways underlying the interplay between cannabinoid receptors and oxidative stress modulation
may be cell type–specific [177].
Notably, as well as responses mediated by CB1, further data showed that the modulation of CB2
signaling, either by using specific CB2 agonists [223–225] or by inhibiting 2-AG degrading enzyme
MAGL [226], can ameliorate the morphological changes induced by oxidative stress and attenuate
cerebral β-amyloid plaque accumulation in a mouse model of Alzheimer’s disease carrying mutated
human APPswe and PS1dE9 genes [227,228].
Interestingly, in vitro studies revealed that a selective CB1 agonist, arachidonyl-2-chloroethylamide,
decreased the Fe2+-induced lipid peroxidation in the brain, through a metal-chelating mechanism, as well
as the •OH radicals generated by the Fenton system [229].
Moreover, the activation of the recently discovered mitochondrial CB1 by arachidonyl-2-chloroethylamide
has been demonstrated to reduce oxidative stress, thereby exerting neuroprotective effects in I/R
injury [227]. To this regard, CB2 activation also appeared to have a role in attenuating I/R damage
through lowering ROS/RNS production and lipid peroxidation [227].
The involvement of CB2 in I/R injury has also been investigated in a context of propofol
cardioprotection in an in vivo model of myocardial I/R injury, in which it has been observed that CB2
inactivation reverses propofol cardioprotective and anti-oxidative effects [230]. These findings imply
that the enhancement of ECs release and the subsequent activation of CB2 signaling are responsible for
the reduced oxidative stress mediated by propofol cardioprotection in myocardial I/R injury [230].
Furthermore, CB2 are expressed in the bladder [231] and are involved in the treatment of
hemorrhagic cystitis, a common side effect of Cyclophosphamide, an antineoplastic alkylating agent
usually metabolized by the liver to ACR, which is accumulated in urine and therefore is considered to
be the main responsible for Cyclophosphamide-induced cystitis [232]. The findings of this study
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revealed that, following stimulation, CB2 attenuated ACR-induced cystitis through modulating
ERK1/2 MAPK pathways (Figure 5) [232].
AEA and 2-AG are also involved in the progression of cancer, where they were shown to exert
protective effects against increased ROS/RNS production–induced tumor [233], leading to apoptosis
in normal and cancer cells by modulating ERK and ROS/RNS pathways [234].
5. Modulation of Oxidative Stress and Lipid Peroxidation through the Transient Receptor
Potential Vanilloid Channels by Endocannabinoids and Their Lipid Analogues
The transient receptor potential (TRP) channels superfamily is a wide group of tetrameric channels
formed by six transmembrane domains and a cation-selective pore. On the basis of its amino acid
sequence homology, TRP superfamily, in mammals, is organized into six subfamilies, which include
TRP canonical, TRP melastatin, TRP ankyrin, TRP mucolipin, TRP vanilloid, and TRP polycistin
channels. TRP channels are ubiquitously expressed in most mammalian cells [235,236] and they
depolarize cells by altering membrane potential or intracellular Ca2+ concentration. With the exception
of some TRP channels, most of them are non-selective and weakly voltage-sensitive [237]. TRP channels
are fundamental players of sensory physiology as they respond to environmental stimuli such as taste,
light, sound, smell, touch, temperature, and osmolarity [238]. Today, only a few endogenous ligands are
known to activate TRP channels, and it is not yet clear how they are activated in vivo [237]. However,
several experiments performed on knockout mice are revealing the complexity and the different
functions of TRP channels [238–240].
In this review, we will focus mainly on the vanilloid TRP (TRPV) channels subfamily and how
they respond to oxidative stress and lipid peroxidation-induced cell damage. Currently, six TRPV
channels (TRPV1-6) have been identified and divided into two subgroups: TRPV1-4 and TRPV5-6,
based on their amino acid sequence, functions, and cation selectivity. A detailed review on TRPV
channels pharmacology has been provided by Vriens and colleagues [241]. Briefly, TRPV1 is expressed
in primary sensory neurons, in few brain regions (hypothalamus, intrafascicular, supramammillary
and rostral raphe nuclei, entorhinal cortex, hippocampus, and periaqueductal gray), as well as in
smooth muscle cells of several thermoregulatory tissues (skin, dura, tongue, trachea, cremaster
muscle, and ear) [242]. TRPV1 seem to be activated by heat above 43 ◦C, by low pH [243–245],
by vanilloid compounds (e.g., capsaicin and capsinate) [243,246], by ethanol [247,248], as well as by
several endogenous compounds such as AEA [127], OEA [249], NADA [250], N-oleoyldopamine
(OLDA) [251], and arachidonic acid-derived metabolites released by LOXs [252]. Moreover, TRPV1
activity is modulated by various intracellular molecules and signals including calmodulin [253,254],
ATP [255], phosphatidylinositol 4,5-bisphosphate (PIP2) and phosphatidylinositol 3,4,5-trisphosphate
(PIP3) [256], PKC [257], PKA [258], as well as protein phosphatase calcineurin [259].
Among the main functions, in addition to acting as a thermoreceptor, TRPV1 regulates the normal
functioning of urinary bladder [260], controls the gut afferent sensitivity to distension and acids [261]
and it also allows the taste perception of sodium chloride [262]. From a physiopathological point
of view, TRPV1 has a direct role in the behavioral response to ethanol [247,248,263], as well as in
inflammatory airway diseases [264]. Moreover, TRPV1 is also involved in vascular dementia as well as
in Huntington’s disease, where its activation promotes neuroprotection, increase learning and memory,
and reduce oxidative stress [265–267].
Differently, TRPV2 is a weakly Ca2+-selective channel, which seems to be activated by thermal
stimuli above 53 ◦C but not by low pH or vanilloid compounds [268]. TRPV2 is expressed in
different tissues including brain, spinal cord, spleen, and intestine, as well as in vas deferens, bladder,
heart, kidney [269], and immune cells such as monocytes and dendritic cells [270]. It is noteworthy
that TRPV2 signaling plays an important role in the endosomal pathway, where TRPV2 modulates
the fusion between endosomal membranes by releasing Ca2+ from early endosomes [271,272] as well
as in phagocytosis [273,274].
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TRPV3 is a non-selective cation channel activated by temperatures of 33–39 ◦C, which showed a
marked sensitization following repeated heat stimuli [275,276]. Moreover, TRPV3 could be activated
by several vegetable-derived molecules, such as eugenol, thymol, camphor and carvacrol [277,278].
Furthermore, other agents such as PIP2/PIP3, calmodulin, ATP, and inflammatory mediators like
histamine, bradykinin, and PGE2 are able to sensitize TRPV3 function [278–281]. Moreover, it was
hypothesized that, in rodent skin cells, heat-induced TRPV3 signaling could mediate an autonomous
response to heat stimulation, thus acting as thermoreceptors in keratinocytes [275,282]. In support
of this evidence, TRPV3 knock-out mice showed strong deficits in response to heat stimulation [277].
Likewise, TRPV4 is also activated by heat, in particular by temperatures of 27–34 ◦C, as well as by
osmotic and mechanical stimuli [283,284]. Among putative endogenous ligands, it was observed that
AEA, 2-AG, and arachidonic acid indirectly activate TRPV4 by epoxyeicosatrienoic acids released from
cytochrome P450 epoxygenases [285,286]. As for TRPV1 and TRPV3, TRPV4 activity is modulated
by PIP2/PIP3, calmodulin and ATP [287–289] and by several protein kinases, such as PKA, PKC,
Src family kinases (SFKs), and serum glucocorticoid-induced protein kinase-1 (SGK1) [290–293].
TRPV4 channels are widely expressed in epithelial cells of the renal convoluted tubule, trachea,
submucosal glands, as well as in neutrophils, in autonomic nerve fibers, in peripheral sensory ganglia,
in hair cells of the inner ear, and brain structures such as vascular organ of the lamina terminalis and
the hypothalamic median preoptic region [283,294,295]. Due to its widespread expression, TRPV4 is
involved in several physiological functions. In particular, it mediates temperature sensation in skin
keratinocytes, anterior hypothalamus, and sensory ganglia [275,283,284]. TRPV4 is also involved in
mechanosensation [296] and contribute to the normal functioning of the urinary bladder [297,298]
and pulmonary alveoli [299,300] and to the development of mechanical hyperalgesia in inflammatory
states [301].
TRPV5 and TRPV6 share a high sequence homology (74% of identity) and form highly
Ca2+-selective channels, which are not activated by heat [302–304]. As for the other TRPV family
members, the activity of TRPV5 and TRPV6 is modulated by a variety of second messengers,
including Ca2+, Mg2+, ATP, PIP2, calmodulin, and PKC [302,303,305–313]. TRPV5 is expressed in
several tissues but is mostly abundant in renal tubules, where it regulates transcellular transport and
reabsorption of Ca2+ [314]. Furthermore, TRPV5 is also involved in bone remodeling [315,316]. TRPV6
is widely expressed [305,317,318] but is mostly distributed in the intestine, kidney, and placenta, where
it respectively modulates the Ca2+ transcellular entry, reabsorption, and transfer to fetus [319–322].
Among endogenous ligands of TRPV, or endovanilloids, there are leukotriene B4
and 12-hydroperoxyeicosatetraenoic acid that belong to the eicosanoid family, produced by
lipoxygenase-mediated oxidation of PUFAs (especially arachidonic acid), which are potent activators
of TRPV1 [252,323]. Other lipid-derived mediators of TRPV are epoxyeicosatrienoic acids, such as
5′,6′-epoxyeicosatrienoic acid, which are synthesized from arachidonic acid by cytochrome P450
epoxygenases and may activate TRPV1 and TRPV4 [286,324].
As AEA is structurally similar to arachidonic acid as well as to PUFAs, it can be metabolized by
COX-2 and LOXs. In particular, COX-2 converts AEA into prostaglandin-ethanolamides, which are
endoperoxide molecules also known as prostamides [325,326]. On the other hand, LOXs convert AEA
into hydroperoxy fatty acids, such as 12- and 15-hydroperoxyeicosatetraenoylethanolamide, which are,
respectively, synthesized by 12-LOX and 15-LOX [327,328]. In guinea-pig bronchi, these oxidized lipid
mediators seem to act as TRPV1 agonists and are also responsible, at least partially, for the contractile
action of AEA [329].
Growing evidence supports a key role for TRPV, especially TRPV1, in the modulation of
oxidative stress and lipid peroxidation mediated by endocannabinoids, their lipid analogues, and other
lipid-related mediators. As known, AEA is considered an endovanilloid because of its ability to activate
TRPV1 [127,136,330]: several in vitro analyses performed on human and rat cell lines have shown
that AEA induces apoptotic effects via a TRPV1-mediated mechanism, which induces and increase in
intracellular Ca2+ levels, mitochondrial uncoupling, oxidative stress due to increased O2•− formation,
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cytochrome c release as well as calpain and caspase-3 activation [331–333]. Similarly, another in vitro
study performed on human bladder cancer T24 cells showed that TRPV1 activation by capsaicin was
correlated in a dose-dependent manner with an increase of cytosolic Ca2+ levels, with mithocondrial
membrane depolarization and a marked ROS/RNS generation, which reduced T24 cells viability
(Figure 5) [334].
Other studies showed that AEA was able to increase ROS/RNS production by targeting
TRPV1, [335,336], which lead to the activation of the Ca2+/calmodulin-dependent protein kinase
II (CAMKII), and to the upregulation of NOX5 [337–339].
Moreover, it was observed, in the human esophageal epithelial cell line Het1A, that acid-
or capsaicine-induced activation of TRPV1 leads to an increased production of intracellular
ROS/RNS levels as well as to increased ROS/RNS- or HNE-modified proteins. In the same study,
immunoprecipitation analyses of 4-HNE-stimulated Het1A cells revealed, also, that TRPV1 was
modified by 4-HNE [340]. In addition to 4-HNE, TRPV1 is directly activated by •NO, oxidants and
other chemical agents through the modification of cysteine free sulfhydryl groups [341]. Moreover,
functional assays with mutated TRPV showed that cysteine residues 553 and 558, between the fifth and
sixth transmembrane domains, are essential for •NO-induced activation of TRPV1, TRPV3, and TRPV4
and thus are potential targets of nitrosylation [342]. In addition, TRPV1 nitrosylation by •NO increased
the intracellular Ca2+ levels and thus enhanced the channel sensitivity to H+ and heat. These sensitizing
effects induced by nitrosylation of cysteine residues were further supported by the use of oxidizing
agents such as diamide and chloramine-T [343]. Furthermore, several studies reported that TRPV1 is
also responsive to other electrophilic compounds generated during oxidative stress. To this regard,
in TRPV1 channel-expressing human embryonic kidney (HEK) cells, a modest TRPV1 activation was
observed following 4-ONE treatment (100 μM) [344]. Another TRPV1 activator is CTA. In particular,
an in vitro study performed on murine cardiomyocytes incubated with CTA showed an increase in
TRPV1 and NOXs levels, in ROS/RNS formation, in apoptotic events, and a decrease in the activity of
mithocondrial proteins such as aconytase, uncoupling protein 2, and peroxisome proliferator-activated
receptor-gamma coactivator-1alpha [345].
6. Modulation of Oxidative Stress and Lipid Peroxidation through the Peroxisome
Proliferator-Activated Receptors-Alpha by Endocannabinoids and Their Lipid Analogues
Because of the high expression of PPAR-α in kidney, liver, heart, and brain, it is well documented
that the activation of these transcription factors exerts protective roles in cardiovascular as well as
renal, hepatic, and neurodegenerative diseases [138,346–349].
There is rising acknowledgment that the beneficial effects of PPAR-α stimulation could be
explained by its ability to dampen oxidative stress in several pathological conditions linked to the redox
impairment. A number of reports point to the involvement of various mechanisms through which
PPAR-α agonists can modulate antioxidants.
In particular, the identification of PPREs elements in promoter regions of CAT and SOD genes in
rat [347] additionally supported the involvement of these nuclear receptors in lowering ROS/RNS
formation and lipid peroxidation products.
Nevertheless, PPAR-α is not only involved in suppressing ROS/RNS generation, but it can
also play a role in modulating enzymes involved in ROS/RNS synthesis and/or scavenging.
Consistently, the decrease in striatal SOD expression, which resulted in the 6-hydroxydopamine
(6-OHDA)-induced Parkinson disease mouse model, was completely counteracted by PPAR-α agonists
confirming the ability of this nuclear receptor to regulate the transcription of antioxidant enzymes
(Figure 5) [138,346,350].
For instance, Diep and colleagues reported that the PPAR-α -induced suppression of oxidative
stress in cardiovascular diseases is mediated by the ability of PPAR-α activators to inhibit angiotensin
II-induced activation of NOXs in the vascular wall [348] and to increase scavenging enzymes as well.
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Among the PPAR-α ligands, ECs and their lipids analogues have been shown to play a prominent
role in affecting redox homeostasis in several oxidative stress-related pathologies, through a PPAR-α
dependent mechanism. Consistently, it has been shown that PPAR-α stimulation by PEA lowers
blood pressure and prevents hypertension-induced renal damage in hypertensive rats by inhibiting
the subunit p47phox of NOXs (a key regulatory subunit essential for NOXs functioning) [349], and by
significantly reducing the hypertension-induced increased levels of MDA in urine and renal tissues
(Figure 5) [348].
Moreover, through PPAR-α activation, PEA appeared to simultaneously enhance the antioxidant
defense by increasing SOD expression in the kidney [348], thus protecting from renal damage.
In agreement with these results, other studies further support the potential beneficial effects of
PEA activated-PPAR-α on kidney diseases [351]. For instance, it has been demonstrated that
PEA, by targeting PPAR-α, is able to prevent kidney damage induced by I/R injury through
dampening the lipid peroxidation products in the kidney, thereby leading to a reduction of neutrophil
recruitment [352].
Moreover, because of the high expression of PPAR-α and its endogenous lipid agonists in the CNS,
it has been demonstrated that PPAR-α activation can exert neuroprotective properties in several
neuropathological conditions, especially in neurodegenerative disorders [169], by modulating the redox
balance that resulted altered in these situations.
Further support for this comes from the observation that the brain areas that display the highest
PPAR-α expression exhibit an overlapping expression pattern with key enzymes involved in ROS/RNS
synthesis and/or scavenging including CAT, SOD1 and acyl-CoA oxidase 1 (ACOX1) [353–355],
whose genes are known to be under the control of PPAR-α [356,357].
Thanks to its anti-oxidative properties, PPAR-α protects against normal brain aging and regulates
the onset and progression of neurodegenerative disorders [358,359]. Interestingly, evidence suggests
that in conditions of neurodegeneration, oxidative stress itself is responsible for the induction of
PPAR-α expression. As a matter of fact, in hippocampal CA1 pyramidal cells of a transgenic
mouse model of Alzheimer’s disease, an increase in the levels of PPAR-α simultaneously with
the production of ACR and 8-hydroxy(de)oxyguanosine, which represent markers of oxidative
imbalance, was observed [360]. Such increase in hippocampal PPAR-α expression could trigger
the induction of its target genes encoding for peroxisomal membrane protein-70 (PMP70) and ACOX1,
which are involved in fatty acyl-CoA transport across peroxisomal membranes and peroxisomal
β-oxidation respectively, by evoking a compensatory response to Aβ-mediated mitochondrial insult
that occurs in early stage of Alzheimer’s disease [4–6,360].
In this context, PEA was demonstrated to protect neurons and glia from oxidative stress by
reducing MDA formation, thereby restoring a proper cellular redox state, and this effect appeared
to be PPAR-α-dependent [171,172,361,362]. It has also been established that PEA neuroprotective
effects are mediated, at least in part, through the de novo synthesis of neurosteroids (particularly
allopregnanolone), which is triggered by PPAR-α activation [362].
The abovementioned findings, coupled with a recent report demonstrating that PEA treatment
(through binding PPAR-α) is able to induce SOD and dampen ROS/RNS-induced oxidative damage
in 6-OHDA-induced mouse model of Parkinson disease, additionally suggest the neuroprotective
scavenging effects of this lipid compound (Figure 5) [363]. Beyond the ECs, several other synthetic
ligands of PPAR-α have been shown to exert antioxidative properties. For instance, Wy14643 through
binding PPAR-α is able to protect rabbit hearts from I/R injury by increasing the expression of
the oxidative stress-inducible isoform of heme oxygenase and to preserve hippocampal neurons from
H2O2 challenge by modulating mitochondrial fusion and fission events [360].
Moreover, it should be noted that the production of PPAR-α endogenous ligands, PEA and OEA
as the mostly characterized, could be differently affected by physiological and pathological oxidative
stress-related conditions. For instance, the ROS/RNS metabolism imbalance, which is responsible
for oxidative stress-induced brain aging and neurodegeneration, can quantitatively and qualitatively
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modify the production of PPAR-α agonists and thus differently modulate PPAR-α-mediated pathways
in neuronal and astroglial cells [169].
Additionally, the interplay between PPAR-α and oxidative-stress-induced lipid peroxidation
comes also from the observation that NOXs activated-4-HNE is able to act as an endogenous
PPAR-α activator leading to the discovery of the so called “lipid peroxidation products–PPARs–NOXs
axis” [364]. The regulation of this axis, which represents an alternative pathway mediating ROS/RNS
production, could ensure additional strategies to counteract oxidative-stress-related disorders.
7. Modulation of Oxidative Stress and Lipid Peroxidation through Other Receptors by
Endocannabinoids and Their Lipid Analogues
Recently, in addition to PPAR-α and TRPV1, the orphan receptors GPR18, GPR55 and GPR119
were assessed as novel cannabinoid-related receptors [365]. Structurally, GPRs are GPCRs and,
among them, GPR18, GPR55 and GPR119 share a limited primary sequence homology with
CB1 and CB2.
GPR18 was discovered for the first time in 1997 by Gantz and colleagues [366]. GPR18 is widely
expressed in testis and spleen, and in lesser extent in several other tissues such as thymus, lymph nodes,
peripheral blood leukocytes, small intestine, and appendix, thus suggesting a regulatory role for
GPR18 in the immune system [366]. Moreover, GPR18 was also found in several brain regions such
as hypothalamus, brainstem, cerebellum, and striatum as well as in lung, thyroid and ovary [367].
Several studies reported that NAGly is the endogenous ligand of GPR18 that induces an elevation
of intracellular Ca2+ levels [176]. The same authors demonstrated also that GPR18 activation was
pertussis toxin-sensitive, suggesting the involvement of a Gαi/o protein in this response [176]. Despite
these first evidence, several authors reported variable responses of GPR18 following the administration
of NAGly [368,369].
For the first time Penumarti and colleagues demonstrated that GPR18 is expressed in the rostral
ventrolateral medulla of rats and exerts tonic restraining influence on blood pressure [370]. In particular,
authors observed that the systemic administration of abnormal cannabidiol, a synthetic agonist of
GPR18, induced a dose-dependent reduction of blood pressure and increased heart rate. In addition,
GPR18 activation increased neuronal adiponectin and •NO, and finally reduced neuronal ROS/RNS
levels. These findings suggested for the first time a sympathoinhibitory role of GPR18 (Figure 5) [370].
More recently, another study confirmed that chronic GPR18 activation with its agonist abnormal
cannabidiol produced hypotension, suppressed the cardiac sympathetic dominance, and improved
left ventricular function in conscious rats [371]. In the same study, ex vivo analysis of plasma,
heart, and vascular tissues of treated rats revealed an increase in cardiac and plasmatic adiponectin
levels, an increase in aortic eNOS expression, augmented levels of vascular and serum •NO,
high levels of myocardial and plasmatic guanosine 3′,5′-cyclic monophosphate (cGMP), an increase
of myocardial Akt and ERK1/2 phosphorylation, and, more importantly, reduced myocardial
ROS/RNS formation [371]. These results suggest a protective role of GPR18 in cardiovascular diseases,
in particular highlights the possibility to consider GPR18 as a viable molecular target for developing
new antihypertensive drugs which are able to improve also the cardiac function.
Human GPR55 receptor was identified for the first time in 1999, through in silico studies, and was
subsequently cloned [372]. GPR55 receptor is widely expressed, and therefore its activity was correlated
with multiple physiological processes. In particular, GPR55 is expressed in the frontal cortex, striatum,
hippocampus, hypothalamus, cerebellum, and brainstem [372,373]. Moreover, GPR55 was also
found in peripheral organs and cells such as dorsal root ganglion [148], spleen, adrenal glands,
jejunum, ileum [373], pancreas [374], bones [375] and microglia [376]. The GPR55 pharmacology
and its downstream signaling are not yet certain. Nevertheless, some authors reported that ECs
such as AEA, 2-AG, and virodhamine can activate both etherologous and native GPR55-expressing
cells [148,273,377], while other groups reported that ECs are weak ligands [378,379], may act as partial
agonists [175], or are not able to activate GPR55 receptors [380,381]. Another open debate regards
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the ability of PEA to activate [373] or not the GPR55 receptors [148,382]. Despite the controversial
results about the ability of ECs to activate GPR55, it is well accepted that the endogenous lipid
L-α-lysophosphatidylinositol (LPI) and its analogue 2-arachidonoyl-sn-glycero-3-phosphoinositol are
endogenous ligand of GPR55 [379–382]. However, it is necessary to specify that LPI is not selective only
for GPR55 [383]. Moreover, GPR55 may also heterodimerize with other receptors, such as CB2 [384],
thus further confounding the results obtained so far.
About the mechanisms of downstream signaling, GPR55 activation was associated with an
increase of intracellular Ca2+ levels, with the activation of RhoA and ERK1/2 pathway, and with
the activation of several transcription factors, such as the nuclear factor of activated T-cells and
the cAMP response element binding protein (CREB) [380,382].
The human orphan receptor GPR119 was identified for the first time in 2003 by sequence
alignment tools analysis [385]. GPR119 is expressed mainly in pancreas and gut, in particular in β-cells
and pancreatic polypeptide-producing PP cells, where its activity modulates the glucose-dependent
insulin secretion [386,387], as well as in enteroendocrine L-cells, where it regulates the secretion of
glucagon-like peptide 1 [388,389]. GPR119 is also expressed in liver [390] and skeletal muscle [Cornall
et al., 2013]. In normal-weight and healthy patients it was observed that gut GPR119 expression rapidly
increased following acute fat exposure [391], thus suggesting a potential involvement of GPR119 in
type 2 dyabetes, metabolic disorder, and obesity.
The main endogenous ligands of GPR119 are, in order of potency, OLDA, OEA, PEA, and
AEA [392,393]. Other endogenous GPR119 agonists are 2-oleoylglycerol [394] and oleoyl-lysophosphati
dylcholine [386]. Clearly, also in this case, further studies are required to better characterize the
pharmacological profile of GPR119.
Increasing evidence suggests that ECs may regulate ROS/RNS levels and thus reactive aldehydes
formation by targeting GPR55. In this regard, Balenga and colleagues showed that GPR55 activity
modulates RhoA-dependent neutrophil migration, and it may prevent oxidative damage [395].
In particular, this study, performed on neutrophils, demonstrated that 2-AG-induced ROS/RNS
production, which was mediated by a CB2-dependent mechanism, appeared to be significantly
decreased following the co-treatment with the GPR55 agonist LPI [395]. This negative interaction
between GPR55 and CB2 was observed during neutrophil respiratory burst. Therefore, after an initial
synergism in inducing chemotaxis, GPR55 and CB2 disengaged and, by a functional repression,
GPR55 decreased CB2-induced oxidative damage by blocking CB2 downstream signaling [395].
Conversely, a recent study performed on human natural killer cells and monocytes unveiled a
proinflammatory role of GPR55 activation (Figure 5) [396], which could be potentially correlated
with an increase of ROS/RNS production and thus with oxidative stress.
8. The Role of Antioxidant System as Scavenger of ROS/RNS and Reactive Aldehydes
The “endogenous antioxidant system” relies on several enzymes, peptides, cofactors, and other
molecules that are essential for the maintenance of a physiological redox homeostasis. Overall,
endogenous antioxidants may be divided into two main groups, formed by enzymatic and
non-enzymatic antioxidants [6,397]. The enzymatic group include CAT [398], SOD [399,400], GPx,
GR, GT [401], thioredoxin (Trx) and thioredoxin reductase (TrxR) [402] while the non-enzymatic
group include several antioxidant molecules such as GSH, GSSG, [403], vitamin A (retinol) [404],
vitamin C (L-ascorbic acid) [405], vitamin E (tocopherols) [406], coenzyme Q10 (CoQ10) [407],
carotenoids [408], flavonoids, polyphenols [409–411], minerals such as Se2+ [412], Cu2+, and Zn2+ [413],
as well as metabolites such as uric acid, bilirubin [414] and melatonin [415], which also possess
antioxidant properties.
Briefly, CATs are Cu2+/Zn2+-dependent enzymes present in peroxisomes that catalyze
the conversion of H2O2 in water and oxygen [398]. Among SOD enzymes, cytolosic SOD are
Cu2+/Zn2+-dependent enzymes, while mitochondrial SODs are Mn2+-dependent enzymes that
metabolize O2•− into H2O2 and oxygen. Therefore, SOD represents the first line of defense against
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reactive aldehydes formation [400]. GPx, GR and GT are Se2+-dependent enzymes that, together with
GSH and GSSG, constitute the glutathione system, which contributes to eliminate H2O2 and other
reactive molecules [403]. Similarly, Trx, TrxR, and NADPH constitute the thioredoxin system, which is
critical for redox regulation of protein function and signaling via thiol redox control [402].
Vitamin A is produced in the liver, derives from β-carotene and acts as a lipid peroxidation blocker
by preventing the chaining process in the propagation phase [404]. Similarly, also vitamin E acts as a
lipid peroxidation blocker by donating a hydrogen atom to peroxyl radicals, thus forming tocopheroxyl
radicals which are unable to continue the propagation phase of lipid peroxidation [416]. Vitamin C
is effective in scavenging several ROS/RNS as well as in the detoxification of peroxyl and hydroxyl
radicals [405]. CoQ10 is involved in the neutralization of the damages induced by peroxyl radicals and
also in the regeneration of vitamin E [407]. Uric acid is known to prevent protein nitrosylation, as well
as lipid and protein peroxidation, and therefore it is considered as a protectant agent of the CNS [417].
Melatonin is a natural scavenger derived from tryptophan, which is involved in the neutralization
of several ROS/RNS and thus reduces the generation of reactive aldehydes [415]. Finally, flavonoids
and polyphenols are ubiquitous plant-derived molecules, which act as chelators and scavengers of
ROS/RNS as well as of hydroxyl and peroxyl radicals [418,419].
9. Conclusions
Oxidative stress represents an underlying disturbance that is involved in many pathophysiological
conditions. Increasing evidence suggests that tissues with a high oxygen consumption, such as brain
and heart among others, are particularly sensitive to lipid peroxidation products and free radical
accumulation, which are responsible for oxidative stress–induced damages with consequent cell
death [2,4–6,218].
Thus, acting on the cellular processes that suppress the generation of these reactive small
molecules or altering the expression and/or activity of enzymes involved in their formation may be
crucial for the treatment of a growing number of diseases linked with redox homeostasis deregulation.
In this scenario, there is rising acknowledgment about a cross-talk between the ECS and
various redox-dependent processes. Indeed, it has been observed that the redox impairment induces
the enhancement of AEA and 2-AG levels, as a consequence of phospholipid hydrolysis [420,421],
and the upregulation of CB1 and CB2 expression [422,423], as well as the downregulation of
FAAH [422].
A large number of reports point to the involvement of ECs and their lipid analogues in
regulating ROS/RNS and reactive aldehydes generation through targeting CB1 and CB2 [8–10]
and thereby exerting protective effects in cardiovascular as well as renal, hepatic, neuropsychiatric,
and neurodegenerative diseases.
Moreover, it has been observed that, depending on the type of cell and/or injury, cannabinoid
receptors show opposite effects in oxidative stress modulation, since CB1 activation results in a redox
imbalance enhancement, while CB2 stimulation is responsible for lowering oxidative stress [9,223] and
may convey beneficial free radical scavenging effects.
Overall, the mechanisms by which CB2 receptors, following ECs-mediated activation, are involved
in the reduction of oxidative injury seem to be primarily mediated by the reduction of NOX2 and
NOX4, and the simultaneous induction of the antioxidant defense through the increase of the SOD
scavenging enzymes [180,181].
Emerging evidence indicates that the neuroprotective, cardioprotective and renoprotective
effects of ECs and NAEs are additionally mediated by CB1/CB2-independent mechanisms and
involve the contribution of alternative intracellular targets such as PPAR-α, TRPV1, GPR55,
and GPR18 [169,348,349,370,371,395].
In particular, an interplay between PPAR-α and oxidative stress has been suggested from
the observation that an imbalance in the redox state may modulate several signaling pathways,
including PPAR-α signaling, via transcriptional regulation and post-translational modification.
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Among the PPAR-α ligands, PEA appeared to exert beneficial effects by simultaneously enhancing
the antioxidant defense through the increase of SOD expression and inhibiting NOXs activity with a
consequent reduction of the lipid peroxidation products such as MDA [138].
Although the huge amount of knowledge has been gained about the effects of the ECs on oxidative
stress and lipid peroxidation in several pathological conditions, many ECS compounds fail during
clinical trials due to inefficacy or unforeseeable safety concerns. For the treatment of the cardiovascular
diseases, for instance, no cannabinoid-based drugs have been approved so far, except for those acting
as PPARs agonists [348]. Among the limitations that play a role in restricting the translation of ECs
studies into clinical trials, the different animal paradigms as well as the route of administration used
(central vs peripheral) and the differences between species seem to be primarily involved.
Moreover, most of the studies have focused on the role of CB1, CB2, TRPV1, PPARs and less is
known about other candidates such as GPR18, GPR55 and GPR119.
Despite promising goals have been achieved over the last years on ECS research, there is an
urgent necessity to expand the knowledge on the ECs complex signalling in order to better identify an
explanation of the serious side-effects observed in clinical studies. Lessons from clinical experience
should encourage the scientific community to better clarify how to modulate the ECS thus leading to
major breakthroughs in the treatment of many diseases.
Overall, the findings discussed in this review may further elucidate the complex interaction
existing between ECS, oxidative stress, and lipid peroxidation, resulting in a better understanding of
the multiple beneficial effects of this signaling system in several pathological conditions related to a
redox status impairment.
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Abbreviations
•NO = nitric oxide; •OH = hydroxyl radical; 1O2 = oxygen singlet; 2-AG = 2-arachidonoyl-glycerol; 2-AGE =
2-arachidonoylglyceryl ether or noladin ether; 4-HHE = 4-hydroxy-hexanal; 4-HNE = 4-hydroxy-2-nonenal; 4-ONE
= 4-oxo-nonenal; 6-OHDA = 6-hydroxydopamine; AC = adenylyl cyclase; ACOX1 = acyl-CoA oxidase 1; ACR
= acrolein; AEA = N-arachidonoyl-ethanolamine or anandamide; ApoE−/− = Apolipoprotein E-deficient mice;
ARA-S = arachidonoyl-L-serine; AT1 = angiotensin II type 1 receptor; CAMKII = Ca2+/calmodulin-dependent
protein kinase II; cAMP = adenosine 3′,5′-cyclic monophosphate; CAT = catalase; CB1 = cannabinoid
receptor type 1; CB2 = cannabinoid receptor type 2; CD36 = cluster of differentiation 36; CGD = chronic
granulomatous disorder; cGMP = guanosine 3′,5′-cyclic monophosphate; CNS = central nervous system;
CoQ10 = coenzyme Q10; COX-2 = cyclooxygenase type 2; COXs = cyclooxygenases; CREB = cAMP response
element binding protein; CTA = crotonaldehyde; DAGL = diacylglycerol lipase; dG = deoxyguanosine; ECS
= endocannabinoid system; ECs = endocannabinoids; eNOS = endothelial nitric oxide synthase; ERK1/2 =
extracellular signal-related kinases; FAAH = fatty acid amide hydrolase; GPCRs = G-protein-coupled receptors;
GPR18 = G protein-coupled receptor 18; GPR55 = G protein-coupled receptor 55; GPR119 = G protein-coupled
receptor 119; GPx = glutathione peroxidase; GR = glutathione reductase; GSH = glutathione; GSSG = oxidized
glutathione; GT = glutathione transferase; GTPase = guanosine triphosphatase; H2O2 = hydrogen peroxide;
HClO = hypochlorous acid; HEK = human embryonic kidney; I/R = ischemia/reperfusion; JNK = c-Jun
N-terminal kinase; LOXs = lipooxygenases; LPI = L-α-lysophosphatidylinositol; MAG = monoacylglycerols;
MAGL = monoacylglycerol lipase; MAPKs = mitogen-activated protein kinases; MAPK/ERK1/2 =
mitogen-activated protein kinases/extracellular signal-regulated kinases; MDA = malondialdehyde; NADA
= N-arachidonoyldopamine; NAEs = N-acylethanolamines; NAGLy = N-arachidonoylglycine; NAPE =
N-acyl-phosphatidylethanolamine; NAPE-PLD = NAPE-phospholipase D; NF-κB = nuclear factor-κB; NO2
= nitric dioxide; NO2− = nitrite; NO3− = nitrate; NOS = nitric oxide synthase; NOS1 = NOS type 1; NOX2 = NOX
type 2; NOX3 = NOX type 3; NOXs = NADPH oxidase enzymes; Nrf2 = nuclear factor-erythroid 2-related factor 2;
O2•− = superoxide anion; O3 = ozone; ODA = Cis-9,10-octadecanoamide or oleamide; OEA = oleoylethanolamide;
OLDA = N-oleoyldopamine; ONOO− = peroxynitrite; oxLDL = oxidized low-density lipoproteins; PEA =
palmitoylethanolamide; PGE2 = prostaglandin E2; PIP2 = phosphatidylinositol 4,5-bisphosphate; PIP3 =
phosphatidylinositol 3,4,5-trisphosphate; PKA = protein kinase A; PKC = protein kinase C; PMP70 = peroxisomal
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membrane protein-70; PPARs = peroxisome proliferator-activated receptors; PPRES = peroxisome proliferator
response elements; PUFAs = polyunsatured fatty acids; Rap = Ras-related protein; Rap1GAP = Rap1 GTPase
activating protein; RhoGEFs = RhoGTPase nucleotide exchange factors; ROS/RNS = reactive oxygen and nitrogen
species; RXR = retinoid X receptor; SEA = stearoylethanolamide; SFKs = Src family kinases; SGK1 = serum
glucocorticoid-induced protein kinase-1; SOD = superoxide dismutase; TRP = transient receptor potential; TRPV
= transient receptor potential vanilloid; TRPV1 = transient receptor potential vanilloid 1; Trx = thioredoxin; TrxR =
thioredoxin reductase.
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Abstract: Evening primrose (Oenothera L.) is a plant belonging to the family Onagraceae, in which
the most numerous species is Oenothera biennis. Some plants belonging to the genus Oenothera
L. are characterized by biological activity. Therefore, studies were conducted to determine the
dependence of biological activity on the chemical composition of various parts of the evening
primrose, mainly leaves, stems, and seeds. Common components of all parts of the Oenothera biennis
plants are fatty acids, phenolic acids, and flavonoids. In contrast, primrose seeds also contain
proteins, carbohydrates, minerals, and vitamins. Therefore, it is believed that the most interesting
sources of biologically active compounds are the seeds and, above all, evening primrose seed oil.
This oil contains mainly aliphatic alcohols, fatty acids, sterols, and polyphenols. Evening primrose
oil (EPO) is extremely high in linoleic acid (LA) (70–74%) and γ-linolenic acid (GLA) (8–10%),
which may contribute to the proper functioning of human tissues because they are precursors of
anti-inflammatory eicosanoids. EPO supplementation results in an increase in plasma levels of
γ-linolenic acid and its metabolite dihomo-γ-linolenic acid (DGLA). This compound is oxidized
by lipoxygenase (15-LOX) to 15-hydroxyeicosatrienoic acid (15-HETrE) or, under the influence of
cyclooxygenase (COX), DGLA is metabolized to series 1 prostaglandins. These compounds have
anti-inflammatory and anti-proliferative properties. Furthermore, 15-HETrE blocks the conversion
of arachidonic acid (AA) to leukotriene A4 (LTA4) by direct inhibition of 5-LOX. In addition,
γ-linolenic acid suppresses inflammation mediators such as interleukin 1β (IL-1β), interleukin 6 (IL-6),
and cytokine - tumor necrosis factor α (TNF-α). The beneficial effects of EPO have been demonstrated
in the case of atopic dermatitis, psoriasis, Sjögren’s syndrome, asthma, and anti-cancer therapy.
Keywords: evening primrose oil; γ-linolenic acid; linoleic acid; omega-6 fatty acids; eicosanoids
1. Introduction
Evening primrose (Oenothera L.) is a plant belonging to the Onagraceae family. There are about
145 species in the genus Oenothera L., occurring in the temperate and tropical climate zones of North
and South America. Some species have adapted to new areas, inhabiting the countries of the European
continent, and about 70 species are now present in Europe. The most numerous species in the Oenothera
L. family is Oenothera biennis, which also has the best-studied biological activity. It has been indicated
that Oenothera biennis is beneficial in the treatment of many diseases. Therefore, research is ongoing
to determine the chemical composition of these plants and how it relates to the biological activity of
evening primrose. This research mainly concerns extracts from various parts of evening primrose
(e.g., the leaves, stems, and seeds) [1].
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2. Chemical Composition of Evening Primrose (Oenothera biennis)
Methanolic extracts prepared from the aerial parts of Oenothera biennis contain mainly phenolic
acids and flavonoids. Phenolic acids present in the analyzed extracts include the following
compounds: gallic acid and its ester derivatives (e.g., methyl gallate, galloylglucose, digalloylglucose,
and tris-galloylglucose), 3-p-feruloylquinic acid, 3-p-coumaroylquinic acid, 4-p-feruloylquinic acid,
caffeic acid pentoside, ellagic acid and its ester derivatives (e.g., ellagic acid hexoside and ellagic acid
pentoside), and valoneic acid dilactone. Flavonoids present in the extracts include the following
compounds: myricetin 3-O-glucuronide, quercetin 3-O-galactoside, quercetin 3-O-glucuronide,
quercetin 3-O-glucoside, quercetin pentoside, quercetin dihexoside, quercetin glucuronylhexoside,
quercetin 3-O-(2’-galloyl)-glucuronide, kaempferol 3-O-rhamnoglucoside, kaempferol 3-O-glucoside,
kaempferol 3-O-glucuronide, kaempferol 3-O-(2’-galloyl)-glucuronide, and kaempferol pentoside [2].
The aqueous leaf extract of Oenothera biennis contains phenolic compounds (e.g., ellagitannins
and caffeoyl tartaric acid) and flavonoids (quercetin glucuronide and kaempferol glucuronide) [3].
Among the tannins contained in the leaves of the evening primrose are oenothein A and oenothein B.
The carbohydrates present in the extracts include arabinose, galactose, glucose, mannose, galacturonic
acid, and glucuronic acid.
The roots of evening primrose contain the following sterols: sitosterol, oenotheralanosterol A,
and oenotheralanosterol B. The triterpenes maslinic acid and oleanolic acid are also present in the
root, along with the following carbohydrates: arabinose, galactose, glucose, mannose, galacturonic
acid, and glucuronic acid. The following tannins are also found: gallic acid, tetramethylellagic
acid, oenostacin, and 2,7,8-trimethylellagic acid [4]. The methanolic extract of the Oenothera
biennis root also possesses significant amounts of xanthone (9H-xanthen-9-one) and its derivatives,
such as dihydroxyprenyl xanthone and cetoleilyl diglucoside, which possess diverse biological and
pharmacological properties [5].
Evening primrose seeds contain about 20% oil. The amount of oil depends on various factors,
such as the age of the seed, the cultivar, and the growth conditions [6].
Generally, evening primrose oil is obtained from Oenothera biennis seeds using the cold-pressing
method. The oil is a blend of about 13 triacylglycerol fractions, where the dominant combinations consist
of the following fatty acids: linoleic–linoleic–linoleic (LLL, 40%), linoleic–linoleic–γ-linolenic (LLLnγ,
approximately 15%), linoleic–linoleic–palmitic (LLP, approximately 8%), and linoleic–linoleic–oleic
(LLO, approximately 8%) [7]. The oil consists of triacylglycerols—about 98%, with a small amount of
other lipids and about 1–2% non-saponifiable fraction [6].
Evening primrose oil is very high in linoleic (70–74%) and γ-linolenic (8–10%) acids, and also
contains other fatty acids: palmitic acid, oleic acid, stearic acid, and (in smaller amounts) myristic acid,
oleopalmitic acid, vaccenic acid, eicosanoic acid, and eicosenoic acid (see Table 1) [8]. The phospholipid
fraction comprises only 0.05% of the oil, and the following phospholipids have been identified in
it: phosphatidylcholines (31.9%), phosphatidylinositols (27.1%), phosphatidylethanolamines (17.6%),
phosphatidylglycerols (16.7%), and phosphatidic acids (6.7%) [6].
Table 1. Fatty acid composition of evening primrose oil (EPO) (Oenothera biennis L.) [8].
Compound Name Contents (%)
linoleic acid 73.88 ± 0.09
γ-linolenic acid 9.24 ± 0.05
oleic acid 6.93 ± 0.02
palmitic acid 6.31 ± 0.14
stearic acid 1.88 ± 0.02
vaccenic acid 0.81 ± 0.03
eicosenoic acid 0.55 ± 0.01
eicosanoic acid 0.31 ± 0.03
behenic acid 0.10 ± 0.01
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Evening primrose oil includes aliphatic alcohols, which make up about 798 mg/kg of the oil,
1-tetracosanol (about 237 mg/kg oil), and 1-hexacosanol (about 290 mg/kg oil) being present in the
largest amount. The main triterpenes present are β-amyrin (about 996 mg/kg oil) and squalene (about
0.40 mg/kg oil) [8]. The oil contains a small amount of tocopherols: α-tocopherol (76 mg/kg oil),
γ-tocopherol (187 mg/kg oil), and δ-tocopherol (15 mg/kg oil) [6].
Evening primrose seeds also contain phenolic acids, which are present in free acid form and as
ester and glycoside derivatives (see Table 2) [9]. It has been shown that the seeds contain about 15%
protein and 43% carbohydrates (in the form of cellulose, along with starch and dextrin). Lignin is also
found in the seeds. In addition, the seeds contain amino acids: tryptophan (1.60%), lysine (0.31%),
threonine (0.35%), cysteine (1.68%), valine (0.52%), isoleucine (0.41%), leucine (0.87%), and tyrosine
(1.05%). Moreover, the seeds contain minerals, mainly calcium, potassium, and magnesium,
and vitamins A, B, C, and E [10].
Table 2. Phenolic acid composition (mg/kg) in Oenothera biennis L. seed [9].
Acid Name
Included in
Free Esters Glycosides Total
p-hydroxyphenyl acetic n/a 1.03 ± 0.18 0.26 ± 0.05 1.29 ± 0.19
p-hydroxybenzoic 4.12 ± 0.25 0.38 ± 0.07 0.29 ± 0.10 4.79 ± 0.26
2-hydroxy-4-methoxybenzoic 6.52 ± 0.30 n/a 0.83 ± 0.28 7.35 ± 0.41
caffeic 6.48 ± 0.29 0.80 ± 0.14 n/a 7.51 ± 0.33
hydroxycaffeic n/a 0.77 ± 0.18 n/a 0.77 ± 0.18
m-coumaric 4.90 ± 0.45 0.83 ± 0.21 n/a 5.73 ± 0.50
p-coumaric 1.32 ± 0.10 1.96 ± 0.23 0.06 ± 0.06 3.34 ± 0.25
ferulic 4.08 ± 0.30 0.72 ± 0.09 0.22 ± 0.06 5.02 ± 0.32
gallic 1.87 ± 0.22 7.03 ± 0.82 5.91 ± 1.56 14.81 ± 1.78
protocatechuic 50.28 ± 0.77 10.96 ± 0.34 2.16 ± 2.42 63.40 ± 2.56
vanillic 5.22 ± 0.28 0.06 ± 0.02 0.83 ± 0.28 7.35 ± 0.41
veratric n/a 0.41 ± 0.03 0.47 ± 0.15 0.88 ± 0.15
homoveratric n/a 0.43 ± 0.06 n/a 0.43 ± 0.06
salicylic 1.15 ± 0.04 1.40 ± 0.18 n/a 2.55 ± 0.18
n/a—not available.
Evening primrose oil also contains polyphenols, such as hydroxytyrosol (1.11 mg/kg oil), vanillic
acid (3.27 mg/kg oil), vanillin (17.37 mg/kg oil), p-coumaric acid (1.75 mg/kg oil), and ferulic acid
(25.23 mg/kg oil) [8].
The unsaponifiable matter of oil is composed partially of sterols, which comprise 53.16% of this
fraction (see Table 3) [8].
Table 3. Sterol content of EPO (Oenothera biennis L.) [8].
Compound Name Contents (mg/kg of Oil)
β-sitosterol 7952.00 ± 342.25
kampesterol 883.32 ± 0.45
Δ5-avenasterol 429.65 ± 75.20
sitostanol 167.01 ± 39.77
clerosterol 120.44 ± 0.12
Δ5-24-estigmastadienol 94.60 ± 5.68
Δ7-estigmasterol 38.17 ± 14.33
Δ7-avenasterol 27.80 ± 16.07
The seed ash contains a group of macroelements and microelements, including calcium,
magnesium, potassium, phosphorus, manganese, iron, sodium, zinc, and copper (see Table 4) [10].
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Table 4. Macroelements and microelements contributing to seed ash [10].











3. Biological Activity of Evening Primrose Oil (Oenothera biennis)
The biological effect of evening primrose oil is a result of its composition and the biological
properties of its components. Since the most important components in terms of quantity are
polyunsaturated fatty acids (PUFAs), mainly linoleic acid (LA) and γ-linolenic acid (GLA) which
belong to the group of omega-6 acids. The biological significance, especially of these acids, will be
discussed in more detail.
Linoleic acid belongs to the group of essential fatty acids. These are also called exogenous
fatty acids, because the human body does not synthesize them and it is necessary to obtain them
from food [11]. Evening primrose oil contains over 70% linoleic acid (LA) and about 9% γ-linolenic
acid (GLA) [10]. Linoleic acid and γ-linolenic acid contribute to the proper functioning of many
tissues of the human body, because they are precursors of compounds that lead to the generation of
anti-inflammatory eicosanoids, such as the series 1 prostaglandins and 15-hydroxyeicosatrienoic acid
(15-HETrE). On the other hand, the enzymatic conversion of linoleic acid to arachidonic acid (AA)
may form pro-inflammatory compounds, such as series 2 prostaglandins and series 4 leukotrienes [11].
With reference to the above, it is suggested that evening primrose oil may influence inflammatory
diseases, including skin problems.
Linoleic acid [12], among others, plays an important role in the proper functioning of the skin,
especially the stratum corneum, in which it is one of the main components of the ceramides building
the lipid layer. It has been shown that the presence of this acid prevents the skin from peeling and the
loss of water through the epidermis, while at the same time improving skin softness and elasticity and
regulating the process of epidermal keratinization. A deficiency of linoleic acid, which is contained in
large quantities in ceramide 1, leads to its replacement by oleic acid. This causes a deterioration in the
protective properties of the epidermis [12,13].
Under the influence of Δ-6-desaturase (D6D), linoleic acid undergoes dehydrogenation to form
γ-linolenic acid. The activity of Δ-6-desaturase in human cells depends on various factors and is
reduced under the influence of nicotine, alcohol, magnesium deficiency, and a poor diet rich in
saturated fatty acids, and under conditions of physiological aging of the body [12,14]. The basic
component of evening primrose oil is linoleic acid, and the possibility of its metabolism to γ-linolenic
acid due to the action of Δ-6-desaturase is an important point. Δ-6-Desaturase (D6D) activity is highest
in the liver, the brain, the heart, and lung cells [15]. D6D activity is several times higher in the fetal
human liver than in the adult human liver [11]. The fatty acid desaturase 2 (FADS2) gene encoding the
Δ-6-desaturase enzyme is also expressed in skin cells: within the sebaceous gland, D6D desaturates
palmitic acid to sapienic acid, which is the major fatty acid of human sebum [16,17]. On the other hand,
the main epidermal cells—keratinocytes—are characterized by their lack of D6D and D5D activity [18]
and the dermal fibroblasts express the D6D mRNA, which is capable of desaturation of the essential
fatty acid (EFA) in the skin [19].
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Δ-6-Desaturase is also present in evening primrose seeds. Huang et al. (2010) report that the
cDNA sequence of the D6D gene was obtained from the developing seeds. The transformation of the
plasmid DNA of a Saccharomyces cerevisiae strain then showed that after the addition of a medium
containing linoleic acid to the yeast cells, a signal was obtained from γ-linolenic acid, indicating the
presence of Δ-6-desaturase in seeds of the species Oenothera biennis [20,21].
A deficiency of γ-linolenic acid and other metabolites of linoleic acid was demonstrated in the
plasma of patients with atopic dermatitis. This is linked to a decrease in Δ-6-desaturase activity,
which makes the conversion of linoleic acid to γ-linolenic acid and the formation of its metabolites
impossible [12,22]. It was found that oral treatment with evening primrose oil, which contains
γ-linolenic acid, may lead to a reduction in the symptoms of atopic dermatitis [22]. However,
subsequent studies have not confirmed that oral supplementation with evening primrose oil improves
the skin condition in patients with atopic dermatitis [23].
The hydrocarbon chain of the emerging or supplied γ-linolenic acid under the influence of an
elongase is elongated to dihomo-γ-linolenic acid (DGLA). The GLA elongation is faster than the
desaturation of linoleic acid [24,25]. Dihomo-γ-linolenic acid is metabolized by cyclooxygenase (COX)
to series 1 prostaglandins, which are eicosanoids with anti-inflammatory activity (see Table 5) [24].
Under the influence of 15-lipoxygenase (15-LOX), DGLA is oxidized to 15-hydroxyeicosatrienoic
(15-HETrE) acid, which has anti-inflammatory and anti-proliferative properties [24,26]. Therefore,
increased levels of GLA and DGLA, which are metabolized to anti-inflammatory compounds, suppress
the inflammatory reaction. However, a decrease in these acids’ levels may lead to the development of
inflammatory diseases [24,27]. In addition, GLA suppresses inflammation mediators such as IL-1β,
IL-6, and TNF-α cytokines [12,28]. In contrast, 15-HETrE acid, which is a product of the oxidation of
dihomo-γ-linolenic acid by 15-LOX, has the ability to inhibit the synthesis of series 4 leukotrienes,
whose elevated levels cause intensified pathological cell hyperproliferation [24]. This contributes to
the inhibition of the pro-inflammatory action of leukotrienes, which are involved, among others, in the
development of asthma [24,29] (see Figure 1).
Regardless of the metabolism of DGLA catalyzed by COXs and 15-LOX, dihomo-γ-linolenic
acid under the influence of Δ-5-desaturase (D5D) is converted to arachidonic acid (AA), which is the
precursor of many lipid mediators in the body, mainly pro-inflammatory [18,24]. Under physiological
conditions, the sources of AA are membrane phospholipids, from which it is released by the hydrolysis
of ester bonds, mainly via the action of phospholipase A2 (PLA2). There are two main ways that
lead to the formation of free arachidonic acid. One pathway leads to the hydrolytic release of AA by
the cytosolic isoform of PLA2. The second way leads to the release of AA by the indirect action of
phospholipase C (PLC) and diacylglycerol (DAG) lipase. DAG lipase and PLC result in the formation
of inositol 1,4,5-triphosphate and DAG. The latter is then hydrolyzed by DAG lipase to form free
arachidonic acid and monoacylglycerol (MAG) [18,30].
In pathological conditions and, for example, in the case of excessive exposure of the skin to UV
radiation, the redox balance is disturbed and oxidative stress occurs, which results in the activation of
cytosolic phospholipase A2 (cPLA2) and PLC in the skin cells [18]. This leads to the excessive release
of AA and the increased production of eicosanoids via cyclooxygenases and lipoxygenases. COX-1
and COX-2 catalyze the transformation of arachidonic acid into the series 2 prostanoids (PGE2, PGD2,
PGI2, TXA2, and TXB2). Moreover, 5-lipoxygenase (5-LOX) metabolizes arachidonic acid to series 4
leukotrienes (LTB4, LTC4, LTD4, and LTE4) [18,31]. Prostaglandins, series 2 thromboxanes, and series 4
leukotrienes belong to the pro-inflammatory eicosanoids [31]. However, 15-lipoxygenase (15-LOX)
catalyzes the conversion of arachidonic acid to 15-hydroxyeicosatetraenoic acid (15-HETE), whose
metabolites are lipoxins. These compounds have anti-inflammatory properties [18,31]. Moreover,
15-HETE can inhibit the formation of 12-HETE, which is a metabolite of 12-LOX’s catalytic action on
arachidonic acid [18].
Because DGLA can be metabolically converted via three different enzyme pathways, it is
important to determine which enzyme has a higher affinity for arachidonic acid and which metabolites
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will dominate—pro-inflammatory or anti-inflammatory. Note that γ-linolenic acid, which is one of the
main acids contained in evening primrose oil, is an important precursor of DGLA, which is a precursor
of anti-inflammatory eicosanoids [32]. It has been shown that GLA or DGLA supplementation causes
a modest increase in the prostaglandin E1 (PGE1) level in tissues in relation to PGE2, but the biological
properties of PGE1 are about 20 times stronger in comparison to PGE2 [24]. However, GLA or DGLA
supplementation may cause their conversion to AA and pro-inflammatory eicosanoids. Therefore, it
is suggested that the metabolism should be directed to anti-inflammatory eicosanoids. An effective
solution is an application of selective Δ-5-desaturase inhibitors, which may stop DGLA’s conversion
to AA and its further pro-inflammatory metabolites [24]. Moreover, as a polyunsaturated fatty acid,
arachidonic acid undergoes peroxidation to form electrophilic aldehydes with low molecular weight
and high reactivity, which may be a cause of the modification of both nucleophilic small molecules
and high-molecular weight compounds, such as proteins, lipids, and DNA, which disturbs cellular
metabolism [33].
Evening primrose oil has a high content of LA and GLA, and strengthens the epidermal barrier,
normalizes the excessive loss of water through the epidermis, regenerates skin, and improves
smoothness, after both topical and oral applications [12].
Figure 1. Linoleic acid (LA) metabolism. 9-HODE: 9-hydroxyoctadecadienoic acid; 13-HODE:
13-hydroxyoctadecadienoic acid; 15-HETrE: 15-hydroxyeicosatrienoic; PGE1: prostaglandin
E1; PGD1: prostaglandin D1; PLA2: phospholipase A2; PLC: phospholipase C; 5-HPETE:
5-hydroperoxyeicosatetraenoic acid; 5-HETE: 5-hydroxyeicosatetraenoic acid; LTA4: leukotriene
A4; LTB4: leukotriene B4; LTC4: leukotriene C4; LTD4: leukotriene D4; LTE4: leukotriene
E4; 15-HPETE: 15-hydroperoxyeicosatetraenoic acid; 15-HETE: 15-hydroxyeicosatetraenoic acid;
LXA4: lipoxin A4; LXB4: lipoxin B4; 12-HPETE: 12-hydroperoxyeicosatetraenoic acid; 12-HETE: 12-
hydroxyeicosatetraenoic acid: PGG2: prostaglandin G2; PGH2: prostaglandin H2; PGI2: prostaglandin
I2: PGD2: prostaglandin D2; 15-d-PGJ2: 15-deoxy-delta-12,14-prostaglandin J2; PGE2: prostaglandin
E2: PGF2: prostaglandin F2: TXA2: thromboxane A2; TXB2: thromboxane B2.
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In addition, due to its linoleic acid content, evening primrose oil has a beneficial moisturizing
effect on the mucous membrane in acne patients treated with isotretinoin [34]. This implies that skin
supplementation with evening primrose oil improves the skin’s water balance, which is weakened by
treatment with isotretinoin. Moreover, γ-linolenic acid, contained in large amounts in the oil, is a source
of the anti-inflammatory eicosanoids 15-HETrE and PGE1, which have anti-proliferative properties
that effectively prevent epidermal hyperproliferation [24,34]. In addition, these compounds inhibit the
proliferation of smooth muscle cells and prevent the development of atherosclerotic plaque [24].
In recent years, it has been found that γ-linolenic acid is cytotoxic to glioma cells, and it can
enhance gamma radiosensitivity [35,36]. It has been suggested that this effect is related to the
accumulation of the toxic products of lipid peroxidation, which are cytotoxic to glioma cells. In cancer
cells responsible for various types of cancer, the over-expression of the human epidermal growth factor
receptor 2 (HER-2/neu) oncogene has been observed. This oncogene causes rapid and uncontrolled cell
growth. However, γ-linolenic acid leads to an increase in the levels of polyomavirus enhancer activator
3 (PEA3), a transcriptional repressor of human epidermal growth factor receptor 2 (HER-2/neu) in
cells, and a decrease in Her-2/neu promoter activity, thus reducing the likelihood of developing breast
cancer [37]. Due to the inhibition of Her-2 expression, GLA administered together with transtuzumab,
which as a monoclonal antibody binds to the Her-2 receptor, increases the process of the apoptosis
of cancer cells and thus increases the effectiveness of pharmacotherapy with transtuzumab [37].
γ-Linolenic acid also causes an increase in the expression of the nm-23 metastasis-suppressor gene
in cancer cells, which favors the inhibition of angiogenesis, cancer cell migration, and consequently,
cancer metastasis [38,39]. The formation of these changes is also associated with a reduction in the
expression of the vascular endothelial growth factor (VEGF), which plays a significant role in cancer
(e.g., in the process of tumor angiogenesis) [40]. The above data suggest that evening primrose oil, as a
rich source of gamma linolenic acid, supports anti-cancer therapy.
Moreover, it has been found that the oral supplementation of evening primrose oil (EPO)
containing both linoleic acid and γ-linolenic acid reduces the inflammatory reaction and eases eye
problems such as burning, dryness, and light sensitivity in people with Sjögren’s syndrome [41].
Moreover, GLA reduces the levels of triacylglycerols and low-density lipoprotein (LDL) cholesterol
in plasma [42]. It has been suggested that phytosterols, which are present in large quantities in EPO,
also contribute to the above action [43].
Table 5. Biological effect and occurrence of selective eicosanoids [18,44,45].
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Table 5. Cont.




- LXA4 inhibits expression of interleukin 6 (IL-6)
and interleukin 8 (IL-8)









































Cys-LT: cysteinyl leukotrienes; LTC4: leukotriene C4, LTD4: leukotriene D4; LTE4—leukotriene E4.
4. Conclusions
After analyzing the chemical composition of evening primrose (Oenothera biennis), especially the
oil from its seeds and the biological activity of its components, it can be stated that it is a natural
preparation supplementing the deficiency of essential fatty acids in the body. Therefore, it is beneficial
in the treatment of chronic inflammation. It supports the metabolism of the body at various levels,
especially in situations leading to the development of pathological conditions.
Author Contributions: M.T.: description of the biological activity of the evening primrose; K.B.: description of
the chemical composition of the evening primrose; E.S.: major contribution in writing the manuscript. All authors
read and approved the final manuscript.
Funding: This research received no external funding.
Conflicts of Interest: The authors declare no conflicts of interest.
References
1. Mihulka, S.; Pysek, P. Invasion history of Oenothera congeners in Europe: A comparative study of spreading
rates in the last 200 years. J. Biogeogr. 2001, 28, 597–609. [CrossRef]
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Abstract: Although Aloe vera contains numerous bioactive components, the activity principles of
widely used A. vera extracts are uncertain. Therefore, we analyzed the effects of genuine A. vera
aqueous extract (AV) on human cells with respect to the effects of hydrogen peroxide (H2O2)
and 4-hydroxynonenal (HNE). Fully developed A. vera leaves were harvested and analyzed for
vitamin C, carotenoids, total soluble phenolic content, and antioxidant capacity. Furthermore,
human cervical cancer (HeLa), human microvascular endothelial cells (HMEC), human keratinocytes
(HaCat), and human osteosarcoma (HOS) cell cultures were treated with AV extract for one hour
after treatment with H2O2 or HNE. The cell number and viability were determined using Trypan
Blue, and endogenous reactive oxygen species (ROS) production was determined by fluorescence,
while intracellular HNE–protein adducts were measured for the first time ever by genuine cell-based
HNE–His ELISA. The AV extract expressed strong antioxidant capacities (1.1 mmol of Trolox eq/g
fresh weight) and cell-type-specific influence on the cytotoxicity of H2O2, as well as on endogenous
production of ROS and HNE–protein adducts induced by HNE treatment, while AV itself did not
induce production of ROS or HNE–protein adducts at all. This study, for the first time, revealed the
importance of HNE for the activity principles of AV. Since HMEC cells were the most sensitive to
AV, the effects of AV on microvascular endothelia could be of particular importance for the activity
principles of Aloe vera extracts.
Keywords: Aloe vera; plant extract; antioxidants; cell growth; oxidative stress; reactive oxygen
species (ROS); hydrogen peroxide; lipid peroxidation; 4-hydroxynonenal (HNE); cell-based ELISA;
HNE–protein adducts; microvascular endothelium
1. Introduction
Aloe barbadensis Miller L. (trivially called A. vera) is one of more than 400 species of the Aloe genus
belonging to family Liliaceae that originated in South Africa, but are indigenous to dry subtropical and
tropical climates [1]. Aloe vera is widely used in different forms of medicinal remedies without a clear
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understanding of the activity principles that could make the basis for its therapeutic properties [2].
In addition to the medicinally most potent A. barbadensis Miller, at least three other species are known
to have medicinal properties: Aloe perryi Baker, Aloe ferox, and Aloe arborescens [2].
The antioxidant composition of A. vera includes mostly α-tocopherol (vitamin E), carotenoids,
ascorbic acid (vitamin C), flavonoids, and tannins. In vitro studies showed the scavenging potential of
A. vera gel for various free radicals. Moreover, phytosterols purified from A. vera, namely lophenol
and cycloartanol, can induce the downregulation of fatty-acid synthesis and show a tendency for
the upregulation of fatty-acid oxidation in the liver, which favors the reduction in intra-abdominal
fat and improvement of hyperlipidemia. It was claimed that the polysaccharides in A. vera gel
have therapeutic properties such as immunostimulation, anti-inflammatory effects, wound healing,
promotion of radiation damage repair, anti-bacterial, anti-viral, anti-diabetic, and anti-neoplastic
activities, as well as stimulation of hematopoiesis and anti-oxidant effects [3]. Lactobacillus brevis strains
isolated from naturally fermented A. vera gel inhibited the growth of many harmful enteropathogens
without restraining most normal commensals in the gut. Moreover, aloin is metabolized by the colonic
flora to reactive aloe emodin, which is responsible for purgative activity. Aloe emodin also inhibits
colon cancer cell migration by downregulating matrix metalloproteinases 2 and 9 (MMP-2/9) [1–3].
Many of the medicinal effects of A. vera extracts were assigned to the polysaccharides found in the
inner leaf parenchymatous tissue, while it is believed that these biological activities could mostly be due
to synergistic action of the compounds contained therein rather than a single chemical substance [4].
The most investigated biomedical properties of A. vera gel involve the promotion of wound healing,
including burns and frostbite, in addition to anti-inflammatory, antifungal, hypoglycemic, and
gastroprotective properties. However, the healing properties of A. vera gel extracts were mostly
tested using animal models. Hence, A. vera gel extract stimulated fibroblast growth in a synovial
model, while also enhancing wound tensile strength and collagen turnover in wound tissue [5].
In another trial, A. vera gel increased levels of hyaluronic acid and dermatan sulfate in granulation
tissue. A. vera treatment of wounded tissue also increased the blood supply, which is essential for the
formation of new tissue. On the other hand, some reports mentioned inhibitory effects of A. vera gel
on wound healing, which should not be a surprise, as the composition of A. vera gel varies even within
the same species and depends on the source and climate of the region of plant growth, as well as on
the processing method [5]. It was suggested that a standardized method could be necessary for the
production of aloe gel products to avoid degradation of the polysaccharides, thereby preventing the
removal of high-molecular-weight molecules in aloe gel extracts [3].
In vivo and in vitro studies demonstrated the potential of A. vera gel as an anti-hyperglycemic
and anti-hyprecholesterolemic agent for type 2 diabetic patients without any significant effects on
other normal blood lipid levels or liver/kidney function. A. vera also helps improve carbohydrate
metabolism, with a recent report suggesting that it helps improve metabolic status in obese
pre-diabetics and in early non-treated diabetic patients by reducing body weight, body fat mass,
fasting blood glucose, and fasting serum insulin in obese individuals [3,6].
It was also shown that A. vera extracts can inhibit inflammatory processes via the reduction
of leukocyte adhesion and the suppression of pro-inflammatory cytokines, thus attenuating lipid
peroxidation and cerebral ischemia/reperfusion injury in rats [1].
The abovementioned effects of A. vera extracts, together with its content of different antioxidants,
suggest that A. vera might influence biomedical effects of lipid peroxidation, and thus, of generated
reactive aldehydes denoted as second messengers of free radicals, due to their high cytotoxic and
mutagenic capacities combined with multiple regulatory activities [7–9]. Among these reactive
aldehydes, of particular interest is 4-hydroxynonenal (HNE), generated from polyunsaturated fatty
acids (PUFAs). In particular, HNE has high affinity for binding to proteins, consequently changing their
structure and function, while still retaining toxic and regulatory activities of the aldehyde, including
regulation of cell proliferation, differentiation, and apoptosis [10,11]. Therefore, HNE is currently
considered to be major biomarker of lipid peroxidation, especially if bound to proteins, which already
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helped us better understand the pathophysiology of lipid peroxidation, as well as inflammatory and
growth-regulating processes, and helped us revise modern concepts of major stress- and age-associated
diseases [12–15].
Therefore, the aim of this study was to evaluate, using in vitro experiments, if A. vera extract
could interfere with the cytotoxicity of reactive oxygen species (ROS), notably of hydrogen peroxide
(H2O2), which is the most common (patho)physiological ROS, and with HNE, acting as a major second
messenger of free radicals.
2. Materials and Methods
2.1. Plant Material and Extract Preparation
To avoid difficulties arising from the use of commercially available A. vera extracts, while also
considering the inconvenience of gel extracts for in vitro studies, we prepared in-house aqueous
extracts from the fresh plant, as can be done easily in any laboratory. Aloe vera (Aloe barbadensis Miller)
plants were subjected to vegetative propagation. Young shoots were removed from the mother plant,
and were planted in sand until the roots were developed. After that, plantlets were transferred in
0.5-kg plastic pots, two plants per pot, containing commercial soil. Plants were irrigated once every two
weeks with tap water and grown under ambient irradiance and temperature (400–1400 μmol m−2 s−1
and 25 ± 1 ◦C, respectively). After one year of growth, the first fully developed leaves, fourth from
the top, were used for crude-extract preparation, as well as for all biochemical analysis. A. vera leaves
were grounded in liquid nitrogen using a pistil and mortar. The obtained leaf powder was used for
further preparations and analyses.
2.2. Total Soluble Phenolic Content and Antioxidant Activity
2.2.1. Phenolic Content
For total soluble phenolic content estimation, approximately 600 mg of leaf powder was used
and extraction was performed for 24 h at −20 ◦C in 2.5 mL of 96% ethanol [16]. The reaction mixture
contained 100 μL of ethanol extract, 700 μL of distilled H2O, 50 μL of Folin–Ciocalteu reagent, and
150 μL of sodium carbonate solution (200 g L−1). Samples were incubated for 60 min at 37 ◦C in a
water bath, and absorbance was measured spectrophotometrically at 765 nm using gallic acid (GA) as
a standard. Total soluble phenolic content was expressed as gallic acid equivalent (GAEq) per g of
fresh weight.
2.2.2. Ascorbic Acid Content
Approximately 600 mg of leaf powder was extracted in 10 mL of distilled water. The homogenates
were centrifuged for 15 min at 3000× g and 4 ◦C. The reaction mixture contained 300 μL of
aqueous extract, 100 μL of 13.3% trichloroacetic acid, 25 μL of deionized water, and 75 μL of
2,4-dinitrophenylhydrazine (DNPH) reagent. The DNPH reagent was prepared by dissolving 2 g of
DNPH in 230 mg of thiourea and 270 mg of CuSO4 in 100 mL of 5 M H2SO4 [17]. Blanks were made
in parallel for each sample as described above without addition of DNPH reagent. Samples were
incubated in a water bath for 60 min at 37 ◦C. After incubation and addition of DNPH reagent to
the blanks, 500 μL of 65% H2SO4 was added to all reaction mixtures. The absorbance was measured
at 520 nm. The concentration of ascorbic acid was obtained from a standard curve with known
concentrations of ascorbic acid (2.5–20 μg mL−1). The ascorbic acid content was expressed in mg per
100 g of fresh weight.
2.2.3. Measurement of Total Carotenoids
Approximately of 0.1 g of leaf tissue was ground in liquid nitrogen with the addition of
Mg(HCO3)2. Fine powder was extracted in absolute acetone for 24 h at −20 ◦C. Samples were
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centrifuged at 18,000× g for 10 min and 4 ◦C; the absorbance was measured at 470 nm, 645 nm, and
662 nm. Absolute acetone was used as a blank test. The content of total carotenoids was estimated
according to the method described by Lichtenthaler and Buschmann [18].
2.2.4. Antioxidant Activity
Antioxidant activity was determined using the Brand-Williams method [19]. The supernatant
obtained by extraction with 96% ethanol for 24 h at −20 ◦C was used. The reaction mixture
contained 20 μL of leaf extract and 980 μL of 0.094 mM 2,2-diphenyl-1-picrylhydrazyl (DPPH)
previously dissolved in methanol. The reaction was carried out in the dark at 22 ◦C for
15 min with occasional stirring. After 15 min, the absorbance at 515 nm was measured. Then,
6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid (Trolox) dissolved in methanol was used
as a calibration standard, as Trolox is a water-soluble synthetic analog of α-tocopherol widely used
as an antioxidant standard when plant extracts are analyzed [20,21]. Hence, the total antioxidant
activity of A. vera extract was expressed as the equivalent (Eq) of Trolox per g of fresh weight of A. vera
leaves (FW).
2.3. Cell Cultures and Treatments
Aiming to evaluate whether the activity principles of A. vera extract include interference with
the bioactivities of ROS and HNE, we used four different human cell lines and three complementary
analytical methods. Each experiment and analysis was done using triplicates of identical cultures,
while statistical evaluation was done using a t-test, with values of p < 0.05 considered as significant.
For these experimental treatments, obtained leaf powder was dissolved with ice-cold physiological
saline solution at a 1:1 w/v ratio, vortexed, and left at 4 ◦C overnight. After centrifugation (5000× g,
4 ◦C, 10 min), supernatants were transferred to and combined in a new tube. Thus, the produced crude
extract was filtered through a 0.45-μm filter (Millipore, Merck, Germany) and stored in a refrigerator
in sterile plastic tubes as 1-mL aliquots before being used further in experimental work. This in-house
prepared A. vera extract is denoted as AV in the study presented.
2.3.1. Cell Cultures
The human uterine cervical carcinoma cell line (HeLa), human dermal microvascular endothelial
cells (HMEC), the human spontaneously transformed aneuploid immortal keratinocyte cell line from
adult human skin (HaCaT), and the human osteosarcoma cell line (HOS), which grows resembling
osteoblast cells in vitro, were purchased from the American Type Culture Collection (ATCC). The cells
were cultivated in T75 cell culture flasks (TPP, Switzerland) in Dulbecco’s modified Eagle’s medium
(DMEM) with 10% (v/v) fetal calf serum (FCS) at 37 ◦C in humidified atmosphere with 5% CO2.
Prior to the experiments, the cells were harvested with 0.25% (w/v) Trypsin/0.53 mM
ethylenediaminetetraacetic acid (EDTA) solution and counted with a Trypan Blue Exclusion Assay in a
Bürker-Türk hemocytometer (Brand). The cells were seeded into 96-microwell plates (TPP, Trasadingen,
Switzerland) at a specific density different for each cell line to acquire optimal short-term culturing
conditions of 4 × 104 cells/well (HMEC and HaCaT), or 1 × 105 cells/well (HeLa and HOS), and left
for 2 h to attach before further treatment.
2.3.2. Experimental Treatments with AV, H2O2, and HNE
In the first set of experiments, the potential influence of AV extract on the acute cytotoxicity of
H2O2, which is the most common (patho)physiological non-radical ROS, was evaluated. To do that,
AV extract was added either as 1% or as 10% final v/v concentration one hour after treating the cells
with either 0.0025% or 0.05% v/v concentration, which should cover the range of median lethal dose
(LD50) for the majority of the cell lines. The respective control cell cultures were either treated only
with H2O2 or with AV extract, or were not treated at all. After 24 h, the cells were harvested and
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analyzed using the Trypan Blue Exclusion Assay in a Bürker-Türk hemocytometer, counting not only
total cells per culture, but also the incidence of live vs. dead cells.
According to the obtained data, the second set of experiments in which HNE was used to treat the
cells was performed. The treatment protocol was almost identical to the first one, except that, instead
of hydrogen peroxide, HNE was used at 50 μM concentration resembling the LD50 for the majority of
the cells, while the AV extract was used only at 1% dose one hour after HNE. During the one-hour
period, the aldehyde should mostly be metabolized, bound to the cellular proteins, or eliminated from
the cells, thereby gaining its major immediate effects [22]. Two hours later, cell cultures were used
for determination of the levels of HNE–protein adducts in the cells or for analysis of the endogenous
(i.e., intracellular) production of ROS, notably of H2O2.
2.3.3. Determination of Intracellular HNE–Protein Adducts Using Cell-Based HNE–His ELISA
After the above-described treatment with HNE and/or AV extract, the cells were treated for 5 min
with 90% ethanol and were fixed with 10% buffered formalin to be processed immunocytochemically
for determination of the intracellular content of HNE–protein adducts. For determination of the
HNE–protein adducts, the genuine monoclonal antibody obtained from the culture medium of the
clone derived from a fusion of Sp2/Ag8 myeloma cells with B-cells of a BALBc mouse immunized
with HNE-modified keyhole limpet hemocyanine specific for the HNE–His adducts (courtesy of
Prof. G. Waeg from KF-University in Graz, Austria) were used [23]. Therefore, the well-known genuine
HNE–His ELISA designed for in vitro research was combined for the first time as a cell-based ELISA
with a standardized immunocytochemical procedure [22,24]. Shortly after the cells were fixed for
24 h, formalin was removed, and possible endogenous peroxidase activity of the samples was blocked
with 1.5% H2O2, 0.1% NaN3, and 2% bovine serum albumin (BSA), and the primary antibody against
HNE–histidine conjugates was added. For detection of the HNE adducts, the immunoperoxidase
technique was used, with secondary rabbit anti-mouse antibody (Dako, Glostrup, Denmark) applying
3,3′-diaminobenzidine tetrahydrocloride (DAB) as a chromogen. After the remaining reagents were
removed, 100 μL of sterile saline was added to each microculture well, which was then analyzed at
620 nm using an ELISA plate reader with a 405-nm reference filter (Multiskan EX; Thermo Fisher
Scientific, Waltham, MA, USA). To allow easier evaluation of the obtained data, the results are presented
as a percentage of respective control values (100%).
2.3.4. Measurement of Intracellular ROS Production
The ROS measurement based on the intracellular oxidation of 2′,7′-dichlorodihydrofluorescein
diacetate (DCFH-DA; Sigma-Aldrich, St. Louis, MO, USA) to fluorescent 2′,7′-dichlorofluorescein
(DCF) was used to determine ROS generation inside the cells [25]. The cells were incubated with
10 μM DCFH-DA at 37 ◦C for 30 min. The medium was replaced with a fresh one and the zero point
was measured with a Cary Eclipse Fluorescence Spectrophotometer (Varian, Agilent, Santa Clara, CA,
USA) with an excitation wavelength of 500 nm and an emission detection wavelength of 530 nm, while
fluorescence was measured after 30 min. To allow easier evaluation of the obtained data, the results
obtained as relative fluorescence units (RFU) measured are presented as a percentage of respective
control values (100%).
3. Results
3.1. The Levels of Antioxidants in A. vera Leaves
The amounts of major antioxidants present in A. vera leaves with respect to antioxidant capacity
expressed in comparison to Trolox are shown in Figure 1.
The total antioxidant activity of A. vera leaves was 1102.42 ± 56.7 mg Trolox Eq/g of FW.
Composition analysis revealed the following amounts of the known antioxidants in the A. vera leaves:
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ascorbic acid (0.172 ± 0.03 mg/g of FW), total carotenoids (0.055 ± 0.002 mg/g of FW), and total
soluble polyphenols (355.9 ± 10.2 mg GAEq/g of FW).
 
Figure 1. Partial characterization of the antioxidant levels of Aloe vera leaves. Values are given as mean
values for triplicates.
3.2. The Effects of H2O2 and AV Extract on Cell Viability
The effects of different concentrations of AV extract added one hour after different doses of H2O2
are shown in Figures 2–5.
Figure 2. The effects of Aloe vera (AV) extract (1 or 10%) on the human cervical cancer (HeLa) cells
with respect to H2O2 treatment (0.0025% or 0.05%). The cell count values (viability determined using
Trypan blue) were obtained 24 h after treatment (H2O2 followed by AV extract 1 h later) and are given
as mean values for triplicates. * significant difference to untreated control; ** significant difference to
H2O2 treatment alone.
The HeLa cells did not show sensitivity to a lower dose of H2O2, while a higher concentration
reduced the cell count and increased the incidence of dead cells, thus indicating a further decay of the
H2O2-treated cells. The AV extract did not show any prominent effects if used at 1% concentration;
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however, at the higher 10% concentration, the growth of the HeLa cells increased slightly and the
cytotoxicity was reduced.
In contrast, in the case of HMEC cells, AV used at the 10% dose reduced the growth of the
cells, while, if used at 1%, it caused a slight enhancement in the growth of these cells, as can be
seen in Figure 3. Despite such concentration-dependent effects of AV on the HMEC cells if given
alone, the plant extract did not influence the concentration-dependent cytotoxicity of H2O2 as could be
expected. This was because 1% AV enhanced the growth of the HMEC cells; as such, its combined effect
with a lower dose of H2O2 resulted in relatively (in comparison to 1% AV alone) more pronounced
cytotoxicity of H2O2, while, in the case of the 10% AV extract, its influence on the cytotoxicity of H2O2
was the opposite. However, in comparison to the cells treated by H2O2 alone, these difference were
not significant (p > 0.05).
Figure 3. The effects of AV extract (1 or 10%) on the human microvascular endothelial cells (HMEC)
with respect to H2O2 treatment (0.0025% or 0.05%). The cell count values (viability determined using
Trypan blue) were obtained 24 h after treatment (H2O2 followed by AV extract 1 h later) and are given
as mean values for triplicates. * significant difference to untreated control.
The concentration-dependent growth-inhibiting effects of AV extract were observed for the HaCaT
cells (Figure 4), although the cytotoxicity of H2O2 for this cell line did not depend on the used dose
of H2O2. The combined treatment with 1% AV did not influence the cytotoxicity of H2O2, while
10% concentration of the plant extract showed obviously additive suppressing (i.e., toxic) effects with
H2O2 for the HaCaT cells.
Finally, it should be said that, for the HOS cells (Figure 5), the AV extract did not show any
prominent effect, although these cells expressed relatively high sensitivity to the cytotoxic effects of
H2O2 (more than 60% inhibition).
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Figure 4. The effects of AV extract (1 or 10%) on the human keratinocyte (HaCaT) cells with respect to
H2O2 treatment (0.0025% or 0.05%). The cell count values (viability determined using Trypan blue)
were obtained 24 h after treatment (H2O2 followed by AV extract 1 h later) and are given as mean
values for triplicates. * significant difference to untreated control; ** significant difference to respective
H2O2 treatment alone.
Figure 5. The effects of AV extract (1 or 10%) on the human osteosarcoma (HOS) cells with respect to
H2O2 treatment (0.0025% or 0.05%). The cell count values (viability determined using Trypan blue)
were obtained 24 h after treatment (H2O2 followed by AV extract 1 h later) and are given as mean
values for triplicates. * significant difference to untreated control.
The toxic effects of H2O2 for the HOS cells did not depend on the dose of peroxide used.
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3.3. The Effects of AV Extract on HNE-Pretreated Cells
In the next set of experiments, the cells were exposed to 50 μM HNE concentration, which was
followed by AV extract after 1 h, applied at 1% concentration. The results of these treatments are
shown in Figures 6 and 7.
3.3.1. The Effects AV on HNE Binding to Cellular Proteins
The amounts of HNE–protein adducts developed in the cells after treatment with HNE and AV
1% extract, or without the plant extract are presented in Figure 6.
Figure 6. The effects of AV extract (1%) on the cellular generation of 4-hydroxynonenal (HNE)–protein
adducts induced by HNE treatment (50 μM). The amounts of HNE–protein adducts were determined
by cell-based HNE–His ELISA and are given as mean values for triplicates. * significant difference to
respective untreated control (ctrl); ** significant difference to respective HNE-treated control.
The treatment with AV extract itself did not induce the production of HNE–protein adducts in
any type of cell used, while increased amounts of HNE–protein adducts developed in the cells after
treatment with HNE were observed for all cell lines (significant for all with respect to the plain controls,
p < 0.05). If the cells were treated with the AV extract one hour after treatment with HNE, a tendency
of enhanced accumulation of the cellular proteins modified by HNE was observed for all cell lines.
However, it was significant only for the HMEC cells.
3.3.2. The Effects of AV on Cellular ROS Production Induced by HNE
The levels of ROS developed in the cells after treatment with HNE and AV 1% extract, or without
the plant extract are presented in Figure 7.
The HMEC cells were the only cell line that responded to HNE treatment in terms of change
in endogenous production of ROS. However, while treatment with HNE slightly increased (by 29%)
intracellular production of ROS in the HMEC cells, the AV extract had no influence, as it did not induce
ROS production in any cell line tested.
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Figure 7. The effects of AV extract (1%) on the cellular generation of reactive oxygen species (ROS;
mostly H2O2) induced by HNE treatment (50 μM). The amounts of the HNE–protein adducts were
determined using luminescence and are given as mean values for triplicates. * significant difference to
respective untreated control.
4. Discussion
The results obtained in this study show that A. vera extract prepared from plant leaves has
prominent antioxidant capacity, most likely reflecting the activities of various antioxidants produced
by the plant. Because the AV extract itself did not induce ROS or HNE production in any cell line
used, its observed bioactivities probably reflect complex interactions of different plant substances
with cellular redox homeostasis challenged by ROS- or HNE-induced oxidative stress. Since the cell
lines used expressed differential sensitivity to the H2O2 toxicity, as well as reacting differently to the
AV treatment, we assume that such complex cell differences might reflect not only redox alterations
differently expressed by different types of cells upon H2O2 treatment interfering with antioxidants
present in the AV extract, but also might be, at least in a part, due to the lipid peroxidation chain
reactions that might generate HNE acting as a second messenger of free radicals. That should not
be surprising since plants exposed to oxidative stress also experience lipid peroxidation generating
reactive aldehydes, indicating that HNE and related aldehydes have important biological roles not only
in animals and humans, but also in plants; these roles are not only toxic, but also regulatory, most likely
related to the activity of antioxidants and regulatory proteins [26]. A possibility that such bioactive
substances of plant origin could also affect the human cells is supported by our findings of enhancing
effects of AV on accumulation of HNE–protein adducts upon HNE treatment, noticed for all cell lines
used, especially for the HMEC cells, which also showed enhanced production of ROS upon HNE
treatment associated with rapid accumulation of the advanced (aldehydic) lipoxidation end products
(ALEs). Since microvascular endothelial cells (such as those used to establish the HMEC cell line) have
crucial roles in various inflammatory and degenerative diseases, and above all, in tissue growth, either
in wound regeneration or cancer development, the findings detailing the highest sensitivity of the
HMEC cells to treatment with AV extract and HNE, in comparison to the other cell lines used, might be
important for better understanding the bioactivity principles of AV extracts. Since this is the first study
which reveals the possible relevance of HNE for the activity principles of AV extracts, we hope it will
encourage further research in the field.
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HNE acts in a concentration- and cell-type-dependent manner, regulating the majority of cellular
processes interfering with lipids, especially PUFAs, and carbohydrate metabolism, crucial for cellular
stress response and adaptation to stress, occurring even in yeast cells [27,28]. In the case of mammalian
cells, HNE may interfere with cellular, as well as with extracellular, factors, eventually acting as a
growth-regulating factor suppressing the growth of cancer, and enhancing the growth of non-malignant
cells [29–32]. Among such interactions of HNE, the most important are its effects on enzymes involved
in cellular metabolism and redox homeostasis, as well as on cytokines and their signaling pathways,
which might result either in negative (co-carcinogenic) or positive (anti-cancer) effects [33,34]. Here,
it should be stressed that such bioactivities of HNE occur not only in vitro, but also in vivo, and might
represent an anti-cancer defense mechanism of the non-malignant cells [35–37]. Eventually, that might
be of high importance for a better understanding of the interference of various antioxidants with
carcinogens and anti-cancer therapies [38–41].
Since Aloe vera is a very popular medicinal plant, over 4000 studies were performed on the
effectiveness of AV extracts in medical treatments, out of which many addressed the usefulness and
activity principles of AV for cancer patients. Thus, aloe anthraquinones were quite extensively studied
for their anticancer properties. In fact, the anthraquinones, aloin A and B, as well as aloe emodin,
are structurally similar to DNA-binding drugs such as anthracyclines. The antitumor effect of aloe is
also based on known mechanisms, including the induction of apoptosis and a significant elevation
of key antioxidant enzymes, such as superoxide dismutase (SOD) and glutathione peroxidase (GPx).
Pecere et al. [42] reported on selective in vitro and in vivo killing of neuroectodermal tumor cells by
aloe emodin both in tissue cultures and in animal models. Grimaudo et al. investigated the effect of
purified anthraquinines on sensitive and multidrug-resistant leukemia cells, and showed that only aloe
emodin had reproducible cytotoxic activity, but at concentrations much higher than those of common
anticancer agents such as daunorubicin and etoposide [43]. Lee et al. demonstrated that the time- and
dose-dependent treatment of human lung squamous carcinoma CH27 cells by aloe emodin resulted
in apoptosis, while combined effect of aloe emodin with cisplatinum confirmed that the inhibitory
effect of aloe emodin acted in a dose-dependent manner [44]. Similar to AV extracts, HNE also has a
strong pro-apoptotic capacity, which is related to its protein-binding capacity, while it can act also in
cell-type-specific manner, being selectively toxic for cancer, but not for non-malignant cells [10,11,14,32].
Moreover, HNE can affect tumor–host relationships, acting as an effector of anti-cancer activities of
leukocytes, stromal cells, and non-malignant cells bordering invading cancer, and might even result in
the spontaneous regression of cancer, such as W256 [35,36,45].
Furthermore, concomitant administration of the potent antioxidant pineal indole melatonin (MLT)
and A. vera extract had better effects than those obtained by MLT used alone in patients suffering
either from lung cancer, gastrointestinal tract tumors, breast cancer, or glioblastoma, all of which are
otherwise known to be associated with the synthesis of HNE–protein adducts [37,38,46,47]. Treatment
with MLT plus A. vera extracts produced therapeutic benefits, at least in terms of stabilization of
disease and survival, in patients with advanced solid tumors for whom no other standard effective
therapy was available [48]. Since HNE has an important role in defense activities of normal cells
against primary and metastatic cancer, and can reflect the overall tumor–host relationship, especially
on a metabolic level, we believe that further studies on AV should include immunohistochemical
evaluation of the HNE–protein adducts in cancer and in surrounding tissue, complemented by their
determination using the HNE–His ELISA in the blood. Such an analytical approach might not only
help better understand the biomedical effects of AV and the pathophysiology of HNE, but could also
further enhance the development of modern integrative biomedicine [49–52].
5. Conclusions
Aloe vera leaves used to prepare the extract (AV) had prominent antioxidant capacity, reflecting the
overall activities of various antioxidants. AV on its own did not at all induce ROS or HNE production
in the cells treated, while its observed bioactivities might reflect a complex interaction of different plant
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substances with cellular redox homeostasis for cells challenged by ROS- or HNE-induced oxidative
stress. The complexity of the biological effects of HNE (regulation of proliferation, differentiation,
and apoptosis), particularly if bound to proteins, plays an important role in the pathogenesis of
various diseases, including cancer, but also in the cellular and systemic defense against stress-
and age-associated diseases. In particular, the effects of AV on microvascular endothelia could
be an important activity principle of AV; thus, we suggest further studies on AV to include
an immunohistochemical evaluation of HNE–protein adducts in cancer and surrounding tissue,
complemented with their determination using HNE–His ELISA in the blood.
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Abstract: Lipids and proteins of skin cells are the most exposed to harmful ultraviolet (UV) radiation
contained in sunlight. There is a growing need for natural compounds that will protect these
sensitive molecules from damage, without harmful side effects. The aim of this study was to
investigate the effect of sea buckthorn seed oil on the redox balance and lipid metabolism in UV
irradiated cells formed different skin layers to examine whether it had a protective effect. Human
keratinocytes and fibroblasts were subjected to UVA (ultraviolet type A; 30 J/cm2 and 20 J/cm2) or
UVB (ultraviolet type B; 60 mJ/cm2 and 200 mJ/cm2, respectively) radiation and treated with sea
buckthorn seed oil (500 ng/mL), and the redox activity was estimated by reactive oxygen species
(ROS) generation and enzymatic/non-enzymatic antioxidants activity/level (using electron spin
resonance (ESR), high-performance liquid chromatography (HPLC), and spectrophotometry). Lipid
metabolism was measured by the level of fatty acids, lipid peroxidation products, endocannabinoids
and phospholipase A2 activity (GC/MS (gas chromatography/mass spectrometry), LC/MS (liquid
chromatography/mass spectrometry), and spectrophotometry). Also, transcription factor Nrf2
(nuclear erythroid 2-related factor) and its activators/inhibitors, peroxisome proliferator-activated
receptors (PPAR) and cannabinoid receptor levels were measured (Western blot). Sea buckthorn oil
partially prevents UV-induced ROS generation and enhances the level of non-enzymatic antioxidants
such as glutathione (GSH), thioredoxin (Trx) and vitamins E and A. Moreover, it stimulates the activity
of Nrf2 leading to enhanced antioxidant enzyme activity. As a result, decreases in lipid peroxidation
products (4-hydroxynonenal, 8-isoprostaglandin) and increases in the endocannabinoid receptor
levels were observed. Moreover, sea buckthorn oil treatment enhanced the level of phospholipid
and free fatty acids, while simultaneously decreasing the cannabinoid receptor expression in UV
irradiated keratinocytes and fibroblasts. The main differences in sea buckthorn oil on various skin cell
types was observed in the case of PPARs—in keratinocytes following UV radiation PPAR expression
was decreased by sea buckthorn oil treatment, while in fibroblasts the reverse effect was observed,
indicating an anti-inflammatory effect. With these results, sea buckthorn seed oil exhibited prevention
of UV-induced disturbances in redox balance as well as lipid metabolism in skin fibroblasts and
keratinocytes, which indicates it is a promising natural compound in skin photo-protection.
Keywords: fibroblasts; keratinocytes; sea buckthorn seeds oil; UV radiation; lipid metabolism
1. Introduction
Skin has been recognized as an organ that performs synthesis and processing of an astounding
range of structural proteins, lipids, and signaling molecules. Moreover, skin is an integral component
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of the immune, nervous and endocrine systems, and therefore is also responsible for the first line of
information and defense in the immunity process [1]. However, skin also protects the organism against
the influence of the environment and is well-known as crucial for the maintenance of temperature,
electrolyte and fluid balance [2]. As a natural biological barrier, skin is constantly exposed to numerous
external factors that can impair the functioning of this barrier, including ultraviolet (UV) radiation
contained in sunlight. High energy UVB (ultraviolet type B; 280–320 nm) and UVA (ultraviolet
type A; 320–400 nm) radiation absorption by the skin may trigger mechanisms that defend skin
integrity and also induces skin pathology, such as cancer [3]. These effects occurs as a result of the UV
electromagnetic energy transduction into chemical, hormonal, and neural signals, defined by the nature
of the chromophores and tissue compartments receiving specific UV wavelength. However, despite of
the wavelength differences, both of them are characterized by high penetration into the deep layers of
the epidermis and dermis [4]. UV radiation can upregulate local cytokines, corticotropin-releasing
hormone, urocortins, proopiomelanocortin peptides expression, however, they can be released into
circulation to exert systemic effects, including activation of the central hypothalamic-pituitary-adrenal
axis, opioidogenic effects, and immunosuppression [5]. Similar effects of UV radiation on human
organism are seen after exposure of the eyes and skin to UV, through which UV exerts very rapid
stimulatory effects on the brain and central neuroendocrine system and impairs body homeostasis [5].
Moreover, UV radiation promotes the generation of reactive oxygen species (ROS) as well as impairs
the antioxidant capacity of skin cells [6]. As a result, the redox imbalance leading to oxidative
stress is increased. UV-induced oxidative stress in skin enhances the collagen degradation and
elastin modification causes premature skin aging [7,8]. Moreover, increased oxidative phospholipid
metabolism disturbs the function of cellular membranes, and promotes the generaton of reactive
electrophiles, such as 4-hydroxyalkenals [9]. These reactive electrophiles interact with membrane
phospholipids and proteins, including receptors, causing irreparable skin damage. Additionally,
UV-induced oxidative stress affects phospholipid metabolism which influences the endocannabinoid
system [10]. The main endocannabinoids, such as anandamide and 2-arachidonoylglycerol (2-AG),
participate in cell signalling and are ligands for transmembrane receptors-CB1 and CB2 (cannabinoid
receptor type 1 and 2) [11]. Activation of CB1 is responsible for ROS generation, whereas CB2 prevents
ROS generation and inflammation, while also stimulating the MAP kinase (mitogen-activated protein
kinase) pathway [12].
In connection with the permanent exposure to harmful UV radiation, cells from different skin
layers-epidermal keratinocytes and dermal fibroblasts create a number of defense mechanisms that
protect against UV-induced oxidative stress. Examples of such mechanisms are the high activity of
repair and antioxidant enzymes, a large pool of non-enzymatic antioxidants, and redox-sensitive
transcription factors including Nrf2 that is responsible for cytoprotective protein expression [13].
Despite the above well-developed mechanisms, skin cells exposed to long-lasting UV radiation
are vulnerable to the depletion of the natural antioxidants present and therefore there is still a need
for compounds with cytoprotective properties against UV-induced changes. One potential source are
seed oils, the main source of phospholipids and triacylglycerols, which are solvents for other lipophilic
compounds, i.e., sterols, fat-soluble vitamins (vitamin A and E), carotenoids, phenolic compounds,
and free fatty acids [14]. One good source of seed oil is sea buckthorn (Hippophae rhamnoides L.) [15],
which is increasingly appearing in skin care preparations. Its antioxidant potential is based on high
content of polyphenols, vitamins (C and E), carotenoids as well as sterols [16–18]. In addition to the
antioxidant activity, sea buckthorn also shows antibacterial and antifungal activity [19]. Carotenoids
contained in the oil stimulate collagen synthesis, while phytosterols regulate inflammatory processes
and have anticancer effects [20]. Because of the high concentration of these compounds sea buckthorn
seed oil has been found as a promising therapeutic agent in the treatment of dermatitis [21]. However,
there is no research on the effect of sea buckthorn seed oil on the UV-induced oxidative lipid metabolism
of skin cells.
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The aim of this study was to estimate the effect of sea buckthorn seed oil on the correlation
between redox balance, lipid metabolism and endocannabinoid system in in vitro cultured human
keratinocytes and fibroblasts exposed to the UV-radiation.
2. Materials and Methods
2.1. Examination of Sea Buckthorn Seed Oil Composition
Sea buckthorn (Hippophae rhamnoides L.) seed oil fatty acids levels as well as vitamins A and E
were described below in the paragraphs Determination of fatty acids levels and Determination of
non-enzymatic antioxidant levels.
2.1.1. Determination of Squalene Levels
Squalene level was analyzed with separation on HP-5ms capillary column (0.25 mm; 0.25 μm,
30 m) of GC/MS system (Agilent Technologies, Palo Alto, CA, USA) with 7890A GC–7000
quadrupole MS/MS (Agilent Technologies, Palo Alto, CA, USA). Operating conditions were as follows:
Oven programming −50 ◦C (10 min), rate 2 ◦C/min to 310 ◦C (30 min); ion source (EI) −230 ◦C;
electron energy −70 eV [22]. The mass spectrometer source was run in selective ion monitoring (SIM)
mode for the following ions: 191 and 81 m/z.
2.1.2. Phytosterols Profile
The content of sterols in oils was determined by GC/MS system with 7890A GC–7000 quadrupole
MS/MS (Agilent Technologies, Palo Alto, CA, USA) [23]. Samples were separated on HP-5ms capillary
column (0.25 mm; 0.25 μm, 30 m). Operating conditions were as follows: oven programming −50 ◦C
(2 min), rate 15 ◦C/min to 230 ◦C, to 310 ◦C at the rate of 3 ◦C/min (10 min); ion source (EI)
−230 ◦C; electron energy −70 eV. The mass spectrometer source was run in selective ion monitoring
(SIM) mode for the following ions: 372 and 217 m/z for 5-α-cholestane (IS), 458 and 368 m/z for
cholesterol, 470 and 255 m/z for brassicasterol, 382 and 343 m/z for campesterol, 394 and 255 m/z
for stigmasterol and 396 and 357 m/z for β-sitosterol. The quantifications were carried out using the
internal standard method.
2.1.3. Determination of β-Carotene Levels
HPLC methods was used to detect the level β-carotene [24]. Samples were dissolved in
1 mL of 2-propanol and 20 μL was taken analysis. Separation was performed using C18 column
(150 nm × 4.6 mm) with UV detection at 454 nm. The concentration was determined using a calibration
curve range 0.5–50 mg/L.
2.2. Cell Culture
Human skin cell lines used in experiment were obtained from American Type Culture Collection and
cultured cultured in a humidified atmosphere of 5% CO2 at 37 ◦C. Human immortalized keratinocytes
(CDD 1102 KERTr) were transformed with human papillomavirus 16 (HPV-16) E6/E7, while fibroblasts
(CCD 1112Sk) were isolated from normal foreskin of Caucasian newborn male and used in passage 11.
The growth media for each line were prepared as follows: for keratinocytes-keratinocyte-SFM medium
with 1% Bovine Pituitary Extract (BPE) and human recombinant Epidermal Growth Factor (hEGF);
for fibroblasts-Dulbecco’s Modified Eagle Medium (DMEM) with 10% fetal bovine serum (FBS). Media
were supplemented with 50 U/mL penicillin and 50 μg/mL streptomycin. All sterile and cell culture
reagents were obtained from Gibco (Grand Island, NY, USA).
Cells were exposed to UV radiation after reaching the 70% confluence. Radiation doses for
keratinocytes were 30 J/cm2 for UVA (365 nm, power density at 4.2 mW/cm2) and 60 mJ/cm2 for UVB
(312 nm, power density at 4.08 mW/cm2), while for fibroblasts were 20 J/cm2 for UVA and 200 mJ/cm2
for UVB (Bio-Link Crosslinker BLX 312/365, Vilber Lourmat, Germany). The distance of the cells from
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lamps was 15 cm. Exposure doses were chosen corresponding to 70% cell viability measured by the
MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) assay [25], what was previously
shown as a doses that lead to the activation of pro-oxidative conditions, response of cell antioxidants,
as well as activation of Nrf2 pathway and increases endocannabinoid system action [6]. Control cells
were incubated in parallel without irradiation.
To examine the effect of sea buckthorn (Hippophae rhamnoides L.) seed oil (produced by “Szarłat”
M i W Lenkiewicz Sp. J., Poland) on UV radiated skin cells, after keratinocytes and fibroblasts were
exposed to UV radiation they were incubated 24 h under standard conditions in medium containing
500 ng/mL plant oil in 0.1% DMSO. The oil concentration was chosen corresponding to 100% cell
viability compared to control cells measured by the MTT assay [25]. Parallel cells were cultured in
medium containing plant oil without irradiation.
2.3. Examination of Pro-Oxidative Activity
2.3.1. Determination of ROS Generation
The superoxide anions generation was detected using stable nitroxide CM-radicals formation
and detection with EPR spectrometer (Noxygen GmbH/Bruker Biospin GmbH, Germany) [10,26].
The results were reported in micromolar concentration of ROS per minute and normalised per
milligram of protein.
2.3.2. Determination of Pro-Oxidants Enzyme Activities
NADPH oxidase (NOX-EC 1.6.3.1) activity was analysed by luminescence measurement using
lucigenin as luminophore [27]. Enzyme specific activity was described in relative luminescence units
(RLU) per milligram protein.
Xanthine oxidase (XO-EC1.17.3.2) activity was estimated by uric acid formation from xanthine [28].
Enzyme specific activity was described in microunits per milligram of protein.
2.4. Examination of Antioxidant Defence System
2.4.1. Determination of Antioxidant Enzymes Activity
Glutathione peroxidase (GSH-Px-EC.1.11.1.6) activity was assessed spectro-photometrically [29].
Enzyme specific activity was described in microunits per milligram of protein.
Glutathione reductase (GSSG-R-EC.1.6.4.2) activity was measured by monitoring the oxidation of
NADPH at 340 nm [30]. Enzyme specific activity was described in milliunits per milligram of protein.
Superoxide dismutase (Cu/Zn–SOD-EC.1.15.1.1) activity was determined according to the method
of Misra and Fridovich [31] as modified by Sykes [32]. Enzyme specific activity was calculated in
milliunits per milligram of protein.
The thioredoxin reductase (TrxR-EC. 1.8.1.9) activity was measured using a commercially available
kit (Sigma-Aldrich, St. Louis, MO, USA) in accordance with the included instruction [33]. Enzyme
activity was measured in units of microunits per milligram of protein.
2.4.2. Determination of Non-Enzymatic Antioxidant Levels
Thioredoxin level were quantified using the ELISA (enzyme-linked immunosorbent assay) [34].
The ELISA plates coated with samples were incubated at 4 ◦C overnight with anti-thioredoxin primary
antibody per well (diluted in 1% bovine serum albumin in phosphate buffered saline (PBS)) (Abcam,
Cambridge, MA, USA). After washing and blocking the plates were incubated with goat anti-rabbit
secondary antibody solution (Dako, Carpinteria, CA, USA). As a chromogen substrate solution
0.1 mg/mL 3,3′, 5,5′-tetramethylbenzidine was used. Spectral absorption was read at 450 nm with the
reference filter at 620 nm. Thioredoxin levels were described in micrograms per milligram of protein.
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Glutathione level was measured using the capillary electrophoresis (CE) [35] with separation on
47 cm capillary operated at 27 kV. UV detection was set at 200 ± 10 nm. Calibration curve range of
1–120 nmol/mL (r2 = 0.9985) was prepared to determined GSH concentration that was subsequently
normalized for milligrams of protein.
To detect the level of vitamins A and E HPLC method was used [36]. Vitamins were extracted
using hexane. The concentration of vitamins detected at 294 nm was determined using a calibration
curves range: 0.125–1 mg/L (r2 = 0.9998) for vitamin A, and 5–25 mg/L (r2 = 0.9999) for vitamin E.
2.4.3. Determination of Protein Expression
Protein expression level was analyzed using Western blot technique [37]. Cell lysates or nuclear
fractions (in the case of phosphorylated protein Nrf2) were separated by 10% Tris-Glycine SDS-PAGE
(sodium dodecyl sulfate polyacrylamide gel electrophoresis). Following electrophoresis, separated
proteins were transferred into a membrane and blocked with 5% skim milk. Primary antibodies against
phospho-Nrf2 (pSer40), HO-1, Keap1, p21, p62, and peroxisome proliferator-activated receptors
(PPARα, γ, and δ) (Sigma-Aldrich, St. Louis, MO, USA) were diluted 1:1000. Protein bands were
visualized calorimetrically using the BCIP/NBT (5-bromo-4-chloro-3-indolyl-phosphate/nitro blue
tetrazolium) Liquid substrate system (Sigma-Aldrich, St. Louis, MO, USA). Protein level was expressed
as a percentage of control cells.
2.5. Examination of Lipid Metabolism
2.5.1. Determination of Cellular Membrane Integrity by LDH Test
Keratinocyte and fibroblast cellular membrane integrity was monitored using the assay based
on the determination of the release of lactate dehydrogenase (LDH) into the medium. Cells were
seeded into a 96 well plates in 200 μL of growth media at 5 × 103 for 24 h and then subjected to UV
radiation or oil treatment range 5 ng/mL–5 mg/mL. Following 24 h incubation the activity of LDH in
medium and in cell lysates was measured after 24 h. Spectrophotometric detection was carried out
at 340 nm. The final concentrations of NADH and pyruvate in the reaction mixture were 1 mM and
2 mM, respectively [25]. The rate of LDH released from the treated cells was calculated by comparing
its activity in medium to cell lysates. The results were expressed as the percentage of LDH activity
obtained for control cells.
2.5.2. Determination of Fatty Acids Levels
Fatty acids profiles were determined by gas chromatography [38]. Free fatty acids (FFA) and
phospholipids (PL) were methylated to fatty acid methyl esters (FAMEs). FAMEs were analyzed by
Clarus 500 Gas Chromatograph (Perkin Elmer, Shelton, CT, USA) following separation on capillary
column (50 m × 0.25 mm, ID 0.2 μm, Varian, Walnut Creek, USA). Identification of FAMEs was made
by comparison to their retention time with authentic standards. Quantitation was achieved using an
internal standard method.
2.5.3. Phospholipase A2 Activity
The activity of cPLA2 (cytosolic phospholipase A2) activity was measured using a commercially
available kit (Cayman, No. 765021). To detect cPLA2 activity specific inhibitors of sPLA2
(thioetheramide-PC) and iPLA2 (bromoenol lactone) were added to samples [39]. Enzyme specific
activity was presented in nanomol of free thiol released per minute normalized per milligram of protein.
2.5.4. Determination of Lipid Peroxidation Products
Lipid peroxidation was estimated by measuring the level of 4-hydroxynonenal (4-HNE) and
8-Isoprostaglandin F2α.
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Aldehydes were measured by GC/MS in selected ion monitoring (SIM) mode, as the O-PFB-oxime
or O-PFB-oxime-TMS derivatives using benzaldehyde-D6 as an internal standard [40]. Aldehydes
were analyzed using a 7890A GC—7000 quadrupole MS/MS (Agilent Technologies, Palo Alto, CA,
USA) equipped with a HP-5ms capillary column (30-m length, 0.25-mm internal diameter, 0.25-μm film
thickness). Target ion with a m/z 333.0 and 181.0 for 4-HNE-PFB-TMS and m/z 307.0 for IS derivatives
were selected. Obtained results were normalized for milligrams of protein.
8-Isoprostaglandin F2α (8-isoPGF2α) level was measured using LC-MS (Agilent 1290 LC with
triple quadruple mass spectrometer in negative multiple reaction mode [41]. SEP-PAK C18 column
were used to samples purification. Target ions with a m/z 353→193 were selected. Target ion with a
m/z 353→193 was selected.
2.5.5. Determination of Endocannabinoid System
Anandamide (AEA) and 2-arachidonoylglycerol (2-AG) were quantified using UPLC-MS/MS
system (Agilent 1290 UPLC system interfaced with an Agilent 6460 triple quadrupole mass
spectrometer) [42]. As internal standards AEA-d8 and 2-AG-d8 were used. The samples were analyzed
in positive-ion mode using multiple reaction monitoring (MRM) and the transition of the precursor to
the product ion were: m/z 348.3→62.1 for AEA, and m/z 379.3→287.2 for 2-AG. Endocannabinoids
concentrations were expressed as femtomols per milligram of protein.
The levels of endocannabinoid receptors CB1/2 were measured by Western blotting described
above (Determination of protein expression). Primary monoclonal antibodies against CB1 and CB2 (Santa
Cruse Biotechnology, Santa Cruz, CA, USA) were used at a concentration of 1:1000. Receptor level was
expressed as a percentage of control cells.
2.6. Statistical Analysis
Data were analyzed using standard statistical analyses, including t-test, and the results are
expressed as the mean ± standard deviation (SD) for n = 5. Experiment was performed on cell lines
and all replicates were technical repetitions and do not reflect biodiversity. p-values less than 0.05 were
considered significant.
3. Results
3.1. The Sea Buckthorn Seed Oil Composition
The composition of sea buckthorn seed oil is presented in Table 1. In addition to the large amount
of fatty acids in the free form as well as in the form of DG, TAG and PL, the seed oil of sea buckthorn
also contains phytosterols, such as cholesterol, brassicrakol, campesterol, stigmasterol and β-sitosterol,
as well as antioxidants such as vitamins A and E, squalene and β-carotene.
Table 1. The fatty acids composition, antioxidant components and phytosterols in sea buckthorn
(Hippophae rhamnoides L.) seeds oil. Mean values ± SD of five independent experiments are presented.
Fatty Acids Composition of Sea Buckthorn Needs Oil
PL TG DG FFA
mg/mL
14:0 0.060 ± 0.003 4.58 ± 0.14 0.240 ± 0.007 0.070 ± 0.003
16:0 1.14 ± 0.03 308.60 ± 9.25 3.10 ± 0.09 1.65 ± 0.05
18:0 0.51 ± 0.02 8.05 ± 0.24 0.47 ± 0.01 0.100 ± 0.003
20:0 n.d. 2.13 ± 0.06 0.130 ± 0.003 0.060 ± 0.002
22:0 n.d. 0.95 ± 0.03 0.140 ± 0.003 n.d.
24:0 n.d. 1.08 ± 0.03 0.170 ± 0.004 0.070 ± 0.002
SFA 1.71 ± 0.05 325.40 ± 9.76 4.26 ± 0.13 1.95 ± 0.06
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Table 1. Cont.
Fatty Acids Composition of Sea Buckthorn Needs Oil
PL TG DG FFA
mg/mL
16:1n7 0.48 ± 0.01 310.85 ± 9.33 4.56 ± 0.14 2.22 ± 0.07
18:1n9c 0.150 ± 0.005 45.34 ± 1.36 0.89 ± 0.03 0.34 ± 0.01
18:1n7 0.110 ± 0.003 45.25 ± 1.35 0.83 ± 0.02 0.48 ± 0.01
18:2n6 0.230 ± 0.007 87.68 ± 2.63 7.15 ± 0.21 1.53 ± 0.05
18:3γ n.d. 1.79 ± 0.05 n.d. n.d.
18:3α 0.280 ± 0.008 7.05 ± 0.21 n.d. 0.210 ± 0.006
MUFA 0.74 ± 0.02 401.44 ± 12.04 6.29 ± 0.19 3.04 ± 0.09
PUFA 0.51 ± 0.02 96.51 ± 2.90 7.15 ± 0.21 1.74 ± 0.05
USFA 1.25 ± 0.04 497.95 ± 14.94 13.44 ± 0.40 4.78 ± 0.14
Sum 2.95 ± 0.09 823.35 ± 24.70 17.70 ± 0.53 6.73 ± 0.20
Antioxidant Components of Sea Buckthorn Needs Oil [mg/100 g]
Squalene β-Carotene Vitamin E Vitamin A
240±11 15.11 ± 0.46 98.92 ± 2.89 648.0 ± 19.7
Phytosterols in Sea Buckthorn Needs Oil [mg/100 g]
Cholesterol Brassicasterol Campesterol Stigmasterol β-Sitosterol Total phytosterols
0.51 ± 0.01 4.90 ± 0.14 17.61 ± 0.48 4.95 ± 0.12 223.88 ± 6.76 251.87 ± 7.48
Abbreviations: PL: phospholipid; DG: diacylglycerol; TG: triacylglycerol; EFA: essential fatty acid; n.d.: not detected.
3.2. The Effect of Sea Buckthorn Seed Oil on Skin Cells Redox Balance
Sea buckthorn seed oil treatment was found as a factor that partially prevented the UV-induced
disturbances in redox balance occurring in experimental skin cells. It was found that fibroblast
incubation with sea buckthorn oil caused decrease in ROS generation by approximately 25% as well as
a decrease in the activity of NOX and XO by approximately 15% following UVA and 25% following
UVB radiation. Similar character of changes was observed in the case of keratinocytes only following
UVB radiation, were sea buckthorn oil caused decrease in NOX and XO activity by 10% and 15%,
respectively (Table 2).
Table 2. The reactive oxygen species (ROS) generation, xanthine oxidase and NADPH oxidase activity
in keratinocytes and fibroblasts after exposure to UVA (30 J/cm2 and 20 J/cm2) and UVB radiation (60




Oil Control UVA UVB Control UVA UVB
ROS
[nM/min/mg protein]
- 32.8 ± 1.6 89.1 ± 4.3 x 98.9 ± 4.8 x 50.6 ±2.4 126.5 ± 6.1 x 132.1 ± 6.4 x
+ 63.5 ± 3.1 x 80.8 ± 3.9 xy 96.5 ± 4.7 xy 54.7 ±2.6 94.6 ± 4.6 xya 96.5 ± 4.7 xyb
NOX
[RLU/mg protein]
- 158 ± 7.7 229 ± 11.2 x 256 ± 12.5 x 179 ± 8.7 321 ± 15.7 x 398 ± 19.5 x
+ 173 ± 8.4 231 ± 11.3 xy 227 ± 14.0 xyb 216 ± 10.5 x 268 ± 13.1 xya 321 ± 15.7 xyb
XO
[mU/mg protein]
- 164 ± 8.1 267 ± 13.1 x 297 ± 14.5 x 114 ± 5.5 248 ± 12.1 x 487 ± 23.8 x
+ 158 ± 7.7 248 ± 12.1 xy 254 ± 12.4 xyb 278 ± 13.6 x 215 ± 10.5 xya 348 ± 17.1 xyb
Mean values ± SD of five independent experiments are presented. x statistically significant differences vs. control
group, p < 0.05; y statistically significant differences between UVA/UVB and oil treated groups vs. oil treated control
group, p < 0.05; a statistically significant differences between UVA and oil treated group vs. UVA treated group,
p < 0.05; b statistically significant differences between UVB and oil treated group vs. UVB treated group, p < 0.05.
Abbreviations: UVA: ultraviolet type A; UVB: ultraviolet type B; ROS: reactive oxygen species; NOX: NADPH
oxidase; XO: xanthine oxidase.
Simultaneously, sea buckthorn oil altered the antioxidant system (Table 3), what was primarily
visible in the case of the non-enzymatic antioxidant thioredoxin, its level was significantly increased
by sea buckthorn oil in the keratinocytes and fibroblasts exposed to UV radiation by about 60% and
37% respectively in the case of UVA, and by 37% and 175%, respectively in the case of UVB radiation.
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Sea buckthorn oil also enhanced the level of glutathione in UV exposed cells; it was increased 2.5 fold
in the UV irradiated keratinocytes, and a 25% and 80% increase was observed in the case of UVA and
UVB irradiated fibroblasts, respectively. In the case of vitamin levels, sea buckthorn oil treatment
caused an increase in vitamin A levels in UVA and UVB irradiated keratinocytes by approximately 50%
and 60%, respectively; and in UVA and UVB irradiated fibroblasts by about 20% and 15%, respectively.
Also, the level of vitamin E following UV radiation was partially restored; by 55% in keratinocytes and
by 30% in fibroblasts following both UV types. Described changes were accompanied by enhanced
GSH-Px activity in keratinocytes (by 15% following UVA and even 2 times following UVB radiation).
Moreover, sea buckthorn oil cell treatment lead to 4- and 3-fold increase in TrxR activity in keratinocytes
following UVA and UVB radiation, and by 20% and 30% increases in the enzyme activity in fibroblasts
following UVA and UVB radiation, respectively. However, in the case of SOD activity sea buckthorn
oil additionally decreased its activity by 15% in the case of both cell lines.
Table 3. The activity of antioxidant enzymes (GSH-Px, GSSG-R, SOD, TrxR) and the level of
non-enzymatic antioxidants (GSH, Trx, vitamins A, E, and C) in keratinocytes and fibroblasts after
exposure to UVA (30 J/cm2 and 20 J/cm2) and UVB radiation (60 mJ/cm2 and 200 mJ/cm2, respectively)




Oil Control UVA UVB Control UVA UVB
GSH-Px
[mU/mg protein]
- 13.6 ± 0.6 10.8 ± 0.5 x 7.8 ± 0.4 x 11.8 ± 0.6 26.4 ± 1.2 x 29.5 ± 1.4 x
+ 15.6 ± 0.7 x 12.4 ± 0.6 ya 14.8 ± 0.7 b 16.3 ± 0.8 x 26.9 ± 1.3 xy 31.2 ± 1.5 xy
GSSG-R
[mU/mg protein]
- 26.3 ± 1.2 23.8 ± 1.2 x 19.2 ± 0.9 x 22.3 ± 1.1 45.6 ± 2.2 x 56.2 ± 2.7 x
+ 22.5 ± 1.1 x 21.8 ± 1.1 x 18.7 ± 0.9 xy 26.9 ± 1.3 x 34.6 ± 1.7 xy 49.3 ± 2.4 xy
SOD
[mU/mg protein]
- 28.4 ± 1.3 23.1 ± 1.1 x 21.6 ± 1.1 x 26.3 ± 1.2 21.3 ± 1.0 x 14.6 ± 0.7 x
+ 30.5 ± 1.5 25.6 ± 1.2 xy 24.7 ± 1.2 xyb 20.6 ± 1.0 x 18.5 ± 0.9 xya 12.3 ± 0.6 xyb
TrxR
[μU/mg protein]
- 112 ± 5 93 ± 4 x 84 ± 4 x 331 ± 16 204 ± 10 x 141 ± 7 x
+ 104 ± 5 421 ± 11 xya 300 ± 9 xyb 312 ± 15 243 ± 11 xya 182 ± 8 xyb
Trx
[μg/mg protein]
- 1.5 ± 0.07 1 ± 0.07 x 0.8 ± 0.07 x 0.9 ± 0.04 0.4 ± 0.01 x 0.4 ± 0.02 x
+ 1.6 ± 0.08 1.6 ± 0.08 xa 1.1 ± 0.07 xb 1.5 ± 0.07 x 1 ± 0.04 xya 1.1 ± 0.05 xyb
GSH
[nmol/mg protein]
- 26.2 ± 1.2 11.4 ± 0.5 x 9.6 ± 0.4 x 14.6 ± 0.7 8.2 ± 0.4 x 5.6 ± 0.3 x
+ 37.7 ± 1.8 x 27.7 ± 1.3 ya 22.3 ± 1.1 xyb 15.6 ± 0.8 10.4 ± 0.5 xya 10.1 ± 0.5 xyb
vitamin A
[nmol/mg protein]
- 53 ± 2.5 39 ± 1.9 x 35 ± 1.7 x 41 ± 2.1 34 ± 1.6 x 33 ± 1.6 x
+ 63 ± 3.0 x 59 ± 2.8 xa 56 ± 2.7 yb 46 ± 2.2 41 ± 2.1 a 38 ± 1.8 xyb
vitamin E
[nmol/mg protein]
- 453 ± 22.1 325 ± 15.9 x 303 ± 14.8 x 336 ± 16.5 287 ±1 4.1 x 269 ± 13.1 x
+ 517 ± 25.3 x 491 ± 24.1 ya 478 ± 23.4 yb 401 ± 19.5 x 381 ± 18.6 xa 351 ± 17.2 yb
Mean values ± SD of five independent experiments are presented. x statistically significant differences vs. control
group, p < 0.05; y statistically significant differences between UVA/UVB and oil treated groups vs. oil treated
control group, p < 0.05; a statistically significant differences between UVA and oil treated group vs. UVA treated
group, p < 0.05; b statistically significant differences between UVB and oil treated group vs. UVB treated group,
p < 0.05. Abbreviations: UVA: ultraviolet type A; UVB: ultraviolet type B; GSH-Px: glutathione peroxidase; GSSG-R:
glutathione reductase; SOD: superoxide dismutase; TrxR: thioredoxin reductase; Trx: thioredoxin; GSH: glutathione.
3.3. The Effect of Sea Buckthorn Seed Oil on Skin Cells Transcription Factors
Sea buckthorn oil treatment also stimulated the antioxidant system, increased expression of
phosphorylated factor Nrf2 in skin cells following UV radiation was observed in both cell lines as
well as in the case of expression of Nrf2 targeted protein—HO-1. On the other hand, sea buckthorn
oil restored the decreased activity following UV radiation, Keap1 level in UVA irradiated skin cells,
and in UVB irradiated keratinocytes. Simultaneously, sea buckthorn oil lead to the decrease in Nrf2
activators—p21 and p62, in skin cells following both UVA and UVB radiation (Figure 1).
Additionally, sea buckthorn oil treatment following UV radiation induced various effects
in keratinocytes and fibroblasts and in the other transcription factors such as peroxisome
proliferator-activated receptors (PPARα, γ, and δ). In keratinocytes sea buckthorn oil lead to a decrease
by 8% in PPARα expression following UVA radiation and by 20% in PPARδ expression following UVB
radiation, while in UVA and UVB irradiated fibroblasts increases by 10% in PPARα, by 50% in PPARδ,
and 2-fold in PPARγ expression were observed following sea buckthorn oil treatment (Figure 2).
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Figure 1. The expression of transcription factor phospho-Nrf2 (pSer40), its main target HO-1, and its
inhibitor/activators-Keap1, p21, p62 in keratinocytes and fibroblasts after exposure to UVA (30 J/cm2
and 20 J/cm2) and UVB radiation (60 mJ/cm2 and 200 mJ/cm2, respectively) and sea buckthorn
seeds oil (500 ng/mL) treatment. Mean values ± SD of five independent experiments are presented.
x statistically significant differences vs. control group, p < 0.05; y statistically significant differences
between UVA/UVB and oil treated groups vs. oil treated control group, p < 0.05; a statistically
significant differences between UVA and oil treated group vs. UVA treated group, p < 0.05; b statistically
significant differences between UVB and oil treated group vs. UVB treated group, p < 0.05.
Figure 2. The expression of peroxisome proliferator-activated receptors (PPARα, γ, and δ) in
keratinocytes and fibroblasts after exposure to UVA (30 J/cm2 and 20 J/cm2) and UVB radiation
(60 mJ/cm2 and 200 mJ/cm2, respectively) and sea buckthorn seeds oil (500 ng/mL) treatment.
Mean values ± SD of five independent experiments are presented. x statistically significant differences
vs. control group, p < 0.05; y statistically significant differences between UVA/UVB and oil treated
groups vs. oil treated control group, p < 0.05; a statistically significant differences between UVA and oil
treated group vs. UVA treated group, p < 0.05; b statistically significant differences between UVB and
oil treated group vs. UVB treated group, p < 0.05.
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3.4. The Effect of Sea Buckthorn Seed Oil on Skin Cells Lipid Metabolism
The composition of sea buckthorn oil also had an impact on skin cells lipid metabolism.
The greatest protective effect of this oil on membrane conditions was observed in the case of fibroblasts,
where sea buckthorn oil not only reduced the permeability of the membrane compared to the control
cells measured by LDH test (in the concentration rage 5 ng/mL–5 μg/mL), but also significantly
prevented UVA and UVB-induced membrane damage (in the concentration rage 5 ng/mL–50 μg/mL).
These effects were not observed in the case of keratinocytes (Figure 3).
Figure 3. The effect of different concentrations ranging 50 ng/mL–5 μg/mL of sea buckthorn seed oil on
the membrane conditions of control and UV irradiated keratinocytes and fibroblasts measured by LDH
test. Total doses of UV irradiation for each cell line were: 30 J/cm2 and 60 mJ/cm2 for keratinocytes,
and 20 J/cm2 and 200 mJ/cm2 for fibroblasts for UVA and UVB, respectively. Mean values ± SD of
five independent experiments are presented. x statistically significant differences vs. control group,
p < 0.05; y statistically significant differences between UVA/UVB and oil treated groups vs. oil treated
control group, p < 0.05; a statistically significant differences between UVA and oil treated group vs. UVA
treated group, p < 0.05; b statistically significant differences between UVB and oil treated group vs. UVB
treated group, p < 0.05.
On the other hand, sea buckthorn oil treatment on skin cells significantly increased the level of
all detected phospholipids as well as free fatty acids in both keratinocytes and fibroblasts (Table 4).
Moreover, sea buckthorn oil influenced the UV-decreased level of numerous fatty acids, which was
particularly evident in the case of keratinocytes and fibroblasts treated with oil following UVB radiation.
Additionally, sea buckthorn oil treatment effects on short fatty acids (16:0; 16:1) in UVA irradiated
cells was stronger in fibroblasts than in keratinocytes, while sea buckthorn oil treatment effect on the
level of longer fatty acids (20:4) was visible only in the case of keratinocytes (Table 3). The Figure S1
presents the correlation between the level of free fatty acids in sea buckthorn seeds oil and changes in
the level of free fatty acids in keratinocytes and fibroblasts.
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Table 4. The level of phospholipid and free fatty acids in keratinocytes and fibroblasts after exposure
to UVA (30 J/cm2 and 20 J/cm2) and UVB radiation (60 mJ/cm2 and 200 mJ/cm2, respectively) and
sea buckthorn seeds oil (500 ng/mL) treatment.
Keratinocytes Fibroblasts
Oil Control UVA UVB Control UVA UVB
Phospholipid fatty acids [ug/mg protein]
14:0
- 5.3 ± 0.3 4.5 ± 0.2 4.5 ± 0.2 1.4 ± 0.1 1.2 ± 0.1 1.2 ± 0.1
+ 12.4 ± 0.6 x 11.3 ± 0.6 xa 11.8 ± 0.6 xb 6.3 ± 0.1 x 2.5 ± 0.1 xya 5.1 ± 0.3 xyb
16:0
- 152 ± 7.3 129 ± 6.5 x 128 ± 6.4 x 80 ± 4 68 ± 3.4 68 ± 3.4
+ 662 ± 33.1 x 145 ± 7.3 y 260 ± 13.0 xyb 190 ± 9.5 x 90 ± 4.5 ya 122 ± 6.1 xyb
16:1
- 15.6 ± 0.8 13.2 ± 0.7 13.1 ± 0.7 13.6 ± 0.7 11.6 ± 0.6 11.5 ± 0.6
+ 29.9 ± 1.5 x 27.5 ± 1.4 xa 28.5 ± 1.4 xb 23.2 ± 1.2 x 17.7 ± 0.9 xya 15.9 ± 0.8 xyb
18:0
- 123 ± 6.2 104 ± 5.2 x 103 ± 5.2 x 69 ± 3.5 58 ± 2.9 x 58 ± 2.9 x
+ 412 ± 20.6 x 137 ± 6.9 xya 187 ± 9.4 xyb 126 ± 6.3 x 109 ± 5.5 xya 110 ± 5.5 xyb
18:1nc
- 199 ± 10.1 169 ± 8.5 x 168 ± 8.4 x 112 ± 5.6 95 ± 4.8 x 94 ± 4.7 x
+ 580 ± 29.1 x 129 ± 6.5 xya 386 ± 19.3 xyb 181 ± 9.1 x 167 ± 8.4 xa 114 ± 5.7 yb
18:1nt
- 47 ± 2.4 39 ± 2.1 x 39 ± 2.1 x 18 ± 0.9 16 ± 0.8 15 ± 0.8 x
+ 170 ± 18.5 x 48 ± 2.4 ya 139 ± 7.1 xyb 58 ± 2.9 x 22 ± 1.1 xya 36 ± 1.8 xyb
18:2
- 116.2 ± 5.8 98.8 ± 4.9 x 98.1 ± 4.9 x 45.4 ± 2.3 38.6 ± 1.9 x 38.3 ± 1.9 x
+ 162.7 ± 8.1 x 111.4 ± 5.6 ya 137.2 ± 6.9 xyb 69.8 ± 3.5 x 60.4 ± 3.0 xya 64.5 ± 3.2 xb
18:3n3
- 24.6 ± 1.2 20.9 ± 1.1 x 20.8 ± 1.1 x 6.2 ± 0.3 5.2 ± 0.3 5.5 ± 0.3
+ 29.5 ± 1.5 x 30.2 ± 1.5 xa 31.2 ± 1.6 xb 12.5 ± 0.6 x 7.8 ± 0.4 xya 8.5 ± 0.4 xyb
20:4
- 38.1 ± 1.9 32.4 ± 1.6 x 32.2 ± 1.6 x 35.6 ± 1.8 30.2 ± 1.5 30.1 ± 1.5
+ 197.4 ± 9.9 x 36.4 ± 1.8 ya 104.7 ± 5.2 xyb 81.7 ± 4.1 x 30.3 ± 1.5 y 57.5 ± 2.9 xyb
22:6
- 11.1 ± 0.6 9.4 ± 0.5 9.3 ± 0.5 8.2 ± 0.4 6.9 ± 0.3 6.9 ± 0.3
+ 30.1 ± 1.5 x 18.1 ± 0.9 xya 23.1 ± 1.2 xyb 41.6 ± 2.1 x 16.2 ± 0.8 xya 33.8 ± 1.7 xyb
Free fatty acids [μg/mg protein]
16:0
- 8.8 ± 0.4 7.5 ± 0.4 7.4 ± 0.4 2.9 ± 0.1 2.4 ± 0.1 2.4 ± 0.1
+ 26 ± 1.3 x 14.1 ± 0.7 xya 19.8 ± 1 xyb 9.8 ± 0.5 x 3.9 ± 0.2 xya 7 ± 0.4 xyb
16:1
- 1.7 ± 0.1 1.4 ± 0.1 1.4 ± 0.1 0.7 ± 0.1 0.6 ± 0.1 0.6 ± 0.1
+ 5.5 ± 0.3 x 1.2 ± 0.1 y 4.4 ± 0.2 xyb 2.1 ± 0.1 x 1.3 ± 0.1 xya 1.6 ± 0.1 xyb
18:0
- 7.6 ± 0.4 6.4 ± 0.3 6.4 ± 0.3 3.4 ± 0.2 2.9 ± 0.1 2.9 ± 0.3
+ 16.8 ± 0.8 x 8.8 ± 0.4 ya 8.2 ± 0.4 yb 8.8 ± 0.4 x 3.2 ± 0.2 y 5.5 ± 0.3 xyb
18:1nc
- 13.3 ± 0.7 11.3 ± 0.6 11.2 ± 0.6 3.8 ± 0.2 3.3 ± 0.2 3.5 ± 0.2
+ 54.3 ± 2.7 x 51.1 ± 2.6 xa 45.1 ± 2.3 xyb 6.8 ± 0.3 x 4.1 ± 0.2 ya 5.5 ± 0.3 xyb
18:1nt
- 6.1 ± 0.3 5.2 ± 0.3 5.1 ± 0.3 1.1 ± 0.1 0.9 ± 0.1 0.9 ± 0.1
+ 9.8 ± 0.5 x 8.5 ± 0.4 xya 8.3 ± 0.4 xyb 4.5 ± 0.2 x 1.5 ± 0.1 xya 4.1 ± 0.2 xb
18:2
- 11.7 ± 0.6 9.9 ± 0.5 9.8 ± 0.5 3.2 ± 0.2 2.7 ± 0.1 2.7 ± 0.1
+ 15.1 ± 0.8 x 10.5 ± 0.5 y 12.7 ± 0.6 xyb 5.4 ± 0.3 x 3.3 ± 0.2 ya 3.3 ± 0.2 y
20:4
- 2.2 ± 0.1 1.8 ± 0.1 1.8 ± 0.1 0.7 ± 0.1 0.6 ± 0.1 0.6 ± 0.1
+ 9 ± 0.5 x 5.4 ± 0.3 xya 5.6 ± 0.3 xyb 3.4 ± 0.2 x 0.6 ± 0.1 y 2.7 ± 0.1 xyb
22:6
- 0.9 ± 0.1 0.8 ± 0.1 0.8 ± 0.1 0.3 ± 0.1 0.3 ± 0.1 0.3 ± 0.1
+ 11.3 ± 0.6 x 11.4 ± 0.6 xa 4.8 ± 0.2 xyb 2.3 ± 0.1 x 2.2 ± 0.1 xa 2.2 ± 0.1 xb
Mean values ± SD of five independent experiments are presented. x statistically significant differences vs. control
group, p < 0.05; y statistically significant differences between UVA/UVB and oil treated groups vs. oil treated control
group, p < 0.05; a statistically significant differences between UVA and oil treated group vs. UVA treated group,
p < 0.05; b statistically significant differences between UVB and oil treated group vs. UVB treated group, p < 0.05.
Obtained results showed that sea buckthorn oil partially prevented UV-induced increase in
phospholipase A2 activity by 50% in the case of UV irradiated keratinocytes, and by about 15% in the
case of UV irradiated fibroblasts (Figure 4). As a result of UV-induced lipid oxidative metabolism a
strong increase in the level of lipid peroxidation products was observed. Sea buckthorn oil treatment
significantly prevented these changes in the case of 4-HNE levels, which was decreased by 15% in
oil treated keratinocytes, and 30% in oil treated fibroblasts. Also, the level of isoprostaglandin in
fibroblasts exposed to UV radiation was decreased by 25% following sea buckthorn oil treatment.
However, in the case of isoprostaglandin levels in keratinocytes sea buckthorn oil lead to increases by
approximately 20% under standard conditions and did not have a significant effect on irradiated cells
(Figure 4).
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Figure 4. The activity of phospholipase A2 and level of lipid peroxidation products (4-HNE and
8-Isoprostaglandin F2α) in keratinocytes and fibroblasts after exposure to UVA (30 J/cm2 and 20 J/cm2)
and UVB radiation (60 mJ/cm2 and 200 mJ/cm2, respectively) and sea buckthorn seeds oil (500 ng/mL)
treatment. Mean values ± SD of five independent experiments are presented. x statistically significant
differences vs. control group, p < 0.05; y statistically significant differences between UVA/UVB and oil
treated groups vs. oil treated control group, p < 0.05; a statistically significant differences between UVA
and oil treated group vs. UVA treated group, p < 0.05; b statistically significant differences between
UVB and oil treated group vs. UVB treated group, p < 0.05.
Sea buckthorn oil treatment on UV irradiated skin cells was found as a factor influencing the
endocannabinoid system. In both cell lines a significant increase in endocannabinoid levels were
observed, however, keratinocytes exhibited greater susceptibility to oil treatment (approximately 3-fold
and 7-fold increase in the case of AEA; and 2-fold and 3-fold increase in the case of 2-AG, compared
to UVA and UVB irradiated cells, respectively, were observed). Moreover, endocannabinoid receptor
expression was decreased by half in relation to UV irradiated keratinocytes. Parallel, in fibroblasts
sea buckthorn oil following UV irradiation caused increases in the endocannabinoid levels by
25–30% compared to UVA or UVB irradiated cells. Also, the expression of endocannabinoid receptor
CB1 was decreased by 25% compared to UVA or UVB irradiated cells. However, in the case of receptor
CB2, sea buckthorn oil treatment decreased its expression only in fibroblasts exposed to UVB radiation
(Figure 5).
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Figure 5. The level of endocannabinoids (AEA, 2-AG) and endocannabinoid receptors (CB1, CB2) in
keratinocytes and fibroblasts after exposure to UVA (30 J/cm2 and 20 J/cm2) and UVB radiation
(60 mJ/cm2 and 200 mJ/cm2, respectively) and sea buckthorn seeds oil (500 ng/mL) treatment.
Mean values ± SD of five independent experiments are presented. x statistically significant differences
vs. control group, p < 0.05; y statistically significant differences between UVA/UVB and oil treated
groups vs. oil treated control group, p < 0.05; a statistically significant differences between UVA and oil
treated group vs. UVA treated group, p < 0.05; b statistically significant differences between UVB and
oil treated group vs. UVB treated group, p < 0.05.
4. Discussion
Since the major components of the outer skin layer are lipids, it can be assumed that the use of lipid
derivatives will enhance skin conditions. Therefore, plant oils can be used as a source of compounds
that may protect skin cells due to their multidirectional activities, including anti-inflammatory,
antibacterial and antioxidants, as well as the source of fatty acids [43]. Sea buckthorn (Hippophae
rhamnoides) seed oil has been traditionally used for accelerating wound healing [44] as well as treating
skin diseases such as the first stage of atopic dermatitis [45], however it is not widely used in skin
protection [46].
4.1. Sea Buckthorn Seeds Oil Effect on Antioxidant System
Due to the high content of polyphenolic compounds and vitamins, the sea buckthorn extract has
been found as a antimicrobial factor, with strong antioxidant activity in in vitro examinations [47].
Moreover, it has been suggested that sea buckthorn seed oil may reduce ROS levels under oxidative
conditions by its ability to scavenge free radicals [48].
This study indicates the effectiveness of the antioxidant actions of sea buckthorn oil in relation to
the oxidative conditions found in skin cells exposed to UV radiation. However, in physiological
conditions it is not so unambiguous, because by increasing the activity of cytosolic enzymes
such as NADPH oxidase and xanthine oxidase this oil contributes to the intensification of ROS
generation. After UV radiation, sea buckthorn oil promotes reduction of the above enzyme activity and
consequently ROS generation in fibroblasts. This may be the result of a stronger fibroblast susceptibility
to external factors including oxidative factors such as UVA and UVB radiation and for antioxidative
factors in oils, which was also indicated for pomegranate seed oil [49]. It has been suggested that high
content of unsaturated acids in plant oils are substrates for cellular oxygenases which can be a source
of oxidation products in skin cells [50].
Independent of modifications of prooxidative conditions, sea buckthorn oil promotes increases in
antioxidant enzyme activity and non-enzymatic antioxidant levels in control cells as well as cells treated
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with UV irradiation. Results of this study partially confirm earlier observations that sea buckthorn oil
may lead to enhanced antioxidant abilities by promotion of glutathione accumulation in the whole
animal body in the case of rats treated with this oil [51]. It was also shown that supplementation of
rats with compounds of sea buckthorn extracts activate the enzymes superoxide dismutase, catalase,
glutathione peroxidase, glutathione reductase and glutathione S-transferase in animal blood [52].
However, in this study sea buckthorn oil shows the tendency to decrease fibroblast Cu, Zn-SOD
activity in control and UV-irradiated cells. This may be explained by the sea buckthorn oils ability
to capture electrons and extinguish the singlet oxygen or superoxide anion [53] that is the main
substrate of SOD in cell cytoplasm. Another important cellular redox regulator is the thioredoxin
system consisting of thioredoxin and thioredoxin reductase (TrxR) [54]. This expression is diminished
in skin cells after UV irradiation and enhanced after sea buckthorn oil treatment of keratinocytes and
fibroblasts. Previously it has been shown that this system plays a significant role in the pathogenesis of
a number of diseases, but it also participates in cellular protection against toxic compounds, which are
reduced by thioredoxin or inhibited by thioredoxin reductase [55,56]. It has been indicated that sea
buckthorn includes high levels of proteins containing thioredoxin domains and prevents the disulfide
bond formation in oxidizing environments and stabilizing the tertiary and quaternary structure
of proteins [57]. It has also been shown that Trx and TrxR synthesis is induced after exposure to
prooxidative factors [58], this explains the strong positive response of this system to UV irradiation,
particularly in fibroblasts. Therefore, enhanced effectiveness of this system after oil treatment may
explain reduction of oxidative stress in these cells.
Cellular antioxidant responses dependent on proteins is promoted by the transcription factor
Nrf2 which is responsible for cytoprotective gene transcription [59]. Under physiological conditions,
cytoplasmic Nrf2 is bound to Keap1 [60], but oxidative stress caused by UV radiation was found
to diminish Keap1 expression which prevents Nrf2–Keap1–Cul3 complex formation. Moreover, as
observed in this paper, high levels of ROS and electrophiles such as 4-HNE may lead to the oxidation of
Keap1 cysteine residues causing lack of binding and/or dissociation of Nrf2 from the complex resulting
in its translocation into the nucleus, which was reported earlier [61]. Nrf2 activation, demonstrated
also as its targeted genes-HO-1 expression, leads to cellular protection against pro-oxidative conditions.
Sea buckthorn oil treatment of UV irradiated skin cells acts in two ways—it supports the cellular
antioxidant capacity by the activation of Nrf2, and at the same time, affects the expression of proteins
strongly related with Nrf2 activation. The results showing enhanced phospho-Nrf2 translocation to
the nucleus despite of the increased Keap1 level in cytoplasm clearly suggest that sea buckthorn oil
disrupts the Nrf2–Keap1 complex formation. Moreover, sea buckthorn seed oil decreases UV-induced
levels of p21 and p62, reducing the possibility of these proteins to create adducts with Nrf2 or Keap1,
thus encouraging Nrf2 inhibition [59,62]. Keap1 might also create adducts with small antioxidant
molecules such as melatonin or GSH, what also prevents Nrf2-Keap1 binding, however, it does not
lead to Keap1 degradation [63,64]. Melatonin has been previously shown to be downregulated in
skin cells following UV radiation [65,66], while UV-induced decrease in GSH level, what is shown in
this study is significantly enhanced as a result of sea buckthorn oil treatment. These modifications
to the activators and inhibitors of the Nrf2 pathway are not able to cancel the protective effect of sea
buckthorn oil to counteract prooxidative conditions.
4.2. Sea Buckthorn Seeds Oil Effect on Lipid Metabolism
The effects of sea buckthorn seed oil on redox balance can directly protect the metabolism of
skin cells. Maintaining redox homeostasis is important for the physiological metabolism of lipids,
which is important for the proper functioning of cells. Phospholipid protection may be associated
with beneficial fatty acids present in sea buckthorn oil [67], which influences the skin cells fatty
acid profile. The strongest correlation between oil fatty acids and increase in the cells fatty acid
level is visible in the case of free fatty acids (FFA) regardless of whether that were control cells
or treated with UV radiation. This relationship between FFA composition of the applied oil and
151
Antioxidants 2018, 7, 110
cells might be associated with 24 h incubation with oil when cells were able only to take up and
assimilate FFA from fatty rich oil composition. Sea buckthorn oil is rich in palmitoleic acid (16:1),
which has been reported to play a role in many metabolic processes including intracellular lipid
mediated signal transduction [68,69], which includes lipid metabolism, and is also responsible for
maintaining the fluidity of biological membranes [70–72]. Palmitoleic acid levels are enhanced in the
phospholipid profile of keratinocytes and fibroblasts after sea buckthorn oil treatment, this also causes
the reduction of mRNA expression of proinflammatory genes, i.e., TNF-α [73], therefore this oil may
affect intracellular signaling based on PI3K/Akt kinase cascades, and have anti-inflammatory activity,
which was also confirmed by experiments on rats with diabetes [74]. Moreover, sea buckthorn oil
contains a large amount of linoleic and α-linolenic acids, which can enhance the level of phospholipid
α-linolenic acid in cells [75,76]. α-Linolenic acid contained in sea buckthorn oil has been found also as a
source of eicosanoid prostaglandin E1, a signal precursor that produces antibacterial and cytoprotective
extracellular fluids [77]. Shown in this study sea buckthorn oil added to skin cells enhances the level of
these acids in phospholipid and free PUFAs fractions. Skin cells phospholipid PUFAs fraction is also
enriched in γ-linolenic acid that is a precursor of anti-inflammatory eicosanoids, such as the 1-series
prostaglandins and 15-hydroxyeicosatrienoic acid (15-HETrE) [78].
It has been previously shown that UV radiation significantly disturbs the metabolism of skin
cell membrane phospholipids [6]. In this study, active compounds contained in sea buckthorn oil
enhances the cell’s antioxidant abilities and prevents lipid peroxidation [47] as well as enzymatic
phospholipid metabolism. Sea buckthorn oil enhances, both phospholipid and free PUFA levels in
keratinocytes and fibroblasts, as well as increases the ROS level favored by ROS-dependent lipid
peroxidation manifested as oxidative fragmentation with enhanced 4-HNE levels and as oxidative
cyclisation with enhanced 8-isoprostane levels. Independently of that, one of the main sources of
peroxidation products-arachidonic acid (AA) is most enhanced in PUFAs of both skin cell lines,
what indicates for huge tributary of this acid from used oil. As a result of AA peroxidation, increases
in the 4-HNE levels can directly act as a signaling molecule or through protein adduct formation
which significantly influences their structure and activity [79]. Phospholipid AA is also metabolized
by enzymes among which the most important are phospholipases including PLA2 [80]. It has been
previously shown that UV radiation significantly increases PLA2 activity [9,81], while PLA2 inhibition
improves skin conditions [82]. Sea buckthorn oil reveals similar as other plant oils PLA2 inhibition
properties, preventing UV-induced lipid metabolism [83]. Despite the observed decrease in PLA2
activity, the levels of endocannabinoids are increased after using sea buckthorn oil. It is believed that
anandamide is a partial or full agonist of the CB1 receptor, depending on tissue and conditions, and is
suggested to have low efficacy for CB2 receptors, whereas 2-AG is a full agonist of both CB1 and CB2
receptors [84]. However, an elevated level of endocannabinoids is accompanied by a down-regulation
of cannabinoid receptors. Such response may indicate that redox and inflammatory regulation is
independent from the cannabinoid receptors. Moreover, oil-induced changes in endocannabinoids
level may influence the skin neuroendocrine capabilities regulated by UV radiation [85], what leads to
disorders in steroid hormones, neuropeptides, and neurotransmitters biosynthesis [86]. Regardless of
the above, it has been shown that a high level of AA delivered to skin cells from sea buckthorn oil may
result in increased generation of the 4-series leukotrienes, which have a strong pro-inflammatory and
hyperproliferative effect [87].
Endocannabinoid levels are enhanced by treating skin cells with sea buckthorn oil, which are
agonists of peroxisome proliferator-activated receptors (PPAR). It is known that PPARs are activated
by fatty acids and their derivatives, including lipid peroxidation products like 4-HNE, which act
as PPAR-α agonists [88,89]. PPARs act as modulators of cellular processes including lipid
metabolism, and thus create a lipid signaling network between the cell surface and the nucleus [89].
Enhanced expression of fibroblast PPARs indicates that sea buckthorn seed oil has anti-inflammatory
activity. PPAR-α controls the expression of proteins that participate in inflammatory response [89],
therefore enhanced activation of PPAR-α observed in fibroblasts indicates preventing NF-κB-dependent
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inflammation [90]. It has also been shown that anandamide as a ligand of PPAR-α can participate
in its anti-inflammatory effect through impaired production of TNF-α [91]. Similarly, enhanced
expression of PPAR-γ decreases the expression of TNF-α [92]. Moreover, sea buckthorn ethanolic
extract has been beneficial in reducing fat pad mass and preventing weight gain in mice. The extract
was effective in producing hypoglycemic effects in animals through up-regulating PPAR-γ and PPAR-α
gene expression [92].
5. Conclusions
In summary, sea buckthorn oil significantly stimulates the antioxidant system in keratinocytes
and fibroblasts. Therefore, sea-buckthorn seed oil prevents UV-induced impair in redox systems as
well as lipid metabolism disorders in skin fibroblasts and keratinocytes, which makes it a promising
natural substance in skin photo-protection. However, the influence of UV radiation on the stability
and durability of oil components, their interactions and impact on the metabolism of skin cells has not
been studied, therefore it is believed that current studies do not allow recommending the use of sea
buckthorn seed oil in direct exposure to UV radiation.
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Abstract: Oxidative stress has been implicated in pathophysiology of different human stress- and
age-associated disorders, including osteoporosis for which antioxidants could be considered as
therapeutic remedies as was suggested recently. The 1,4-dihydropyridine (DHP) derivatives are
known for their pleiotropic activity, with some also acting as antioxidants. To find compounds with
potential antioxidative activity, a group of 27 structurally diverse DHPs, as well as one pyridine
compound, were studied. A group of 11 DHPs with 10-fold higher antioxidative potential than of uric
acid, were further tested in cell model of human osteoblast-like cells. Short-term combined effects of
DHPs and 50 μM H2O2 (1-h each), revealed better antioxidative potential of DHPs if administered
before a stressor. Indirect 24-h effect of DHPs was evaluated in cells further exposed to mild oxidative
stress conditions induced either by H2O2 or tert-butyl hydroperoxide (both 50 μM). Cell growth
(viability and proliferation), generation of ROS and intracellular glutathione concentration were
evaluated. The promotion of cell growth was highly dependent on the concentrations of DHPs used,
type of stressor applied and treatment set-up. Thiocarbatone III-1, E2-134-1 III-4, Carbatone II-1,
AV-153 IV-1, and Diethone I could be considered as therapeutic agents for osteoporosis although
further research is needed to elucidate their bioactivity mechanisms, in particular in respect to
signaling pathways involving 4-hydroxynoneal and related second messengers of free radicals.
Keywords: 1,4-dihydropyridine(s) (DHPs); oxidative stress; reactive oxygen species (ROS);
antioxidant (AO); antioxidative activity (AOA); glutathione; cell viability and proliferation;
4-hydroxynonenal (4-HNE)
1. Introduction
Oxidative stress, defined as an imbalance between pro-oxidants and antioxidants in the favor
of the former [1], has been implicated in the pathogenesis of numerous stress- and age-associated
diseases, whether as a cause or as a consequence of respective illness progression [2]. The consensus
among researchers in this field highlights the need of its better understanding as well as balancing
oxidative homeostasis to the levels that promote health [3]. Indeed, antioxidants per se or drugs
with antioxidative properties are important for reducing the detrimental levels of reactive oxygen
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species (ROS). Yet, the importance of ROS-related redox signaling in normal cellular maintenance
should not be neglected, nor the fact that antioxidative and/or pro-oxidative activity are in the
background of (un)desirable activities of many drugs and physiologically active compounds [3–5].
Thus, studies revealing bioactivities of natural antioxidants are complemented by scientific efforts
aiming to synthetize new bioactive substances with antioxidant features that could help maintaining
oxidative homeostasis of the living cells.
1,4-Dihydropyridine derivatives (DHPs) are a group of pleiotropic physiologically active
compounds (reviewed in Swarnalatha et al. [6] and Velena et al. [7]), among which many 4-nitrophenyl-
and differently substituted DHPs are known as effective antihypertensive agents. While condensed
DHPs were suggested as agents that affect stem cell differentiation [8], several DHPs exert anti- or
pro-oxidant effects in various systems both in vitro as well as in vivo [7,9].
Our present article extends the knowledge about antioxidative and potentially pro-oxidative
activities of the well-known, water-insoluble antioxidant Diethone I (also known as Dietone, Diludine,
Hantzsch ester, HEH) [7], in comparison to the water-soluble antimutagenic [10] and antimetastatic [11]
compound Carbatone (disodium-2,6-dimethyl-1,4-dihydropyridine-3,5-bis(carbonyloxyacetate)) II-1,
which prevents DNA lesions [12–15]. Moreover, comparison was done also with their analogues and
with novel DHPs (see Table 1, compounds mentioned as MM) and their derivatives.
Therefore, a set of 27 structurally diverse (of monocyclic as well as of condensed ring structures,
having symmetric as well as asymmetric alkyl-, alkoxyalkyl-, aryl-, aralkyl- or heteryl- substituents on
positions 2, 3, 4, 5 and 6) synthetic 1,4-dihydropyridine compounds (as well as for comparison one
pyridine type compound, an analogue (oxidized form) of diamide analogue J-12-25 V) (see Table 1
below) of which 14 are water soluble DHP compounds (including antimutagenic, DNA protecting,
antimetastatic, antiischaemic) and 14 are water-insoluble (more lipid soluble): 13 DHP compounds
(including antioxidant and radioprotector Hantzsch ester Diethone (Dietone) I) and one pyridine
analogue were studied.
While possibly beneficial effects of antioxidants are mostly considered for patients suffering
from malignant, cardiovascular, neurodegenerative and inflammatory diseases, osteoporosis is
an age-related disease characterized by bone loss due to the impaired bone formation and increased
bone resorption, which is less often considered as an oxidative stress-associated disease. However,
requests for treatment strategies of this chronic disease that would promote bone formation [16] also
point to oxidative stress as an important factor in pathogenesis of osteoporosis [17,18], consequently
highlighting antioxidants as important factors for prevention and treatment of osteoporosis [17,19].
Therefore, in our study, we used human osteoblast-like cells (HOS cell line) which are well known
as a model of human osteoblasts [20–22] aiming to reveal DHPs that can act as antioxidant(s) in cell-free
systems (Total antioxidative capacity (TAC) and Total oxidative capacity (TOC) assays, respectively)
but could also affect viability and growth of HOS cells under mild oxidative stress induced by two
different stressors (hydrogen peroxide and tert-butyl hydroperoxide).
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Table 1. Chemical structures and solubility of 27 1,4-dihydropyridine derivatives and one pyridine
analogue investigated in this study.
Compounds Trivial Name R3 R4 R5 Solubility Reference
I Diethone Ethanol with10% DMSO [23]
II-1 Carbatone ONa H OCH2COONa Water [24]
II-2 J-9-133-2 ONa H OCH3 Water [25]
II-3 J-9-46 OCH2CH3 H OCH2CH3 Ethanol [25]
II-4 Metcarbatone ONa CH3 OCH2COONa Water [26]
II-5 Etcarbatone ONa CH2CH3 OCH2COONa Water [26]
II-6
J-9-117
(Styrylcarbatone) ONa CH=CHPh OCH2COONa Water *MM
III-1 Thiocarbatone ONa H SCH2COONa Water MM
III-2 TK-2 OCH3 H SCH2COOCH3
Ethanol with
10% DMSO MM
III-3 E-170-4 (TK-1) OCH2CH3 H SCH2COOCH2CH3
Ethanol with
10% DMSO MM
III-4 E2-134-1 ONa H OCH2CH3 Water MM
III-5 E2-135 OCH2CH3 H OCH2CH3 Ethanol MM
III-6 E2-136-2 ONa H OCH2COONa Water MM
III-7 E2-131 ONa CH2CH3 OCH2CH3 Water MM
III-8 E2-130-3 OCH2CH3 CH2CH3 OCH2CH3 Ethanol MM
III-9 E2-120 (ETK-2) OCH3 CH2CH3 SCH2COOCH3 Ethanol MM
III-10 E2-113 (ETK-1) OCH2CH3 CH2CH3 SCH2COOCH2CH3 Ethanol MM
III-11 E-163-1 ONa 3-Py OCH2CH3 Water MM
III-12 E-163-K OCH2CH3 3-Py OCH2CH3 Ethanol MM
IV-1 AV-153 OCH2CH3 ONa OCH2CH3 Water [27]
IV-2 EE-126 OCH3 ONa OCH3 Water MM
IV-3 E3-46 OCH2CH3 OH OCH2COOCH2CH3 Ethanol MM
IV-4 V-6-55-1 OCH2COOCH2CH3 OH OCH2COOCH2CH3 Ethanol MM
IV-5 AV-154-Na CH3 ONa CH3 Water [27]
IV-6 J-11-61B CH3 OH OCH2CH3 Ethanol MM
IV-7 J-11-71-2 OCH2CH3 OH Ethanol MM
IV-8 Glutapyrone OCH2CH3
NHCH(CH2)2COONa
|COONa OCH2CH3 Water [28]
V J-12-25 Ethanol MM
*MM—see in Materials and Methods. DMSO (Dimethyl sulfoxide).
2. Materials and Methods
2.1. Compounds
The studied 27 DHP compounds belong to several (five, I–V, see Table 1) relative types. All tested
DHPs were synthesized at the Latvian Institute of Organic Synthesis [24–30]. Already described
compounds are referenced in Table 1; new compounds have been synthesized by making use of
methods indicated below for each type and indexed as MM (*MM) in Table 1.
Dietone I is the basic most studied compound, all studied types are its derivatives. It could
be used as standard. It has been elaborated and developed, used as radioprotector, antioxidant
to preserve carotene, vitamins A and E, growth stimulant. Dietone I was synthesized according
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to modified Hantzsch syntesis: heterocyclization of acetoacetic ester and urotropine [23]. Type II
compounds (II-1–II-6) or Carbatone II-1 and its derivatives were prepared by making use of 1 or 2
equivalents of ethoxycarbonylmethyl ester of acetoacetic acid instead of or as addition to acetoacetic
ester. For synthesis of soluble in water salts mild hydrolysis of distant ester group was performed.
Compounds (II-1–II-6) were obtained according to procedure described in patents [24–26]. Type III
compounds (III-1–III-12) or Thiocarbatone III-1 and its derivatives were prepared by making use of
one or two equivalents of ethoxycarbonylmethyl ester of acetothioacetic acid instead of or as addition
to acetoacetic ester. Again, for synthesis of soluble in water salts mild hydrolysis of distant ester group
was performed. Compounds (III-1–III-12) were obtained following the reported method [26].
Type IV compounds (derivatives of 1,4-dihydroisonicotinic acid IV-1–IV-8) were synthesized by
making use of glyoxylic acid or its ester as aldehyde part, ethyl or methyl ester of acetoacetic acid
(and/or additionally ethoxycarbonylmethyl ester of acetylacetic acid) and ammonia. AV-153 (IV-1)
can be as intermediate for synthesis of Glutapyrone (IV-8) [28]. Compounds (MM, IV-1–IV-6) were
obtained according to procedure described in [27]. Pyridine derivative J-12-25 (V) was obtained via
oxidation of related DHP with sodium nitrite in acetic acid.
Major features of the substances tested are presented in Table 1.
Fresh stock solutions of DHPs were prepared in adequate solvent (listed in Table 1) in
a concentration of 10 mg/mL prior to each experiment.
2.2. Total Antioxidative Capacity (TAC) Assay
The total antioxidative capacity assay relying on the ability of tested compounds to scavenge
hydrogen peroxide, thus, competing with peroxidase and preventing oxidation of a chromogenic
substrate tetramethylbenzidine (TMB), was performed as previously described [31], with a slight
modification as described. The scavenging ability of DHP compounds was compared to ranging
concentration of uric acid serving as standard antioxidant. Briefly, 25 μL of a standard (uric acid serial
dilutions from 0–12 mM) or a sample (27 DHPs, as well one pyridine type compound) each 10 mg/mL)
were pipetted into each well of the 96-well microplate and mixed with 100 μL Reagent A (0.1 M citric
buffer containing 0.03% (v/v) hydrogen-peroxide). The first absorbance was measured at 450 nm
(Multiscan Ex, Thermo Electron Corporation, Shanghai, China) followed by the addition of 50 μL
Reagent B containing 1.25 mU horse radish peroxidase (HRP; Sigma Aldrich, St. Louis, MO, USA) and
0.416 mM TMB (Sigma Aldrich, St. Louis, MO, USA) in citric buffer. After 15-min incubation time,
reaction was stopped with 2 M H2SO4 and the second absorbance was measured at 450 nm (Multiscan
Ex, Thermo Electron Corporation, Shanghai, China). The difference between the second and the first
absorbance values of the tested compounds was interpolated from the uric acid standard curve and
results are presented as mM Uric acid equivalent.
2.3. Total Oxidative Capacity (TOC) Assay
A total oxidative capacity assay was performed as previously described [32]. The assay determines
peroxides present in the sample by their reaction with peroxidase followed by a color reaction with
chromogenic substrate TMB. Quantification is achieved by serial dilutions of a standard hydrogen
peroxide solution. Briefly, 10 μL of a standard (hydrogen peroxide serial dilutions from 0–0.9791 mM)
or a sample (27 DHPs, as well one pyridine type compound) was pipetted into each well of the
96-well microplate, mixed with 200 μL of reaction mixture (25 mU HRP, TMB, and substrate buffer
in a proportion of 1:10:100 (v:v:v)) and initial absorbance at 450 nm was measured (Multiscan Ex,
Thermo Electron Corporation, Shanghai, China). Plate was further incubated for 20 min and the
second absorbance at 450 nm was measured after stopping the reaction with 2 M H2SO4. The results
are expressed as μM H2O2 hydrogen peroxide equivalent.
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2.4. Cell Culture and Treatments
The human osteosarcoma cell line HOS (ATCC® CRL-1543™), purchased from the American Type
Culture Collection (ATCC, LGC Standards GmbH, Wesel, Germany) was used as an osteoblast model
to test possible the in vitro effects of selected compounds. The cells were cultivated in T75 cell culture
flasks (TPP, Trasadingen, Switzerland) in Dulbecco’s Modified Eagle’s Medium (DMEM) with 10%
(v/v) fetal calf serum (FCS) at 37 ◦C in humidified atmosphere with 5% CO2. Prior to experiments, cells
were harvested with 0.25% (w/v) Trypsin-0.53 mM EDTA (Ethylenediaminetetraacetic acid) solution
and counted with Trypan Blue Exclusion Assay in Bürker-Türk hemocytometer (Brand, Wertheim,
Germany). Thus prepared cells were seeded at a density of 2 × 104 cells/well into 96-microwell plates
(TPP, Trasadingen, Switzerland) and left for 24 h to attach. Afterwards, we evaluated the potential
of selected compounds to influence intracellular ROS production upon administration of hydrogen
peroxide. Cell cultures were either first exposed to 50 μM hydrogen peroxide for one hour before
addition of selected compounds (100 or 1000 μM) or vice versa. The immediate effect on cellular
viability was also evaluated in case of cells that were first exposed to selected compounds for one hour,
followed by one-hour incubation with hydrogen peroxide, aiming to test possible beneficial effects of
the tested substances that might prevent the onset of the cellular oxidative stress.
The second series of experiments were conducted with prolonged (24-h) exposure of cells to
selected compounds before one-hour exposure to hydrogen-peroxide. The experiments are explained
in more details in the following subsections.
2.5. Cellular Viability (Tetrazolium Reduction Assay)
Viability (metabolic activity) of the cultured HOS cells was evaluated with the EZ4U assay
(Biomedica, Wien, Austria) according to manufacturer’s instructions. The assay principle is based on
reduction of tetrazolium salts to colored formazan derivatives by living cells, the intensity of which is
measured spectrophotometrically as proportional to the number of viable cells in the culture sample.
Cells seeded at a density of 2 × 104 cells/well in 96-microwell plates (TPP, Trasadingen,
Switzerland) were left to attach for 24 h prior to treatments. For the short-term treatment, cells
were first treated with selected compounds (100 μM and 1000 μM concentration; except for Diethone I
for which only 100 μM concentration was used because it precipitates at 1000 μM) for 1 h, after which
hydrogen peroxide was added for an additional hour. In case of experiments with longer exposure
to selected compounds, HOS cells were treated with different concentrations of selected compounds
(ranging from 10 μM to 1000 μM, depending on the compound used) and left for additional 24 h,
followed by the change of cell culture medium. Cellular viability was determined for cell culture either
treated just by selected compounds or for those additionally treated with 50 μM hydrogen peroxide
or with 50 μM tert-butyl hydroperoxide (tBHP; Sigma Aldrich, St. Louis, MO, USA) for one-hour,
respectively. Afterwards, the medium was replaced with 200 μL Hanks’ solution (pH 7.4) and 20 μL of
dye solution was added to each well followed by two-hour incubation at 37 ◦C. The absorbance was
measured at 450 nm with a reference wavelength of 620 nm using a microplate reader (Multiscan Ex,
Thermo Electron Corporation, Shanghai, China). Thus obtained results were expressed as percentage
of non-treated control.
2.6. Cell Proliferation (BrdU Assay)
Cell proliferation was determined in the experiments where cells were exposed to selected DHP
compounds for 24-h used alone or in combination with 50 μM hydrogen peroxide or tBHP, as described
in the previous section. The 5-bromo-2′-deoxyuridine (BrdU) colorimetric assay (Roche Applied
Science, Mannheim, Germany) was used, according to the manufacturer’s instruction. The assay
relies on the ability of the BrdU to incorporate into cellular DNA during proliferation which is further
detected by an anti-BrdU antibody. Briefly, after specified time points of treatments (24-h treatment with
the compound alone or followed by 1-h treatment with hydrogen peroxide and tBHP), the BrdU was
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added to each well and left for two-hours at 37 ◦C. The culture medium was removed and the cells were
washed twice with Hanks’ solution before fixation with FixDenat solution for 30 min. Subsequently,
the anti-BrdU-peroxidase (1:100) was added to each well and incubated at room temperature for 90 min.
After removing the unbound antibody conjugate, 100 μL of the substrate solution was added and
allowed to stand for 15 min. The reaction was quenched by adding 25 μL of a 1 M H2SO4 solution.
The absorbance was measured at 450 nm with a reference wavelength of 620 nm using a microplate
reader (Multiscan Ex, Thermo Electron Corporation, Shanghai, China).The results are presented as
percentage of non-treated control.
2.7. Measurement of intracellular ROS production
The ROS measurement is based on the intracellular oxidation of 2′,7′-dichlorodihydrofluorescein
diacetate (DCFH-DA; Sigma-Aldrich, St. Louis, MO, USA) to a fluorescent 2′,7′-dichlorofluorescein
(DCF) that can be measured. Intracellular ROS levels were measured upon short-term (1-h) treatment
and after 24-h treatment with selected DHPs, described hereafter. For all experiments, HOS cells were
seeded at the density of 2 × 104 cells/well into white 96-microwell plates (Thermo Fisher Scientific,
Nunc A/S, Roskilde, Denmark) and left for 24 h to attach.
In the short-term treatment, time-dependent ROS production was measured in cells treated
at specific time points as follows: (a) hydrogen peroxide 1-h + DHPs, or (b) DHPs 1-h + hydrogen
peroxide. Cells were first incubated with 10 μM DCFH-DA at 37 ◦C for 30 min, followed by fresh media
exchange and a zero-point ROS measurement with a Cary Eclipse Fluorescence Spectrophotometer
(Varian Australia Pty Ltd, Mulgrave, Victoria, Australia) with excitation at 500 nm and emission
detection at 530 nm. Treatments were carried out with 1000 μM concentration of DHPs (exception
Diethone I used as 100 μM because it precipitates at 1000 μM) and 50 μM hydrogen peroxide without
the medium change. Further fluorescence measurements were done: immediately after addition of the
first treatment (5-min point), 30- and 60-min points, immediately after addition of the second treatment
(65-min point) and up to four hours afterwards (90-, 120-, 180-, and 240-min points). The results are
expressed as relative fluorescence units (RFU) measured at specified time points.
Intracellular ROS production was also evaluated upon 24-h treatment with selected DHPs.
Following 24-h treatment, media was replaced with the Hanks’ solution containing 10 μM DCFH-DA
and cells were further incubated for 30 min on 37 ◦C. Next, the medium was replaced with the fresh
one and fluorescence was measured prior to the addition of 50 μM tBHP (zero-point) and after 1-h.
Measurements were carried with a Cary Eclipse Fluorescence Spectrophotometer (Varian Australia
Pty Ltd, Mulgrave, Victoria, Australia) as previously stated. Cells were further trypsinized with
0.25% (w/v) Trypsin-0.53 mM EDTA solution and counted with Trypan Blue Exclusion Assay in
a Bürker–Türk hemocytometer (Brand, Wertheim, Germany). The results are expressed in arbitrary
units which are a ratio of the difference in fluorescence (1-h point–zero-point) and cell number.
2.8. Determination of Glutathione (GSH) Levels
Cells were first trypsinized (0.25% (w/v) Trypsin-0.53 mM EDTA solution), washed twice with
phosphate-buffer saline (PBS) and stored as dry pellets at −80 ◦C until analysis. Cell lysates were
obtained by addition of 100 μL PBS and repeated thaw-freeze cycles, followed by centrifugation at
16,000× g/15 min. and collection of a supernatant containing proteins. Protein concentration in each
sample was determined according to Bradford method [33], using bovine serum albumin as a standard.
The total intracellular GSH content (oxidized and reduced) was measured as previously
described [34]. Briefly, 150 μL of each sample, containing 0.03 mg/mL of protein, or standard,
reduced glutathione in serial dilutions (0–20 mg/mL) was pipetted into each well of 96-microwell
plate. Reaction was started by addition of freshly prepared reaction mixture: 1.8 mM
5,5-dithio-bis-2-nitrobenzoic acid, 0.4 U GSH reductase, and 0.6 mM NADPH in phosphate buffer
(100 mM NaH2PO4, 5 mM EDTA pH 7.4). The formation of 2-nitro-5-thiobenzoic acid was monitored
spectrophotometrically in a plate reader at 405 nm (Multiscan Ex, Thermo Electron Corporation,
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Shanghai, China). Total GSH concentration in cell lysates was calculated from the standard curve by
linear regression and expressed as μM of total GSH.
2.9. Statistical Analysis
Cell-free colorimetric assays (TAC and TOC) were conducted in duplicates while cell-based
methods (EZ4U assay, BrdU assay, ROS and GSH measurements) were carried out in at least triplicates.
The respective numbers of biological replicates (n) is given in each figure legend. Data are expressed
as mean values with standard deviations. Results were analyzed with Student’s t-test and values of
p < 0.05 were considered as statistically significant.
3. Results
3.1. Total Antioxidative Capacity
The results of the total antioxidative capacity assay for tested DHPs are listed in Table 2.
In comparison to uric acid, used as a standard, the following compounds (at 1 mM concentration) were
more effective: Diethone I, J-9-133-2 II-2, AV-153 IV-1, AV-154-Na IV-5, J-11-71-2 IV-7, Carbatone II-1,
Thiocarbatone III-1, E-2-134-1 III-4, E-2-136-2 III-6, V-6-55-1 IV-4, and E-3-46 IV-3 (about 10-fold or
more); J-11-61B IV-6 (8-fold); J-9-46 II-3 and E-2-135 III-5 (2-fold). J-9-117 II-6 and E2-130-3 III-8 were
as effective as uric acid while other tested compounds did not have pronounced antioxidative potential.
Accordingly, the DHPs with pronounced antioxidative capacities were selected for the treatment of
human osteoblast-like cells (HOS).
Table 2. Total antioxidant capacity of selected compounds expressed as equivalent to mM uric acid.
Compounds Trivial Name
Concentrations Tested
10 μM 100 μM 1000 μM
Equivalent to mM Uric Acid
I Diethone 1.463 ± 1.016 1.465 ± 0.085 >10
II-1 Carbatone 0.438 ± 0.177 1.534 ± 0.064 9.692 ± 0.036
II-2 J-9-133-2 0.585 ± 0.074 3.756 ± 0.312 >10
II-3 J-9-46 0 0.148 ± 0.088 2.284 ± 0.504
II-4 Metcarbatone 0 0.526 ± 0.033 0.852 ± 0.013
II-5 Etcarbatone 0.027 ± 0.038 0.057 ± 0.019 0.206 ± 0.085
II-6
J-9-117
(Styrylcarbatone) 0.680 ± 0.051 0.421 ± 0.596 1.073 ± 0.04
III-1 Thiocarbatone 1.279 ± 0.046 2.735 ± 0.363 >10
III-2 TK-2 0 0 0
III-3 E-170-4 (TK-1) 0 0 0
III-4 E2-134-1 0.770 ± 0.075 0.541 ± 0.304 >10
III-5 E2-135 0.027 ± 0.302 0.564 ± 0.422 1.968 ± 0.294
III-6 E2-136-2 0.498 ± 0.115 1.082 ± 0.175 >10
III-7 E2-131 0.778 ± 0.085 0 0
III-8 E2-130-3 0.355 ± 0.234 0.285 ± 0.398 0.980 ± 0.129
III-9 E2-120 (ETK-2) 0 0.042 ± 0.007 0
III-10 E2-113 (ETK-1) 0.032 ± 0.195 0.077 ± 0.219 0
III-11 E-163-1 0 0 0
III-12 E-163-K 0 0 0
IV-1 AV-153 0.153 ± 0.216 2.005 ± 0.053 9.828 ± 0.081
IV-2 EE-126 0.856 ± 0.614 0.304 ± 0.078 0.292 ± 0.083
IV-3 E3-46 0.075 ± 0.163 1.542 ± 0.120 >10
IV-4 V-6-55-1 0.636 ± 0.220 4.013 ± 0.228 >10
IV-5 AV-154-Na 0.481 ± 0.028 2.774 ± 0.199 >10
IV-6 J-11-61B 0 0.948 ± 0.056 8.222 ± 0
IV-7 J-11-71-2 0 3.160 ± 0.094 >10
IV-8 Glutapyrone 0.190 ± 0.015 0.127 ± 0.096 0
V J-12-25 0.016 ± 0.193 0.050 ± 0.040 0.012 ± 0.044
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3.2. Total Oxidative Capacity
The results of the total oxidative capacity assay are listed in Table 3. Oxidative potential of the
majority of the tested DHPs was either absent or, if present, not proportional to the concentration used.
AV-153 IV-1, Carbatone II-1 and E-170-4 III-3 (TK1 III-3) were the only compounds showing oxidative
potential somewhat proportional to the concentration used. While pro-oxidative activity of E-170-4
III-3 (TK-1 III-3) was very low, but proportional to the concentration range, mild oxidative potential
of lower concentrations (10 μM and 100 μM) and negligible of the highest (1000 μM) was observed
for AV-153 IV-1 and Carbatone II-1. Still, it was about 2-fold (AV-153 IV-1) and 5-fold (Carbatone II-1)
lower than of hydrogen peroxide.
Table 3. The oxidative capacity of selected compounds expressed as equivalent to μM H2O2.
Compounds Trivial Name
Concentrations Tested
10 μM 100 μM 1000 μM
Equivalent to μM H2O2
I Diethone 1.346 ± 1.904 0 0
II-1 Carbatone 2.692 ± 0.000 18.846 ± 1.088 1.538 ± 0.544
II-2 J-9-133-2 0.250 ± 0.374 0 0
II-3 J-9-46 0 0 0
II-4 Metcarbatone 0 0 0
II-5 Etcarbatone 0 0 0
II-6
J-9-117
(Styrylcarbatone) 0.577 ± 0.816 0 0.192 ± 0.272
III-1 Thiocarbatone 0 0 0
III-2 TK-2 0 0 7.558 ± 1.791
III-3 E-170-4 (TK-1) 0 3.375±1.768 38.529 ± 1.663
III-4 E2-134-1 0 0 0
III-5 E2-135 0 0 0
III-6 E2-136-2 0 0 0
III-7 E2-131 0 5.411 ± 1.663 6.588 ± 3.328
III-8 E2-130-3 0 0 0
III-9 E2-120 (ETK-2) 0 0 13.235 ± 5.407
III-10 E2-113 (ETK-1) 0 0 0.147±0.208
III-11 E-163-1 0 4.5 ± 1.179 13.059 ± 1.664
III-12 E-163-K 0 0 0
IV-1 AV-153 6.923 ± 0.544 41.154 ± 1.088 5.00 ± 4.351
IV-2 EE-126 3.625 ± 0.884 3.938 ± 0.442 3.938 ± 0.442
IV-3 E3-46 0 7.243 ± 0.114 0
IV-4 V-6-55-1 0.481 ± 0.680 0 0
IV-5 AV-154-Na 3.938 ± 0.442 3.625 ± 0.884 0
IV-6 J-11-61B 0 0 0
IV-7 J-11-71-2 0.938 ± 0.000 1.875 ± 0.000 0
IV-8 Glutapyrone 0 0 0
V J-12-25 0 0 0
3.3. Short-Term (1-h) Treatment of HOS Cells with DHPs and Hydrogen Peroxide
3.3.1. Measurement of Intracellular ROS Production
The ability of the tested DHPs to scavenge hydrogen peroxide revealed better reduction of
intracellular ROS levels if DHPs were applied before the addition of the stressor. Such antioxidative
effects were especially pronounced for water-soluble DHPs and Diethone I, observed as reduction of
ROS levels almost to level of non-stressed control (Figure 1A,B). The E3-46 IV-3 was not so effective,
its effects were pronounced after 120 min and were not reaching the effects of the other effective DHPs
(Figure 1B). On the other hand, if the cells were first exposed to hydrogen peroxide for one hour,
the scavenging ability of the majority of tested DHPs was not so pronounced for, still being present
(Figure 1C,D). In this type of treatment, E3-46 IV-3 was the only compound unable to reduce but even
increased ROS levels during 4-h measurement (Figure 1D). In both types of treatments, intracellular
ROS levels of control cells (without stressor) remained low during the course of 4-h measurement.
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Taken together results of both treatments (DHPs before or after stressor) revealed better
antioxidative potential of the tested DHPs given before stressor, i.e., when cells were not already
damaged by hydrogen peroxide. Moreover, ROS reduction indicated direct scavenging of hydrogen
peroxide by the tested DHPs along with possible induction of the cellular protective mechanisms
(endogenous antioxidants).
Figure 1. Intracellular ROS of HOS cells exposed to DHPs and H2O2.Cells were treated with DHPs
and hydrogen peroxide, without the exchange of culture medium, as follows: (A,B) 1-h DHPs +
hydrogen peroxide, or (C,D) 1-h hydrogen peroxide + DHPs. The fluorescence reflecting intracellular
ROS levels was measured at different time points (0—no treatment, 5—immediately after the first
treatment, 30, 60, 65—immediately after the second treatment, 90, 120, 180, 240 min). Results of DHPs
(A,C—water-soluble; B,D—soluble in organic solvents) are presented as mean of relative fluorescence
units (RFU) ± standard deviation (n = 2). Controls: ctrl (untreated cells), ctrl H2O2 (cells treated with
hydrogen peroxide) and solvent-controls (vehicle Diethone I and vehicle E3-46 IV-3).
3.3.2. Cellular Viability
The effects of selected DHPs on cellular viability (Figure 2) were analyzed for cells treated
with DHPs alone (non-stress condition) or in combination with 50 μM hydrogen peroxide
(IC30—corresponding to induction of mild oxidative stress). The E-2-134-1 III-4 (1000 μM) significantly
increased cellular viability both in case of non-stress and in mild-stress culturing conditions (p < 0.05
and p < 0.005, respectively) while for AV-153 IV-1 (1000 μM) and Thiocarbatone III-1 (1000 μM) cellular
viability was significantly increased only under mild-stress conditions (p < 0.005 and p < 0.0005,
respectively). Interestingly decreased cellular viability (metabolism) was observed by EZ4U assay
for Carbatone II-1 and J-9-133-2 II-2, which were previously (Figure 1) found to reduce ROS levels,
even below non-treated control levels.
167
Antioxidants 2018, 7, 123
Therefore, evaluation of ROS production and cellular viability for short-term treatments
have accentuated Thiocarbatone III-1, AV-153 IV-1 and in particular E-2-134-1 III-4 (at 1000 μM
concentration) as likely the most potent and bioactive DHP antioxidants in the tested group due to
their beneficial growth promoting and ROS scavenging effects under mild oxidative stress conditions.
Figure 2. Cellular viability measured by EZ4U assay upon 1 h treatment with DHPs and H2O2. HOS
cells were first treated with DHPs (100 μM and 1000 μM) for one-hour, followed by one-hour treatment
with 50 μM hydrogen peroxide or with plain medium. Values are given as mean ± standard deviation;
n = 3. Statistically significant differences to their respective controls are shown as follows: * p < 0.05;
+ p < 0.005; # p < 0.0005.
3.4. The Effects of 24-h Pre-Treatment of Cells with DHPs before Exposure to Hydrogen Peroxide or
Tert-Butyl Hydroperoxide
3.4.1. Hydrogen Peroxide as a Stressor
The possible growth-promoting potential of DHPs was further evaluated in non-stress (without
addition of stressor) as well as in mild oxidative stress conditions (addition of H2O2 as stressor).
Stimulatory effects of 1000 μM AV-153 IV-1 and AV-154-Na IV-5 on cell viability (EZ4U assay, p < 0.05)
or proliferation (BrdU assay, p < 0.005), respectively, were observed. Other DHPs did not enhance but
have even inhibited cell growth, particularly 1000 μM Carbatone II-1 and J-9-133-2 II-2. Treatment
with hydrogen peroxide affected more cell proliferation than viability. Negative effect of hydrogen
peroxide was attenuated with low concentration (10 μM) of AV-153 IV-1, AV-154-Na IV-5, J-9-133-2 II-2,
Carbatone II-1 and Diethone I (Figure 3A,B).
The results have shown attenuation of oxidative stress-induced suppression of cell growth for
AV-153 IV-1, AV-154-Na IV-5, J-9-133-2 II-2, Carbatone II-1, and Diethone I (when present at low
concentrations), thus suggesting potential beneficial effects as of these DHPs as bioactive antioxidants.
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Figure 3. Cell viability (A) and proliferation (B) upon 24-h treatment with DHPs followed by 1-h
exposure to H2O2. Results are expressed as a percentage of non-treated control. Statistically significant
differences between—(a) DHPs alone vs. non-treated control (pale grey bars) or (b) DHPs treated vs.
treated control (dark grey bars) are shown as follows: a*/b* p < 0.05; a+/b+ p < 0.005; a#/b# p < 0.0005.
Values are given as mean ± standard deviation, n = 4.
3.4.2. Tert-Butyl Hydroperoxide(tBHP) as a Stressor
Cell Viability and Proliferation
Cell viability and proliferation were tested for a range of concentrations (10–1000 μM) of
AV-153 IV-1, AV-154-Na IV-5, J-9-133-2 II-2, Carbatone II-1, and Diethone I (five of previously tested
compounds), as well as for Thiocarbatone III-1, E2-134-1 III-4, E2-136-2 III-6, and E3-46 IV-3 (four
newly tested compounds). The majority of selected DHPs, per se, significantly stimulated cellular
viability, according to the EZ4U assay, but did not affect cell proliferation according to the BrdU assay
(Figure 4A). Hence, different concentrations of DHPs were selected for evaluation of respective DHPs’
effects on HOS cells under mild oxidative stress conditions using 50 μM tBHP as a stressor. As in case
of hydrogen peroxide, tBHP suppressed cell proliferation more than cellular viability. The E2-134-1
III-4 stimulated both, cell viability (500 μM, p < 0.05) and proliferation (250 μM, p < 0.05) while
Carbatone II-1 (250 μM; p < 0.05) and Thiocarbatone III-1 (100 μM; p < 0.05) stimulated either viability
or proliferation (Figure 4B,C).
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Figure 4. Cell viability (EZ4U assay) and proliferation (BrdU assay). (A) just DHPs without tBHP;
(B) and (C) cell cultures treated with 50 μM tBHP. Results are expressed as a percentage of non-treated
control. Values are given as mean ± standard deviation; n = 4. In comparison to the treatment control
(ctrl tBHP), statistically significant differences are shown as follows: * p < 0.05; # p < 0.0005.
Intracellular ROS Production
As expected, pro-oxidant stressor tBHP increased the production of intracellular ROS while DHPs
have shown diverse mostly concentration-dependent patterns (Figure 5). The highest reduction of ROS
was observed with 250 μM Diethone I, which was the only DHP able to decrease ROS levels even below
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that of non-treated controls (p < 0.005). The highest applied concentration (500 μM) of Thiocarbatone
III-1 and of E2-134-1 III-4, decreased ROS levels to the level of non-treated controls (p < 0.0005).
These DHPs were also effective at 250 μM (p < 0.05 and p < 0.005), while the lowest concentration
applied (100 μM) increased intracellular ROS production (p < 0.005 and p < 0.0005). The AV-153 IV-1
and AV-154-Na IV-5 have shown a concentration-dependent bell-shaped curve, whereas in general,
AV-154-Na IV-5 increased ROS levels (suggesting its pro-oxidant role), while similar pro-oxidative
effect of AV-153 IV-1 was just observed in the middle concentration range of the substance used
(250 μM; p < 0.05), to be followed by antioxidant effect of ROS reduction observed for the highest
concentration (100 μM; p < 0.05). Carbatone II-1 was effective in reducing the ROS levels at higher
concentrations (250 μM, p < 0.0005; 500 μM, p < 0.05), while E2-136-2 III-6 was effective as antioxidant
at 250 μM (p < 0.05), not affecting ROS levels in other concentrations. Finally, E3-46 IV-3 and J-9-133-2
II-2 were mostly effective as pro-oxidants, particularly E3-46 IV-3 if used at a lower concentration
range (100 μM, p < 0.05; 250 μM, p < 0.005).
Figure 5. Intracellular ROS levels upon 24-h treatment with DHPs in mild oxidative stress conditions
(1-h treatment with 50 μM t-BHP). Results are expressed in arbitrary units, adjusting the difference
in fluorescence measurement after 1-h treatment with tBHP and zero-point (before addition of tBHP)
with the cell number. Values are given as mean ± standard deviation (n = 3). Statistically significant
differences are shown as follows: * p < 0.05; + p < 0.005; # p < 0.0005 (in comparison to the treatment
control (ctrl tBHP; dotted line)); and a+ p < 0.005 (in comparison to the non-treated control (ctrl;
dashed line)).
Determination of Total Glutathione Level in the Cells
Glutathione depletion was observed in HOS cells upon tBHP treatment (Figure 6). All tested
DHPs were able to amend such tBHP-induced glutathione depletions at least in the case of some used
concentrations. The only case of additional decrease of glutathione below the levels reduced by tBHP
was observed for AV-153 IV-1 (1000 μM; p < 0.05), E2-134-1 III-4 (100 μM; p < 0.05), and J-9-133-2 II-2
(500 μM; p < 0.005). Opposite to that some of tested DHPs were able to increase glutathione above
the level of non-treated control. Such enhancing effect was observed for AV-154-Na IV-5 (1000 μM;
p < 0.05), E2-134-1 III-4 (500 μM; p < 0.05), Diethone I (100 μM; p < 0.05), Carbatone II-1 (250 μM;
p < 0.005), E3-46 IV-3 (250 μM; p < 0.05), and Thiocarbatone III-1 (100 μM; p < 0.005 and 500 μM;
p < 0.05). Surprisingly, Thiocarbatone III-1, while being able to increase glutathione more than the
other tested DHPs (100 μM; p < 0.005), if applied at 250 μM concentration this DHP did not amend the
tBHP-caused glutathione-depletion, thus producing the U-shaped concentration-dependence curve.
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The glutathione levels for other DHPs were either proportional with their increasing concentrations
(e.g., E2-134-1 III-4, E-2-136-2 III-6) or decreasing with their increasing concentrations (e.g., AV-153
IV-1, Diethone I) or forming a bell-shaped curve (e.g., Carbatone II-1, E3-46 IV-3).
Figure 6. Concentration of total glutathione in cell lysates after 24-h treatment with DHPs followed by
1-h exposure to mild oxidative stress (50 μM tBHP). Statistically significant difference between DHPs
and (a) non-treated control (ctrl (dashed line); only for the significant increase) or (b) treated control
(ctrl tBHP (dotted line)) is given as follows: a*/b* p < 0.05; a+/b+ p < 0.005 with the difference between
ctrl vs. ctrl tBHP as + p < 0.005. Values are given as mean ± standard deviation, n = 3.
In summary, the results of 24-h exposure of cells to DHPs prior the induction of mild oxidative
stress (50 μM tBHP) revealed that Thiocarbatone III-1, Carbatone II-1 and in particular E2-134-1
III-4 were the only DHPs able to promote cell growth under oxidative stress conditions, acting
in a concentration-dependent manner. While growth promotion was associated, as expected,
with reduction of ROS and induction of the intracellular glutathione for E2-134-1 III-4 (250 μM
and 500 μM) and Carbatone II-1 (250 μM), in case of the most pronounced increase of glutathione
observed for Thiocarbatone III-1 (100 μM), an increase of intracellular ROS was shown, too.
4. Discussion
The results of our study are in line with emerging evidence supporting pleiotropic, against oxidative
stress-oriented, actions of DHPs. Thus, 4-aryl-2,6-dimethyl-3,5-bis-N-(aryl)-carbamoyl-1,4-dihydropyridines is
already in use as novel skin-protecting agents, which inhibit elastase enzyme and protect against
ROS [35]. In addition, the antioxidative ability of DHPs was used for creating more stable,
light-sensitive DHP polythiophene derivatives (PTDHPs) as better alternatives to fluorescent probes
used for cell imaging. These PTDHPs, via DHP groups, were found to regulate angiotensin-induced
intracellular oxidative stress [36]. Recently, effective ROS radical scavenging was found also
for some mitochondria-targeting DHPs [37]. These Mito-DHPs are promising antioxidants since
they could protect both against radiation- and ROS-induced DNA strand breaks. These findings
further confirm previous data on antioxidant and reductant activities of DHPs (Diethone I and
its analogues) [38,39], pointing to mitochondria as targets for cell protective, bioactive DHP
antioxidants [40,41]. This assumption is further supported by the current study since we observed
differences in biological activities of DHPs in respect to biological parameter analyzed (cell proliferation
vs. viability), which might be due to the fact that cellular viability was analyzed by EZ4U assay that
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reflects mitochondrial dehydrogenase activities. The same stands also for the observed differential
effects of DHPs in respect to their direct pro- and anti-oxidative capacities (TOC/TAC assays based on
hydrogen peroxide/peroxidase activity principle) vs. influence of DHPs on intracellular production
of ROS, which is dependent on cellular oxidative homeostasis affecting viability and mitochondrial
stability of the cells.
This study of pro- and anti-oxidant capacities of 27 structurally different DHPs (as well as one
pyridine type compound) support previous findings, further indicating growth-regulating bioactivities
of several DHPs acting on human osteoblast-like cells. The used DHPs, roughly divided into four
subtypes comprising Diethone (Diludine) I and its analogues, Carbatone II-1 and its analogues,
Thiocartbatone (III-1) and its analogues, as well 1,4-dihydroisonicotinic acid derivatives (such as
AV-153 IV-1) and its analogues, were primarily evaluated for their antioxidative ability (TAC assay)
as well as for their potential pro-oxidative ability (TOC assay). Antioxidative potential of 1 mM
concentration of Diethone I, AV-154-Na IV-5, Thiocarbatone III-1, E2-134-1 III-4, E2-136-2 III-6,
J-9-133-2 II-2, E3-46 IV-3, J-11-71-2 IV-7, V-6-55-1 IV-4, Carbatone II-1, and AV-153 IV-1 was about
10-fold higher than was antioxidant capacity of uric acid, the well-known natural antioxidant used
as standard. There are main, node structures of DHPs possessing quite high antioxidative capacity
known for Diethone I, Carbatone II-1, AV-153 IV-1 and AV-154-Na IV-5, according to the structure:
function analysis. Extension of substituents in positions 3 and 5 of Diethone I (ethoxycarbonyl to
alkoxycarbonyl-methoxycarbonyl) and its thioderivative (E170-4, TK-2 III-2) leads to substantial
diminution of antioxidative capacity. On the contrary, compounds possessing carboxylate anions in
positions 3 (or 3 and 5) of Diethone I possess high antioxidative activity (Carbatone II-1, Thiocarbatone
III-1, also 4-carboxycarbatone V-6-55-1 IV-4, hybrids of Carbatone II-1 or Thiocarbatone III-1 and
Diethone I such as E2-134-1 III-4, J-9-133-2 II-2). Insertion of substituents in position 4 of Carbatone
II-1 (methyl, ethyl, styryl groups) diminishes antioxidative activity to the levels of uric acid for
Styrylcarbatone II-6 (J-9-117 II-6) and Metcarbatone II-4 or almost completely suppresses in case
of Etcarbatone II-5. However, a carboxylate anion in position 4 leads to the already mentioned
antioxidative activity observed for AV-153 IV-1 and AV-154-Na IV-5. Moreover, hybrids of Carbatone
II-1 ester and Diethone I possess high antioxidative capacity if compounds have 4-carboxylate
anion (V-6-55-1 IV-4 and E3-46 IV-3). If carboxylate groups in position 4 are distant from the
DHP cycle (Glutapyrone IV-8), antioxidative activity is absent. The oxidized form (pyridine type
compound J-12-25 V) was found to be inactive. Antioxidant activity mechanisms of DHPs studied
may include direct scavenging of ROS (namely, hydrogen peroxide and free radicals derived from
it) and decomposition of hydrogen peroxide in the manner, in which ROS will be produced in lesser
degree. Namely, it was observed before that Carbatone II-1 and its derivatives scavenge hydroxyl
radicals (spectrophotometric and EPR detection) produced in Fenton reaction [7,14]. Furthermore, EPR
spectroscopy showed that Metcarbatone II-4 acts as effective scavenger of hydroxyl radicals produced
in the Fenton reaction, while Etcarbatone II-5, and Propcarbatone (close analogue of Etcarbatone II-5
having propyl group instead of ethyl group) are less effective, and Styrylcarbatone II-6 is not effective
at all. In addition, DHPs affecting TAC could be converted in their heteroaromatic oxidized form [42].
Pro-oxidative potential, measured by the TOC assay (Table 3), of the majority of the tested
DHPs was either absent or minor. AV-153 IV-1, Carbatone II-1 and E-170-4 III-3 (TK1, III-3) were
the only compounds showing oxidative potential somewhat proportional to the concentration used.
While pro-oxidative activity of E-170-4 III-3 (TK-1 III-3; diethyl ester of Thiocarbatone III-1) was very
low, mild oxidative potential of lower concentrations (10 μM and 100 μM) and negligible of the highest
(1000 μM) were observed for AV-153 IV-1 and Carbatone II-1. Still, it was about 2-fold (AV-153 IV-1)
and 5-fold (Carbatone II-1) lower than of hydrogen peroxide. Therefore, the oxidative ability tested
by this assay was very moderate or absent suggesting that DHPs are less prone to oxidative activity.
Concerning TOC effects, it should be mentioned that Tirzit et al. [43] showed possibility of free-radical
reaction propagation by DHPs in vitro. If water-soluble DHPs (where R4 = H, or CH3, or COONa)
have methyl group in the 4-th position, the possibility of that compounds reactivity against hydroxyl
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radical generation is lowered. However, introduction of strong electron donor group carboxylate-ion
(COONa) causes sharp increase of reaction power. Even the introduction of carboxylate-ion in the
positions 2 and 6 of the DHP ring increased this reactivity. The generation potency was observed at
0.5 mM and 1 mM, respectively 500 μM and 1000 μM concentrations, while at higher concentrations,
the hydroxyl radical (HO•) generation is more pronounced. In addition, both assays, TAC and
TOC, use HRP (horse radish peroxidase)-catalyzed oxidation of 3,3′,5,5′-tetramethylbenzidine (TMB)
(reduced form of this is colorless) which includes either free radical (one-electron oxidation product)
and/or charge transfer complex intermediates, both resulting in the formation of blue-colored reaction
product [44]. However, it is difficult to discriminate between a one-electron and a two-electron
mechanism for the initial enzymatic step in the reaction, thus the DHPs could react even as free
radical quenchers or propagators (by one-electron or two-electron mechanisms) of free radical chain
reactions (depending on assays used, DHPs chemical structure and concentration). Indeed, both, strong
antioxidative activity and mild oxidative potential was observed for Carbatone II-1 and AV-153 IV-1.
Moreover, as being effectors of TAC/TOC systems in the presence of HRP, 1,4-DHPs themselves could
also be enzymatically oxidized [45,46]. Thus, the elementary steps of oxidation of water-insoluble
lipophilic calcium antagonist Nifedipine (NF) catalyzed by enzyme HRP have been described by
analysis of kinetic magnetic field effects (MFEs). It has been shown that the first step of the catalytic
cycle is single electron transfer resulting in formation of NF*(+) radical cation and ferroperoxidase
(Per(2+)) [46]. As a result, comparison with an earlier studied oxidation reaction of NADH catalyzed by
HRP evidenced that the enzymatic oxidations of two substrates, native, NADH, and its synthetic DHP
analogue, NF-catalyzed by HRP in the absence of hydrogen peroxide follow identical mechanisms. It is
likely, that analogous reaction route could proceed in the case of the set of lipophilic DHPs (see Table 1)
studied here. Besides, peroxide oxidation (without peroxidase, in Fenton system a.o.) of DHPs could
occur [47].
Since previous studies have shown that various DHPs can achieve modulation of cellular
responses to oxidative stress and thus influence cell growth and differentiation [30,48], the major
aim of the current study was to find a DHP compound or a group of them that will act as potential
antioxidants and could modify the growth of human–osteoblast cells indicating their possibly beneficial
effects for treatment of osteoporosis and related bone disorders. Since oxidative stress was implicated in
pathogenesis of osteoporosis (manifested as deterioration of bone) and antioxidants, such as lycopene
and polyphenols have been suggested to benefit the therapy of osteoporosis [17,19,49], we studied
the antioxidative potential of the selected DHPs which were 10-fold more effective than uric acid on
HOS cells in mild oxidative stress conditions. Although normal human osteoblasts would be preferred
model, due to their limited availability and donor-related influences, human osteoblast-like cancer cell
lines have been widely used model systems for human osteoblasts, in particular HOS cells are known
as such in vitro model [20–22].
To evaluate short-term, cell-protective (ROS decreasing) effects of DHPs, cells were treated with
the selected DHPs and hydrogen peroxide, in general, for 1-h each. Thiocarbatone III-1, AV-153 IV-1,
E2-134-1 III-4, E2-136-2 III-6, and Diethone I decreased ROS levels showing antioxidative potential,
which was pronounced if the cells were not already damaged by hydrogen peroxide. Moreover,
observed ROS reduction indicates direct scavenging of hydrogen peroxide by the mentioned DHPs
along with possible induction of cellular-protective, antioxidant mechanisms. In addition, while
Diethone I and E2-136-2 III-6 did not affect cell growth, Thiocarbatone III-1, AV-153 IV-1 and in
particular E2-134-1 III-4 did, thus emerging as the most potent antioxidants in the tested group, able to
reduce oxidative stress-induced damage. Noteworthy, we cannot state with certainty whether the
observed beneficial effects upon short-term treatment (DHPs and hydrogen peroxide being present
in the medium at the same time for specified time-points) are just due to scavenging of hydrogen
peroxide by DHPs (which is negligible without added catalysts) or their ability to induce cellular
protective mechanism(s), or even both.
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We further explored whether DHPs can induce cellular protective mechanism(s) under mild
oxidative stress conditions and if longer exposure of cells to DHPs can potentiate possible effects. To do
so, cells were treated with the selected DHPs for 24-h which were removed from the medium prior to
exposure to stressors (1-h treatment). Hydrogen peroxide and tert-butyl hydroperoxide (tBHP) were
used for induction of mild oxidative stress. In addition to the evaluation of cell growth, measurements
of ROS generation along with intracellular glutathione content were carried out with the latter (tBHP)
since it is known as more stable oxidative stress-inducing agent than hydrogen peroxide that provides
more consistent effects [50]. Notably, for HepG2 cells tBHP, but not hydrogen peroxide, was found
to be able to decrease reduced glutathione as wells as to increase malondialdehyde (MDA) levels
and activity of antioxidative enzymes [50]. Moreover, tBHP was shown to induce caspase-dependent
apoptosis in endothelial cells, which was mediated by ROS generation deriving from NADPH oxidase
and mitochondria [51]. However, we should also stress the fact that hydrogen peroxide in very
important natural ROS with multiple positive and negative bioactivities.
Both used stressors decreased cell growth, thus creating mild oxidative stress, while AV-153 IV-1,
AV-154-Na IV-5, J-9-133-2 II-2, Carbatone II-1, and Diethone I (at low concentration) ameliorated
negative effects of hydrogen peroxide, by promoting cell growth and acting as antioxidants.
The more in-depth analysis of the selected DHPs, considering the influence on cell growth, ROS
production and glutathione content, was carried out with tBHP, known to be more stable and consistent
in induction of oxidative stress, unlike hydrogen peroxide, which has multiple biological activities
and is rapidly metabolized as natural ROS. Glutathione is one of the most important intracellular
antioxidants able to scavenge ROS thus becoming oxidized. The increase in ratio oxidized/reduced
glutathione indicates severity of oxidative stress. tBHP is known to increase this ratio thus causing
depletion of reduced glutathione [50]. We measured total glutathione content (oxidized + reduced)
which should be influenced only by de novo synthesis. tBHP decreased glutathione content, also
observed in Rat clone-9 hepatocytes [52] which could be due to attenuated activation of the GCLc
(glutamate cysteine ligase, catalytic subunit) promoter [53], resulting in reduced biosynthesis.
The selected DHPs were able to amend tBHP-induced glutathione depletions at least in some
of the tested concentrations. Such effect was observed in rats exposed to benzo(a)pyrene-induced
oxidative stress, where pre-treatment with Nitrendipine increased the glutathione but also superoxide
dismutase (SOD) levels while decreasing TBARS levels [54].
Moreover, AV-154-Na IV-5 (1000 μM), E2-134-1 III-4 (500 μM), Diethone I (100 μM), Carbatone
II-1 (250 μM), E3-46 IV-3 (250 μM), and Thiocarbatone III-1 (100 μM and 500 μM) were able to induce
glutathione biosynthesis. Indeed, the concentration-dependent diversity in patterns of intracellular
glutathione and of ROS levels was observed in our study. Yet, Thiocarbatone III-1, Carbatone II-1 and
in particular E2-134-1 III-4 were the only DHPs able to promote cell growth under such mild oxidative
stress conditions acting in a concentration dependent manner. While growth promotion was related
to the reduction of ROS and the induction of intracellular glutathione for E2-134-1 III-4 (250 μM and
500 μM) and Carbatone II-1 (250 μM), with the strongest observed increase of glutathione, the increase
of intracellular ROS was also noticed for Thiocarbatone III-1 (100 μM).The major pathway activated
upon stress conditions is NRF2/KEAP1 [55]. NRF2 activates genes that encode phase II detoxifying
enzymes and antioxidant enzymes thus influencing glutathione content. Recently, DHPs (Nifedipine
and Amlodipine) were shown to activate NRF2 via a phosphoinositide 3-kinase (PI3K)-dependent
mechanism [56]. At this point, we cannot fully explain observed concentration-dependent diversities
in ROS and glutathione content, being sometimes reversal as expected, and the others not, or can we
explain lack of linearity. However, we can assume that the onset of lipid peroxidation, generating
reactive aldehydes, especially 4-hydronynoenal known to act as a second messenger of free radicals and
signaling molecules regulating cell growth and inducing endogenous production of ROS, eventually
affecting the activity and synthesis of glutathione might be, at least in part, responsible for that [57–59].
Interestingly, these DHPs did not affect cell growth, unlike growth-supporting DHPs E2-134-1 III-4
and Carbatone II-1, which were found to increase glutathione and reduce ROS production, thus acting
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as potent antioxidants. On the other hand, Thiocarbatone III-1 could not decrease ROS although it
enhanced the growth of the HOS cells. These findings again suggest involvement of other survival
pathway(s) that might include second messengers of free radicals, which are since recently also in
focus of research as growth regulators [60–62]. In favor of this possibility are also pro-oxidative effects
of Thiocarbatone III-1, resembling similar effects of HNE, while the other DHPs were also acting as
pro-oxidants at certain concentration.
This dual phenomenon is characteristic also for some other compounds (e.g., ascorbic acid), acting
either as antioxidants or as pro-oxidants, depending on given conditions [63]. For alpha-tocopherol
(vitamin E) and even for polyphenols and thiols, the persistent rhetoric question is if vitamin E
should be considered as a pro- or an anti-oxidant [64,65]. This question is actual similar for DHPs,
in the case of which the likely answer could be both antioxidants and/or pro-oxidants, depending
on the compound’s individual structure determinants, like C. Winterburn stated: “Antioxidants are
individuals” [65]. The same appears to be valid for bioactive DHP antioxidants, too.
DHPs, such as Thiocarbatone III-1, E2-134-1 III-4, Carbatone II-1, AV-153 IV-1, AV-154-Na IV-5,
J-9-133-2 II-2, and Diethone I were able to attenuate negative effects of oxidative stress in human
osteoblast-like cells. Their action was highly dependent on the concentration used, stressor applied and
treatment set-up. Thus, the observed growth-supporting effects suggest that they might be eventually
considered as promising therapeutic agents in the treatment of osteoporosis as was observed for
Cilnidipine [66] and Amlodipine [67] in murine translation models.
5. Conclusions
Eleven out of the 28 structurally different compounds tested (27 DHP derivatives and one
oxidized form pyridine-type heteroaromatic compound), in particular, Diethone I, AV-154-Na IV-5,
Thiocarbatone III-1, E2-134-1 III-4, E2-136-2 III-6, J-9-133-2 II-2, E3-46 IV-3, J-11-71-2 IV-7, V-6-55-1
IV-4, Carbatone II-1 and AV-153 IV-1 were about 10-fold more effective antioxidants than uric acid
and were further tested in the HOS model of human osteoblast-like cells. From the selected DHPs,
Thiocarbatone III-1, E2-134-1 III-4, Carbatone II-1, AV-153 IV-1, AV-154-Na IV-5, J-9-133-2 II-2, and
Diethone I were able to attenuate negative effects of oxidative stress in human osteoblast-like cells
induced by pro-oxidants. These bioactive DHP antioxidants acted in a concentration-dependent
manner, while their efficiency was also related to the pro-oxidant stressor applied and experimental
treatment set-up. Thiocarbatone III-1, Carbatone II-1 and E2-134-1 III-4 were found to be undoubtedly
the most potent compounds with growth-promoting effects and the only DHPs being able to act so in
tBHP-induced oxidative stress conditions. The observed induction of de novo glutathione synthesis by
HOS cells, observed upon treatment with these DHPs, implicates involvement of the NRF2 signaling
pathway. While Carbatone II-1 and E2-134-1 III-4 have shown concordant reduction in ROS, for
Thiocarbatone III-1, increased ROS contributing to cell growth suggested other survival mechanism(s)
involved. Surprisingly, Diethone I (known antioxidant) did not affect cell growth even though it
decreased ROS and mostly resulted in increasing glutathione in such conditions. Likewise, Diethone I
and AV-153 IV-1 were more protective if hydrogen peroxide was used as a stressor. In addition, AV-153
IV-1 appeared to be more effective if directly acting as a scavenger of hydrogen-peroxide for shorter
time, like Diethone I, while Thiocarbatone III-1 and E2-134-1 III-4 acted seemingly both as scavengers
of ROS and as inducers of growth promoting signaling pathways. Therefore, we assume that HNE and
related second messengers of free radicals generated by lipid peroxidation might be relevant factors
for the bioactivity principles of bioactive DHPs, which should be further studied.
Finally, the results of our study together with supporting evidence for other DHPs [66,67] as
well as with other antioxidants [17], suggest that DHPs could be considered as therapeutic agents for
osteoporosis although further research is needed to elucidate mechanisms involved.
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Brūvere, I.; Bisenieks, E.; Duburs, G.; et al. DNA-binding studies of AV-153, an antimutagenic and DNA
repair-stimulating derivative of 1,4-dihydropiridine. Chem. Biol. Interact. 2014, 220, 200–207. [CrossRef]
[PubMed]
13. Ošin, a, K.; Rostoka, E.; Sokolovska, J.; Paramonova, N.; Bisenieks, E.; Duburs, G.; Sjakste, N.; Sjakste, T.
1,4-Dihydropyridine derivatives without Ca2+-antagonist activity up-regulate Psma6 mRNA expression in
kidneys of intact and diabetic rats. Cell Biochem. Funct. 2016, 34, 3–6. [CrossRef] [PubMed]
14. Ošin, a, K.; Leonova, E.; Isajevs, S.; Baumane, L.; Rostoka, E.; Sjakste, T.; Bisenieks, E.; Duburs, G.;
Vı̄gante, B.; Sjakste, N. Modifications of expression of genes and proteins involved in DNA repair and nitric
oxide metabolism by carbatonides [disodium-2,6-dimethyl-1,4-dihydropyridine-3,5-bis(carbonyloxyacetate)
derivatives] in intact and diabetic rats. Arh. Hig. Rada Toksikol. 2017, 68, 212–227. [CrossRef] [PubMed]
15. Rostoka, E.; Sokolovska, J.; Sjakste, N.; Sjakste, T.; Ošin, a, K. 1,4-Dihidropiridı̄na atvasinājums DNS
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